Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase: PHASE1
Conditions: Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7
Sponsor: National Cancer Institute (NCI)

1 
Protocol Update #07 
XX/XX/2017 
 
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 
_________________________________________ 
PROTOCOL UPDATE TO ALLIANCE A091101 
_________________________________________ 
 
CARBOPLATIN-PACLITAXEL INDUCTION CHEMOTHERAPY AND ABT-888 (VELIPARIB) – A PHASE 
1/RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL 
CARCINOMA OF THE HEAD AND NECK 
NCI-supplied agent(s): ABT-888 (Veliparib) (NSC #737664, IND#77840) 
 
 
 
 
 
X Update: 
 
 
Status Change: 
 
 
 
 
 
 
Eligibility changes 
 
 
Activation 
 
 
 
 
 
X Therapy / Dose Modifications / Study Calendar changes 
 
 
Closure 
 
 
 
 
 
 
Informed Consent changes 
 
 
Suspension / temporary closure 
 
 
 
 
 
 
Scientific / Statistical Considerations changes 
 
 
Reactivation 
 
 
 
 
 
 
Data Submission / Forms changes 
 
 
 
 
 
 
 
 
X Editorial / Administrative changes 
 
 
 
 
 
 
 
 
 
Other :  
 
 
 
 
Expedited review is allowed. IRB (or disapproval) is required within 90 days. Please follow your IRB of 
record guidelines.  
 
UPDATES TO THE PROTOCOL: 
CTSU Contact Information Table 
The table has been updated with the revised CTSU verbiage. 
 
Section 10.0 (Study Calendar) 
-Footnote “***” has been updated. The 3-month time point has been removed from the first sentence. 
-An “X” has replaced the “C” in the Imaging row under the last column, Clinical Follow-up.  Footnote 
“C” has been removed because the timing was not correct. Imaging should be done per footnote “***”. 
Subsequent footnotes have been re-lettered.  
 
UPDATES TO THE MODEL CONSENT: 
No changes have been made to the model consent form.  
 
A replacement protocol and model consent document have been issued. 
____________________________________________________________ 
ATTACH TO THE FRONT OF EVERY COPY OF THIS PROTOCOL 
  ___________________________________________________________ 

Alliance A091101 
 
Version Date: 08/11/2017 
1 
Update #07 
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 
 
 
ALLIANCE A091101 
 
 
CARBOPLATIN-PACLITAXEL INDUCTION CHEMOTHERAPY AND ABT-888 (VELIPARIB) – A PHASE 
1/RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL 
CARCINOMA OF THE HEAD AND NECK 
 
NCI-supplied agent: ABT-888 (Veliparib) (NSC #737664, IND#77840) 
 
ClinicalTrials.gov Identifier: NCT01711541 
 
Study Chair 
Everett E. Vokes, M.D. 
John E. Ultmann Professor 
Chairman, Department of Medicine 
Physician-in-Chief, University of Chicago Medicine and Biological Sciences 
5841 S. Maryland Ave, MC 6092 
Chicago, IL 60637 
Tel: 773-702-9306  Fax: 773-702-4427 
evokes@medicine.bsd.uchicago.edu 
 
Community Oncologist Co-Chair 
Bruce Brockstein, M.D. 
Tel: 847-570-2112 Fax: 847-570-1041 
BBrockstein@northshore.org 
 
 
Committee Co-Chair 
Committee Co-Chair 
Pamela Munster, M.D. 
Gary K. Schwartz, M.D. 
Tel: 415 502-3598 Fax: (415) 353-7779 
Tel: 212-305-2055 Fax: 212- 717-3085 
Pmunster@medicine.ucsf.edu 
schwartzg@columbia.org 
 
 
Primary Statistician 
Protocol Coordinator 
Nathan R. Foster, MS 
Krista L. Garbacz 
Tel: (507) 284-5051   
Tel: 773-702-9269 Fax: 312-345-0117 
foster.nathan@mayo.edu 
kgarbacz@uchicago.edu 
 
 
Open to the following NCTN institutions:  
Cleveland Clinic Florida 
Northshore University HealthSystem 
Northwestern University 
University of Chicago 
University of Massachusetts  
University of North Carolina at Chapel Hill 
Washington University School of Medicine 

Alliance A091101 
Version Date: 08/11/2017 
2 
 Update #07 
Alliance Protocol Operations Program Office 
125 West Wacker Drive, Suite 1600 
Chicago, IL  60606 
Tel: 773-702-9171 Fax: 312-345-0117 
www.allianceforclinicaltrialsinoncology.org 
Alliance Statistics and Data Center 
Mayo Clinic 
200 First St. SW 
Rochester MN 55905 
 
Expedited Adverse Event Reporting 
https://eapps-ctep.nci.nih.gov/ctepaers 
Medidata Rave iMedidata portal 
https://login.imedidata.com 
OPEN (Oncology Patient Enrollment Network) 
https://open.ctsu.org 
 
Protocol Resources: 
A091101 Data Manager 
Deborah Papenfus 
507-284-4918  
papenfus.deborah@mayo.edu 
A091101 Nursing Contact 
Nicole Hannigan 
The University of Chicago 
E-mail: nhannigan@bsd.uchicago.edu 
A091101 Pharmacy Contact 
Heidi Finnes, PharmD, BCOP 
507-538-7066 
finnes.heidi@mayo.edu  
 
Alliance Biorepository at Ohio State University (OSU) 
The Ohio State University 
Innovation Centre 
2001 Polaris Parkway 
Columbus, OH 43240 
Tel: 614-293-7073  Fax: 614-293-7967 
path.calgb@osumc.edu 
 
 
Protocol-related questions may be directed as follows: 
Questions 
Contact (via email) 
Questions regarding patient eligibility, treatment, 
and dose modification: 
Study Chair, Nursing Contact, Protocol 
Coordinator, or (where available) Data Manager  
Questions related to data submission, RAVE or 
patient follow-up: 
Data Manager  
Questions regarding the protocol document and 
model informed consent: 
Protocol Coordinator 
Questions related to IRB review: 
regulatory@alliancenctn.org 
Questions regarding CTEP-AERS reporting: 
Regulatory Affairs Manager, 
regulatory@alliancenctn.org, (773) 702-9814 
 
Document History 
Effective Date: 
 
 
Activation 
October 22, 2012 
Update #4 
12/15/2015 
Update #1 
08/05/2013 
Update #05 
07/01/2016 
Update #2 
08/01/2014 
Update #06 
06/15/2017 
Update #3 
08/01/2015 
Update #07 
XX/XX/2017 

Alliance A091101 
 
Version Date: 08/11/2017 
3 
Update #07 
CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT INFORMATION 
CONTACT INFORMATION 
 
For regulatory requirements: 
For patient enrollments: 
For study data submission: 
Regulatory documentation must 
be submitted to the CTSU via 
the Regulatory Submission 
Portal. 
Regulatory Submission Portal: 
(Sign in at www.ctsu.org,            
and select the Regulatory 
Submission sub-tab under the 
Regulatory tab.)  
 
Institutions with patients 
waiting that are unable to use 
the Portal should alert the 
CTSU Regulatory Office 
immediately at 1-866-651-2878 
to receive further instruction 
and support. 
 
Contact  the CTSU Regulatory 
Help Desk at 1-866-651-2878 
for regulatory assistance. 
Please refer to the patient 
enrollment section of the protocol 
for instructions on using the 
Oncology Patient Enrollment 
Network (OPEN) which can be 
accessed at 
https://www.ctsu.org/OPEN_SYS
TEM/ or https://OPEN.ctsu.org. 
 
Contact the CTSU Help Desk 
with any OPEN-related questions 
at ctsucontact@westat.com. 
 
 
Data collection for this study 
will be done exclusively through 
Medidata Rave.  Please see the 
data submission section of the 
protocol for further instructions.  
 
The most current version of the study protocol and all supporting documents must be downloaded 
from the protocol-specific Web page of the CTSU Member Web site located at https://www.ctsu.org.  
Access to the CTSU members’ website is managed through the Cancer Therapy and Evaluation Program 
- Identity and Access Management (CTEP-IAM) registration system and requires user log on with 
CTEP-IAM username and password. Include this statement if applicable: Permission to view and 
download this protocol and its supporting documents is restricted and is based on person and site roster 
assignment housed in the CTSU RSS.   
 
For clinical questions (i.e. patient eligibility or treatment-related) contact the Study PI of the Lead 
Protocol Organization 
For non-clinical questions (i.e. unrelated to patient eligibility, treatment, or clinical data 
submission) contact the CTSU Help Desk by phone or e-mail:  
CTSU General Information Line – 1-888-823-5923, or ctsucontact@westat.com.  All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU Website is located at https://www.ctsu.org. 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
4 
Update #07 
 
Carboplatin-Paclitaxel Induction chemotherapy and ABT-888 (Veliparib) – a Phase 1/Randomized 
Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head 
and Neck 
 
Phase 1 
 
Patient Eligibility 
Required Lab Values 
Eligible patients are newly diagnosed and treatment naïve: 
leukocytes ≥ 3,000/mm3 
- Stage IVa-b SCC other than OPC, OR 
ANC ≥ 1,500/ mm3 
- OPC HPV-negative, Stage IVa-b 
platelets ≥ 100,000/ mm3 
Patients must have measurable disease (see §3.1.2) 
total bilirubin ≤ 1.5 Institutional upper limit  
ECOG performance status 0-1 
 of normal (ULN) 
Age >18 years 
SGOT(AST) or  
Must be able to swallow the drug 
SGPT(ALT) ≤ 2.5 x ULN 
Able to understand and sign a written informed consent document Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with 
creatinine levels above ULN* 
No other investigational agents 
No active seizure or history of seizure 
* As calculated by Cockcroft-Gault. 
No allergies to similar agents of ABT-888 (see §3.1.10) 
No impairment of GI function (see §3.1.11) 
No uncontrolled intercurrent illness (see §3.1.12) 
No pregnant or nursing women (see §3.1.13) 
No HIV-positive patients on combination antiretroviral therapy (see §3.1.14) 
No patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (see §3.1.15) 
No patients with other malignancies in the past 2 years (except carcinoma of the cervix or basal or squamous cell carcinoma of 
the skin or surgically treated early stage solid tumors) 
 
 
Phase 1 Schema 
 
 
Induction 
 
Concomitant 
Chemoradiotherapy 
 
 
 
 
 
 
 
Carboplatin-Paclitaxel + ABT-888 
(veliparib) 
 
Concurrent accelerated RT and cisplatin 
(One 6-week cycle) 
 
 
(Two 3-week cycles) 
 
R  
 
 
Cisplatin 100 mg/m2 IV Days 1 and 22 
Radiotherapy 72 Gy over 6 weeks 
E  
Carboplatin AUC 6 IV on Day 1 
 
G  
Paclitaxel 100 mg/m2 IV on Days 1, 8, 15 
 
I 
 
 
 
 
S  
 
 
OR 
T  
PLUS ABT-888 (veliparib) 
 
 
E  
p.o. b.i.d. Days 1-7 (dose based on dose 
cohort) 
 
TFHX 
 (Five 2-week cycles) 
R  
 
 
 
 
 
Hydroxyurea 500 mg p.o. b.i.d., Days 1-5 
5-FU 600 mg/m2/day IV on Days 1-5 
Paclitaxel 100 mg/m2 IV on Day 1 
Radiotherapy 150 cGy b.i.d. on Days 1-5 
 
 
 
 
 
 
See Section 5.1.1 for more information 
 
 
 
on dose cohorts 
 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
5 
Update #07 
Carboplatin-Paclitaxel Induction chemotherapy and ABT-888 (Veliparib) – a Phase 1/Randomized 
Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head 
and Neck 
 
Phase 2 
 
Patient Eligibility 
Required Lab Values 
Eligible patients are treatment naïve and: 
leukocytes 
≥ 3,000/mm3 
- Stage IVa-b SCC other than OPC, OR 
ANC 
≥ 1,500/ mm3 
- OPC HPV-negative, Stage IVa-b, OR 
platelets 
≥ 100,000/ mm3 
- OPC HPV positive with greater than 10pack-year 
total bilirubin 
≤ 1.5 Institutional upper limit  
smoking history and N2b-N3 disease 
 
of normal (ULN) 
Patients must have measurable disease (see §3.2.2) 
SGOT(AST) or   
ECOG performance status 0-1 
SGPT(ALT) 
≤ 2.5 x ULN 
Age >18 years 
Must be able to swallow the drug 
Able to understand and sign a written informed consent 
Creatinine 
clearance  
≥ 60 mL/min/1.73 m2 for 
patients with creatinine levels 
above ULN* 
document 
* As calculated by Cockcroft-Gault. 
No other investigational agents 
No active seizure or history of seizure 
 
 
No allergies to similar agents of ABT-888 (see §3.2.10) 
No impairment of GI function (see §3.2.11) 
No uncontrolled intercurrent illness (see §3.2.12) 
No pregnant or nursing women (see §3.2.13) 
No HIV-positive patients on combination antiretroviral therapy (see §3.2.14) 
No patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (see §3.2.15) 
No patients with other malignancies in the past 2 years (except carcinoma of the cervix or basal or squamous cell carcinoma 
of the skin or surgically treated early stage solid tumors) 
Phase 2 Schema 
 
 
 
 
Induction 
 
Concomitant 
Chemoradiotherapy 
 
 
Two 3-week cycles 
 
 
 
 
 
 
 
 
 
Carboplatin AUC 6 IV on Day 1 
 
Concurrent accelerated RT and cisplatin 
(One 6-week cycle) 
 
 
Paclitaxel 100 mg/m2 IV on Days 1, 8, 15 
 
 
R 
 
 
 
Cisplatin 100 mg/m2 IV Days 1 and 22 
Radiotherapy 72 Gy over 6 weeks 
A 
 
ABT-888 (Veliparib) (dose  
 
N 
 
determined in phase I of study) 
 
D 
 
b.i.d. on Days 1-7 
 
 
O 
 
 
 
OR 
M  
 
 
 
I 
 
Carboplatin AUC 6 IV on Day 1 
 
TFHX 
 (Five 2-week cycles) 
Z 
 
Paclitaxel 100 mg/m2 IV on Day 1, 8, 15 
 
E 
 
 
 
Hydroxyurea 500 mg p.o. b.i.d., Days 1-5 
5-FU 600 mg/m2/day IV on Days 1-5 
Paclitaxel 100 mg/m2 IV on Day 1 
Radiotherapy 150 cGy b.i.d. on Days 1-5 
 
 
Placebo b.i.d. on Days 1-7 
 
 
 
 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
6 
Update #07 
TABLE OF CONTENTS 
 
SECTION                                                                             
 
                    
 
          PAGE 
1.0 
OBJECTIVES ....................................................................................................................... 8 
1.1 Primary Objectives ............................................................................................................................. 8 
1.2 Secondary Objectives (Phase II) ........................................................................................................ 8 
2.0 
BACKGROUND ................................................................................................................... 8 
2.1 Locally Advanced Head and Neck Cancer (LAHNC) ....................................................................... 8 
2.2 Patterns of Failure in LAHNC ............................................................................................................ 9 
2.3 Induction Chemotherapy .................................................................................................................... 9 
2.4 Concurrent chemoradiotherapy ........................................................................................................ 10 
2.5 Risk Stratification in LAHNC .......................................................................................................... 12 
2.6 ABT-888 (Veliparib) ......................................................................................................................... 14 
2.7 Rationale for Combination of ABT-888 and Induction Chemotherapy ............................................ 21 
2.8 Correlatives Studies Background ..................................................................................................... 21 
3.0 
PATIENT SELECTION ..................................................................................................... 23 
3.1 Eligibility Criteria for Phase 1 Component ...................................................................................... 23 
3.2 Eligibility Criteria for Phase 2 Component ...................................................................................... 24 
3.3 Inclusion of Women and Minorities ................................................................................................. 26 
4.0 
REGISTRATION/RANDOMIZATION PROCEDURES AND STRATIFICATION ...... 26 
4.1 Phase I Patient Registration .............................................................................................................. 26 
4.2 Phase II Patient Registration ............................................................................................................ 28 
4.3 Stratification Factors ........................................................................................................................ 29 
5.0 
TREATMENT PLAN ......................................................................................................... 29 
5.1 Phase I .............................................................................................................................................. 29 
5.2 Phase II ............................................................................................................................................. 42 
5.3 Concomitant Medication and Supportive Care Guidelines .............................................................. 44 
5.4 Duration of Therapy ......................................................................................................................... 44 
5.5 Duration of Follow Up ..................................................................................................................... 44 
5.6 Criteria for Removal from Study ...................................................................................................... 45 
6.0 
DOSE MODIFICATIONS FOR PHASE I ONLY ............................................................. 46 
6.1 Dose Reduction and Delays during Induction .................................................................................. 46 
6.2 Dose Modifications during Chemoradiotherapy, Option 1 (cisplatin) for phase I ........................... 49 
6.3 Dose modifications during Chemoradiotherapy, Option 2 (hydroxyurea/5FU/paclitaxel) for phase 
I  .................................................................................................................................................... 50 
7.0 
ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS .............................. 51 
7.1 Comprehensive Adverse Events and Potential Risks List (CAEPR) ............................................... 51 
7.2 Adverse Event Characteristics .......................................................................................................... 55 
7.3 Expedited Adverse Event Reporting ................................................................................................ 55 
7.4 Routine Adverse Event Reporting .................................................................................................... 57 
8.0 
PHARMACEUTICAL INFORMATION ........................................................................... 58 
8.1 CTEP IND Agent ABT-888 (NSC 737664; IND #77840; veliparib) .............................................. 58 
8.2 Commercial Agents .......................................................................................................................... 61 
9.0 
CORRELATIVE SCIENCE COMPANION STUDY ........................................................ 63 
10.0 STUDY CALENDAR ......................................................................................................... 64 

Alliance A091101 
 
Version Date: 08/11/2017 
7 
Update #07 
11.0 Treatment Evaluation Using RECIST Guideline ................................................................ 65 
11.1 
Schedule of Evaluations .............................................................................................................. 65 
11.2 
Definitions of Measurable and Non-Measurable Disease ........................................................... 65 
11.3 
Guidelines for Evaluation of Measurable Disease ...................................................................... 66 
11.4 
Measurement of Effect ................................................................................................................ 67 
11.5 
Formal statistical definitions ....................................................................................................... 70 
12.0 DATA REPORTING / REGULATORY REQUIREMENTS ............................................ 70 
12.1 
Data Reporting ............................................................................................................................ 70 
12.2 
Collaborative Agreements Language .......................................................................................... 70 
13.0 STATISTICAL CONSIDERATIONS ................................................................................ 72 
13.1 
Study Design/Endpoints .............................................................................................................. 72 
13.2 
Sample Size/Accrual Rate ........................................................................................................... 73 
13.3 
Stratification Factors ................................................................................................................... 73 
13.4 
Analysis of Secondary Endpoints ............................................................................................... 73 
13.5 
Reporting and Exclusions ........................................................................................................... 74 
14.0 REFERENCES .................................................................................................................... 75 
APPENDIX A- Performance Status Criteria .............................................................................. 79 
APPENDIX B - Head & Neck Staging......................................................................................... 80 
APPENDIX C - ABT-888 PATIENT MEDICATION CALENDAR .......................................... 85 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
8 
Update #07 
1.0 
OBJECTIVES 
1.1 
Primary Objectives 
1.1.1 Phase I  
Determine the maximum tolerated dose (MTD), recommended Phase II dose, dose limiting 
toxicity (DLT), and safety of ABT-888 (veliparib) with carboplatin and paclitaxel induction 
chemotherapy in locoregionally advanced head and neck (LAHNC) patients. 
1.1.2 Randomized Phase II 
Compare magnitude of tumor shrinkage (response) following 2 cycles of induction 
chemotherapy with and without ABT-888 in LAHNC. 
1.2 
Secondary Objectives (Phase II) 
Compare progression-free (PFS), disease-specific (DSS), and overall survival (OS) in subjects 
treated with or without ABT-888. 
2.0 
BACKGROUND 
2.1 
Locally Advanced Head and Neck Cancer (LAHNC) 
The paradigm of combined chemoradiotherapy for LAHNC dates to the early 1990s. Several 
publications on randomized controlled trials of radiation alone versus radiation plus 
chemotherapy were then reported. The outcome of these trials varied, but several meta-analyses 
showed consistent increased response rates, increased disease control, and improved survival in 
the trials incorporating concurrent cisplatin-based chemoradiotherapy.1-5 When the analysis was 
restricted to concurrent cisplatin-based chemotherapy with radiation, an 8% absolute survival 
advantage at 5 years was observed. This benefit corresponded to a 19% reduction in the risk of 
death. Notably, the meta-analysis data sets represent more than 16,000 patients treated on more 
than 80 randomized controlled trials with median follow-up in excess of 5 years. Further, a meta-
analysis of 32 randomized controlled trials with 10,225 patients in aggregate confirmed the 
advantage of chemoradiotherapy over radiation when using either hyperfractionated or 
accelerated radiation.5 In this meta-analysis, 5-fluorouracil outperformed cisplatin in terms of 
median survival benefit. Concurrent chemoradiotherapy has thus been the mainstay of treatment 
for LAHNC. 
Improvements in survival have come at the cost of increased acute toxicity and the realization 
that chemoradiotherapy can impact long-term function which, in turn, is related to radiotherapy 
volumes. Despite numerous efforts at incorporating protective agents as part of 
chemoradiotherapy regimens there has been minimal success in improving long-term toxicity in 
a substantial manner. Radiotherapy planning techniques, especially intensity modulated 
radiotherapy (IMRT), have the ability to spare normal structures from receiving full doses of 
radiotherapy compared to conventional methods. This has been best demonstrated by reduction 
in rates of chronic xerostomia in patients treated with IMRT compared to 3-D conformal 
planning. Nonetheless, even with IMRT planning, currently accepted standards for radiotherapy 
volumes based on location of gross disease still incorporate tissues critical to swallowing. Long-
term dysphagia is increasingly recognized as having a major impact on quality of life in patients 
treated with curative intent concurrent chemoradiotherapy. Therefore, strategies that would 
preserve the survival gains achieved with chemoradiotherapy while improving long-term 
function are needed. 

Alliance A091101 
 
Version Date: 08/11/2017 
9 
Update #07 
2.2 
Patterns of Failure in LAHNC 
A retrospective analysis of 5-FU, hydroxyurea and radiotherapy (FHX) trials utilizing intensive 
concomitant chemoradiotherapy conducted from 1993 to 1998 including 210 patients has 
revealed a distinct failure pattern based on TNM staging. That is, patients with T4 tumors tended 
to fail locally while those with N2 or N3 disease failed distantly, usually in the lungs.6 Distant 
failure in these patients is devastating, as there is no opportunity for salvage with either surgery 
or re-irradiation, supporting the importance of a potentially lower distant failure rate associated 
with the introduction of induction chemotherapy (neoadjuvant). 
2.3 
Induction Chemotherapy 
Recently, the addition of neoadjuvant (induction) chemotherapy has garnered interest with the 
completion of phase 3 studies demonstrating the activity and efficacy of a three drug regimen 
consisting of cisplatin, 5FU, and a taxane (TPF). TPF induction chemotherapy is effective but 
is associated with significant toxicity especially myelosuppression and mucositis.  
Induction chemotherapy has been under investigation for more than two decades in locally 
advanced squamous cell carcinoma of the head and neck.  Most regimens are used for 2 to 3 
cycles and consist of drugs with documented single agent activity in patients with recurrent 
disease (i.e., methotrexate, cis- or carboplatin, 5-fluorouracil, bleomycin, paclitaxel, docetaxel). 
High overall response rates exceeding 80% and complete response (CR) rates ranging from 20 
to 54% have been reported. Some of these will be histologically confirmed at surgery. Achieving 
a complete response (CR) to chemotherapy, particularly if confirmed histologically, correlates 
with a good prognosis; and patients not responding to induction chemotherapy generally are 
unlikely to respond to subsequent standard radiotherapy; the administration of chemotherapy 
generally does not jeopardize the administration of subsequent standard local therapy. 
There is increasing evidence suggesting that systemically active chemotherapy may prevent 
recurrences at distant sites. Distant recurrence after the eradication of the primary tumor and 
locoregional disease is presumably due to micrometastatic disease that the lower doses of 
chemotherapy administered as a component of chemoradiotherapy do not adequately treat. Even 
though in early trials a survival benefit could not be found, serious methodological deficiencies 
limit these trials (inadequate design, substandard local therapy, etc.). 
Induction chemotherapy continues to be frequently used in centers around the world and 
represents a good trial approach to investigate novel therapies and/or molecular correlates. In 
recent years randomized trials have further substantiated the finding that induction 
chemotherapy including a taxane and cisplatin can increase survival rates. Induction 
chemotherapy can produce CR rates in 30–65% of patients and overall response rates of 70–
85%. Two newer European studies have shown evidence of a survival benefit with induction 
chemotherapy: the Italian GSTTC study (Gruppo di Studio sui Tumori della Testa) demonstrated 
increased cure rates in a subset of nonoperable subjects and the French GETTEC trial (Groupe 
d’Etude des Tumeurs de la Tete et du Cou), which was closed early due to clear benefit. 
Furthermore a large meta-analysis by Pignon et al demonstrated a 5% increase in survival only 
for trials using a cisplatin/fluorouracil (5-FU) combination, reaching statistical significance 
(P<0.05). 
In addition, two trials comparing the triplet combination of a taxane (docetaxel or paclitaxel), 
cisplatin, and 5-FU (TPF) with doublet cisplatin/5-FU (PF) showed a survival benefit of the 
triplet over the doublet combination. However, the high rates of toxicity reported in TAX 323 
and TAX 324 led many oncologists to question the feasibility of TPF. In TAX 324, 21% of 
patients did not proceed to protocol-defined chemoradiotherapy and 7% of patients did not 
proceed to potentially curative therapy.7,9 Carboplatin and paclitaxel were used together in a 
phase II study consisting mainly of stage IV patients where a clinical complete RR of 100%, 3-

Alliance A091101 
 
Version Date: 08/11/2017 
10 
Update #07 
year OS of 70% and a 3-year progression-free survival (PFS) of 90% were demonstrated 
following completion of definitive chemoradiotherapy.12 Although the regimen was less toxic 
compared with TPF, RR to induction chemotherapy was preserved; RR to TPF in TAX 323 and 
TAX 324 was 68 and 72%, respectively. The single institution experience of our center 
comparing induction chemotherapy with carboplatin and paclitaxel (CT) with TPF showed that 
the 1 year locoregional control was 80.5% for CT compared to 55.5% for TPF (HR 
0.32,P = .0002).53 The 1 year progression free survival was 73.2% for CT compared to 60.7% 
for TPF (HR 0.57;P = .02). On multivariable analysis, CT remained significant for LRC (HR 
0.28; P = 0.04). TPF induction chemotherapy was associated with worse renal toxicity as 
measured by peak creatinine increases during induction chemotherapy (P = 0.001). TPF was 
also associated with a trend toward more chemotherapy dose reductions or changes in systemic 
agents during concurrent chemoradiotherapy (43.4% for TPF vs. 27.8% for CT; P = 0.06). 
Further evidence to support not using TFP in this clinical trial comes from an early version of 
this phase 1 protocol, where three patients with locally advanced disease were treated with ABT-
888 40mg bid and TPF. Remarkably, all three patients developed neutropenic fever, what would 
require dose reductions, even at supposedly low doses of ABT-888 (40mg bid). To justify this 
statement, the ABT-888 MTD in combination with carboplatin and paclitaxel in the GOG 9923 
in metastatic ovarian cancer was 200mg bid. Further, several groups have demonstrated that 
induction chemotherapy with carboplatin–paclitaxel provided a complete response rate and 
partial response rate from 8% to 33% and from 50% to 85%, respectively.54-58 Furthermore, the 
PFS and OS were consistently between 60-80%. In many of these prospective series, patients 
tolerated CT and subsequent concurrent chemoradiotherapy with minimal additional toxicity. 
This protocol thus elected to use carboplatin-paclitaxel as the induction chemotherapy regimen.  
Carboplatin is a commonly used platinum compound that acts by binding to DNA and 
interrupting cell division.  It is approved by the FDA for the treatment of patients with 
ovarian cancer. It is also used for the treatment of non-small cell lung cancer, small cell lung 
cancer, head and neck cancer, endometrial cancer, metastatic seminoma and more recently 
in breast cancer. Carboplatin is eliminated by renal excretion. The clearance is related to the 
glomerular filtration rate. Therefore it is dosed based on the GFR and the target area under the 
concentration versus time curve (AUC). The main side effect of carboplatin is 
myelosuppression. Other toxicities include nausea, vomiting, renal and neurotoxicity. 
2.4 
Concurrent chemoradiotherapy  
Results of many recently published phase III trials
 
show that chemotherapy given concurrently 
with radiation yields better LRC and survival rates than radiation alone in patients with locally 
advanced squamous cell carcinoma of the head and neck (SCCHN).1-5 
2.4.1 Concurrent accelerated radiotherapy and cisplatin 
The Radiation Therapy Oncology Group (RTOG) 0522 trial (N = 940) is the most recent 
Cooperative group trial that showed benefit of concurrent accelerated radiotherapy and 
cisplatin (AFX-Cis).5 The primary objective of this study was to evaluate whether the 
addition of cetuximab to cisplatin would improve disease-free survival. Secondly, the study 
assessed overall survival, local-regional control, acute and late toxicities and quality of life. 
It showed no benefit to adding cetuximab to the radiation/cisplatin platform for front-line 
therapy of advanced head and neck squamous cell carcinoma. At 2 years, progression-free 
survival was approximately 64% in both arms; overall survival was 79.7% with 
chemoradiotherapy (P = .68) and 82.6% with the addition of cetuximab (P = .17). Rates of 
locoregional relapse and distant metastases were also similar. However, cetuximab 
increased grade 3/4 mucositis (43% vs 33%;P < .004), in-field skin toxicity (25% vs 
15%;P < .001), and out-of-field skin reactions (19% vs 1%;P < .001), but toxicity beyond 

Alliance A091101 
 
Version Date: 08/11/2017 
11 
Update #07 
90 days was similar between the arms. Given that this was a Cooperative Group Trial with 
several participating institutions, this protocol will allow concurrent chemoradiotherapy 
with concurrent accelerated radiotherapy and cisplatin.  
2.4.2 TFHX Regimen 
Many clinical trials for patients with LAHNC in the Chicago Oral Cancer Center Network 
have continued to use the hydroxyurea, 5-FU, paclitaxel and radiotherapy (TFHX) regimen 
as previously defined. Despite the high locoregional control and high survival rates, three 
problems were identified: distant failure emerged as the predominant site of failure, 
mucositis was often severe and sometimes resulted in long-term functional impairment, and 
toxicities related to chemotherapy (specifically neuropathy and myelosuppression) often 
resulted in dose reduction and patient impairment. To address the first problem, we added 
induction chemotherapy to precede concomitant chemoradiotherapy. In designing the 
induction chemotherapy regimen, we selected the combination of carboplatin and paclitaxel, 
a regimen that is well tolerated and that would not result in mucositis or dermatitis as 
significant toxicity to avoid overlapping toxicities with the subsequent administration of 
TFHX. 
 We also addressed the second goal of reducing toxicity and improving functional 
performance. The exceedingly high local and regional control rates observed in all TFHX 
studies suggested that a careful attempt to reduce the radiation therapy field sizes to 
minimize long-term treatment sequelae would be feasible. The results of this trial 2 
involving 69 patients revealed response to induction chemotherapy to be PR 52% and CR 
35%. Symptomatically, there was a significant reduction in mouth and throat pain. The most 
common grade 3 or 4 toxicity was neutropenia (36%) while 33% of patients experienced 
neuropathy. Best response following completion of TFHX was CR in 83%. Toxicities of 
TFHX consisted of grade 3 or 4 mucositis (74% and 2%), and dermatitis (47% and 14%). 
At a median follow up of 28 months, locoregional or systemic disease progression have each 
been noted in five patients. The overall three year progression-free survival is 80% (95% 
confidence interval (CI): 71%-90%) and the two and three year overall survival rates are 
77% (95% CI: 66%-87%) and 70%, (95% CI: 59%-82%), respectively. At 12 months, 5 
patients were completely feeding tube dependent (patients who died without disease 
progression were censored from the PFS analysis). Similar results were reported in two 
follow-up studies using the TFHX platform.9 Thus the TFHX regimen can serve as a solid 
institutional standard chemoradiotherapy regimen to follow novel investigational induction 
chemotherapy regimens. 
2.4.3 Radiotherapy 
Radiotherapy doses currently employed during concurrent chemoradiotherapy are largely 
empirically derived from tumor control and normal tissue toxicity probabilities of patients 
treated with radiotherapy alone. The gross tumor volume (GTV) includes all known gross 
disease detected on physical or radiographic examination both at the primary and neck 
before. Planning target volume 1 (PTV1) includes the GTV plus a 1.5 cm expansion. PTV2 
includes PTV1 plus the first echelon of uninvolved lymph nodes. The PTV1 is a margin of 
error around visible tumor and this area receives the maximum dose of radiotherapy. In 
addition, areas at risk for microscopic disease encompassing draining lymph nodes are also 
treated and usually include bilateral cervical lymph node stations. In a subset analysis of 
data assessing disease recurrence from multi-institutional studies administering FHX-based 
chemoradiotherapy, it became apparent that locoregional failures overwhelmingly occurred 
in PTV1. This was especially true in subjects who attained a complete response to induction 
chemotherapy where no failures were recorded outside PTV1 in these patients. However, 

Alliance A091101 
 
Version Date: 08/11/2017 
12 
Update #07 
much of the long-term toxicity of chemoradiotherapy can be directly attributed to inclusion 
of cervical lymph nodes at risk for microscopic disease.  
2.5 
Risk Stratification in LAHNC 
It is critical that the appropriate patient population be studied if any benefit is to be identified. 
Under the hypothesis that patients unlikely to develop distant metastases are also unlikely to 
benefit from the addition of induction chemotherapy, the question of what the best information 
that might allow us to best select the patients at highest risk for this event is paramount.  
Prior published studies at the University of Chicago indicate that advanced nodal stage is a 
predictor for the development of distant metastatic disease after aggressive concurrent 
chemoradiotherapy6. In addition, there is also evidence that T stage, or local extension of the 
tumor, is also a predictor of distant failure after concurrent chemoradiotherapy.11 Thus, nodal 
and T-stage will be used to stratify patients at randomization into low versus high risk groups 
for distant metastases. (T1-3 and N0-N2a versus N2b-.N3 and/or T4, respectively).  
Given the fact that institutions will be able to select between 2 different chemoradiotherapy 
regimens prior to treating their patients, patients will be also stratified by treating institution. 
2.5.1 Oropharyngeal cancer and Human papillomavirus (HPV) 
The presence of HPV DNA is strongly associated with oropharynx cancer and thought to be 
an etiologic agent. Patients with HPV positive oropharynx cancer not only appear to have a 
different clinical phenotype than HPV- cancers but multiple large studies have demonstrated 
a better outcome for these patients even when correcting for other known prognostic 
factors.12 Thus, patients with HPV+ oropharynx cancer, compared to their HPV- 
counterparts, demonstrate higher response rates to induction chemotherapy, better 
locoregional control when treated with concomitant chemoradiotherapy, and better overall 
survival. Interestingly, tobacco exposure, especially greater than 10 pack-years, appears to 
modulate the effect of HPV positivity on outcomes and increases the risk of disease 
recurrence and mortality. Patients with HPV+ oropharynx cancer with significant tobacco 
exposure (>10 pack-years) appear to have an intermediate risk of dying from disease 
between HPV+/non-smokers and HPV- patients. Therefore, the outcome of any therapeutic 
approach must now be evaluated in the context of subject HPV status while some 
investigators have advocated for clinical trials de-intensifying treatment to HPV+ patients. 
A recently reported large phase III trial of the Radiation Therapy Oncology Group (RTOG 
0129) revealed no differences in the overall survival (OS) and progression free survival 
(PFS) rates between accelerated fractionation and standard fractionation when combined 
with concurrent high-dose cisplatin.12 The success rate in collecting a high number of 
pretreatment tumor specimens enabled the investigators to establish firmly that the tumor 
HPV status is to date the strongest, independent prognostic factor in patients treated with 
radiation-cisplatin regimen. In addition, the investigators were able to divide patients into 
categories of low, intermediate or high risk of death based on HPV status, smoking history, 
and tumor stage.  
Recursive-partitioning analysis showed that the HPV status of the tumor was the major 
determinant of overall survival, followed by the number of pack-years of tobacco smoking 
(≤10 vs. >10) and then nodal stage (N0 to N2a vs. N2b to N3), for HPV-positive tumors, or 
tumor stage (T2 or T3 vs. T4), for HPV-negative tumors. Their analysis classified patients 
with oropharyngeal squamous-cell carcinoma into three categories with respect to the risk 
of death: low risk, with a 3-year rate of overall survival of 93.0%; intermediate risk, with a 
3-year rate of 70.8% (hazard ratio for the comparison with low risk, 3.54; 95% CI, 1.91 to 
6.57); and high risk, with a 3-year rate of 46.2% (hazard ratio for the comparison with low 

Alliance A091101 
 
Version Date: 08/11/2017 
13 
Update #07 
risk, 7.16; 95% CI, 3.97 to 12.93). Patients with HPV-positive tumors were considered to 
be at low risk, with the exception of smokers with a high nodal stage (i.e., N2b to N3), who 
were considered to be at intermediate risk; patients with HPV-negative tumors were 
considered to be at high risk, with the exception of nonsmokers with tumors of stage T2 or 
T3, who were considered to be at intermediate risk.  
Risk-stratification algorithms based on biomarkers, especially HPV status, in LAHNC have 
recently been incorporated into clinical trials. The option that CRT and the addition of 
biologics should focus on HPV-negative patients, and that for HPV-positive patients, 
researchers should look at less intense options that might spare these patients some of the 
long-term morbidities of CRT (mainly the radiotherapy component) is very attractive. This 
approach has been studied by the Eastern Cooperative Oncology Group (ECOG) - trial 
ECOG 1308 - targeting specifically HPV-positive patients, and the Radiation Therapy 
Oncology Group (RTOG), with both groups assessing the addition of cetuximab. 
In order to differentiate low risk patients from others, we will be applying similar 
classification criteria for study inclusion, based on Ang et al.12 Please notice we will be 
adding non-OPC tumors as high-risk and dividing the patients into 2 groups: low-risk and 
high-risk. We will be condensing the original Ang et al “intermediate and high-risk groups” 
into a high risk group, given the similarity of the confidence intervals of overall survival, as 
below. 
The 3-year rates of overall survival were 93.0% (95% CI, 88.3 to 97.7) in the low-risk group, 
70.8% (95% CI, 60.7 to 80.8) in the intermediate-risk group, and 46.2% (95% CI, 34.7 to 
57.7) in the high-risk group. Adapted from Ang et al.12 
In summary, the risk classification criteria used for study inclusion will be: 
Low risk Locally Advanced Head and Neck Cancer (LAHNC), not eligible for study 
inclusion:  
• Oropharyngeal cancer (OPC), HPV positive, with less than 10 pack year smoking history 
(any nodal status) 
• OPC, HPV positive, with at least a 10 pack year smoking history, and N0-N2a disease 
High risk LAHNC: 
• Stage IVa-b Squamous Cell Carcinoma (SCC) other than OPC, OR  
• OPC, HPV negative, Stage IVa-b SCC 
• OPC, HPV positive with at least a 10 pack-year smoking history, and N2b-N3 disease 
are not eligible for the Phase 1 study component, but eligible for Phase 2 
HPV Determination 
Patients with oropharyngeal cancers must have their tumor HPV status (either positive or 
negative) prior to stratification.  There is currently no standard approach for HPV testing of 
clinical samples and, as such, individual institutions can determine the tumor HPV status by 
their method of choice. Acceptable methods of determination include: 
• P16 by immunohistochemistry (IHC) as a surrogate for the function of the high-risk 
(HR) HPV E7 protein. 
• HPV 16 insitu hybridization (ISH) 
• HPV DNA detection by polymerase chain reaction (PCR) 

Alliance A091101 
 
Version Date: 08/11/2017 
14 
Update #07 
2.6 
ABT-888 (Veliparib) 
ABT-888 is an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase 
(PARP).  PARP is an essential nuclear enzyme that plays a role in recognition of DNA damage 
and facilitation of DNA repair.  Therefore, inhibition of PARP is expected to enhance the effects 
of DNA damage.  Expression of PARP is higher in tumor cells as compared to normal cells.  This 
overexpression has been linked to drug resistance and the ability of tumor cells to withstand 
genotoxic stress.  Hence, it is anticipated that PARP inhibitors will function as sensitizing agents 
for chemotherapy and radiation therapy that are designed to cause DNA damage. 
2.6.1 Mechanism of Action 
Poly (ADP-ribosyl)ation (PAR) occurs after single or double-stranded DNA damage and 
represents the posttranslational modification of histones and other nuclear proteins by PARP.  
Based on conserved genetic sequences, encoded for by 18 different genes, 18 nuclear 
proteins have been classified as members of the PARP superfamily.  The superfamily is 
further subdivided into three branches, the PARP-1 group, the tankyrase group, and other 
PARP enyzmes.  The PARP-1 group of NAD+-dependent enzymes has been extensively 
studied, and its members PARP-1 and PARP-2 are generally considered as the primary 
enzymes involved in DNA repair 13. 
PAR has been implicated in many cellular processes including replication, transcription, 
differentiation, gene regulation, protein degradation, and spindle maintenance.  Enhanced 
PARP-1 expression and/or activity in tumor cells, as compared to normal cells, has been 
demonstrated in malignant lymphomas 14, hepatocellular carcinoma 15, cervical carcinoma 
16, colorectal carcinoma 17, non-Hodgkin's lymphoma 18, leukemic lymphocytes 19, and colon 
adenomatous polyps 20.  PARP-1 and PARP-2 are nuclear proteins and are the only members 
of the PARP family with zinc-finger DNA binding domains.  These domains localize PARP-
1 and PARP-2 to the site of DNA damage.  PARP-1 is highly conserved and has three 
structural domains (N-terminal DNA-binding domain; automodification domain, and the 
NAD+-binding domain).  The catalytic domain is located at the C-terminus end of the 
protein.  In knockout mouse models, deletion of PARP-1 is sufficient to impair DNA repair 
21-23.  The residual PARP-dependent repair activity (~ 10%) is due to PARP-2.  This suggests 
that only PARP-1 and PARP-2 need to be inhibited to impair DNA repair 24-26. 
The zinc finger domain of PARP binds to both single- and double-stranded DNA breaks, 
resulting in increased catalytic activity 24,26,27.  Once activated, PARP cleaves NAD+ and 
attaches multiple ADP-ribose units to the target nuclear protein. This results in a highly 
negative charge on the target protein and affects its function.  Overactivation of PARP can 
be induced by DNA damage, leading to the depletion of NAD+ and energy stores and, thus, 
cellular demise by necrosis.  An alternate mechanism has been identified where PARP 
overactivation can induce cell death through apoptosis by releasing the Apoptosis Inducing 
Factor (AIF) from mitochondria 28.  Consequently, multiple mechanisms to prevent 
overactivation of PARP exist.  First, auto-PAR negatively regulates PARP activity 29.  In 
addition, the cleavage of PARP by caspases yields a peptide fragment that acts as a trans-
dominant negative inhibitor for uncleaved PARP.  PAR of proteins is a dynamic process with 
a short half-life (t1/2) of <1 min.  The enzymes responsible for degrading these polymers are 
poly(ADP-ribose) glycohydrolase (PARG), which cleaves ribose-ribose bonds, and ADP-
ribosyl protein lyase, which removes the protein proximal to the ADP-ribose monomer. 
Increased PARP activity is one of the mechanisms by which tumor cells avoid apoptosis 
caused by DNA damaging agents.  PARP activity is essential for the repair of single-stranded 
DNA breaks through the base excision repair (BER) pathways 26,30. Therefore, inhibition of 
PARP sensitizes tumor cells to cytotoxic agents (e.g. alkylators [temozolomide, 

Alliance A091101 
 
Version Date: 08/11/2017 
15 
Update #07 
cyclophosphamide, BCNU] and topoisomerase I inhibitors [irinotecan, camptothecin, 
topotecan]) which induce DNA damage that would normally be repaired through the BER 
system.  A significant therapeutic window appears to exist between a PARP inhibitor’s 
ability to potentiate therapeutic benefit versus potentiation of undesirable side effects.  As 
expected, PARP inhibitors do not potentiate agents that do not cause DNA damage. 
Ionizing radiation induces both double- and single-stranded DNA breaks.  While part of the 
radiosensitization caused by PARP inhibition is through the inhibition of the single-stranded 
break repair pathways, it appears likely that repair of double-stranded breaks, which are 
thought to be more cytotoxic, is also affected.  Double-stranded breaks are strong activators 
of PARP-1, resulting in PARP-1 mediated activation of DNA-PK and Ku80, important 
components of the non-homologous end-joining (NHEJ) double-stranded break repair 
pathway 31,32.  Also, small molecule inhibitors of PARP can directly inhibit the repair of 
double-stranded breaks 21,33.  Thus, it is likely that PARP activity is important for repair of 
both the single- and double-stranded stranded DNA breaks caused by ionizing radiation. 
2.6.2 Nonclinical Activity 
 
 
 
 
  The extent of DNA damage 
in cells was indicated by γ-H2AX levels.  To determine the effect of ABT-888 in 
combination with cytotoxic agents on DNA damage, the cellular content of γ-H2AX in C-
41 cells was assayed by flow cytometry using an anti-γ-H2AX antibody.  Addition of 1 mM 
of temozolomide alone resulted in increased numbers of γ-H2AX foci, a result which was 
further potentiated by ABT-888 in a dose-dependent manner.  When cell survival was 
measured by an AlamarBlue assay, ABT-888 potentiated cytotoxicity in the same 
concentration range as used in the γ-H2AX assay, demonstrating that ABT-888 potentiates 
cytotoxicity of temozolomide by delaying DNA repair.  ABT-888 achieved a maximal 
potentiation of approximately 15-fold.  ABT-888 also potentiates the DNA damage cause 
by irinotecan. 
 
 
 
 
PARP inhibition was shown to sensitize cells that are 
mismatch repair (MMR)-deficient to a greater extent than cells that are MMR competent 34.  
Alkylating agents such as temozolomide form methyl adducts in DNA and resistance is 
frequently encountered in the clinic with either the overexpression of O6-alkylguanine DNA 
alkyltransferase (AGT) or functional defects in the MMR system.  However, when PARP 
was inhibited, cells were sensitized to methylpurine formation, regardless of their resistance 
factors 35. 
There are data to suggest that PARP inhibitors have activity against some BRCA-deficient 
cells in the absence of any DNA damaging agent 36,37.  These inhibitors did not demonstrate 
single agent activity in BRCA-competent cells, and restoring functional BRCA to deficient 
cells abrogated single agent cytotoxicity.  It is possible that, in BRCA-deficient cells, PARP 
inhibition stops the BER pathway, and thus single-stranded breaks are carried through DNA 
synthesis, resulting in double-stranded breaks.  The increase in double-stranded breaks 
cannot be repaired by homologous recombination (HR), due to the lack of BRCA1 or 2, 

Alliance A091101 
 
Version Date: 08/11/2017 
16 
Update #07 
resulting in increased cell death.  However, since not all BRCA deficient cells are sensitive 
to the PARP inhibitors, it is unclear why single agent cytotoxicity is observed in some 
BRCA-deficient cells. 
Consistent with PARP-1 being a radiosensitization target, PARP-1 knockout mice showed 
enhanced sensitivity to γ-radiation 38,39.  There is evidence to suggest that PARP inhibitors 
sensitize cancer cells to radiation, both in vitro and in vivo 40-42.  Furthermore, a PARP 
inhibitor in the same class as ABT-888 potentiated radiation in the HCT116 colon 
carcinoma model.  ABT-888 was tested, in combination with cytotoxic agents, in several 
tumor models and demonstrated a similar profile of antitumor activity to that seen in the 
literature.  ABT-888 substantially increased the efficacy of cytotoxic therapies, when 
measured by either treated/control tumor volumes (%T/C) or by increased time for tumors 
to grow to a particular size (%ILS). 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
17 
Update #07 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
18 
Update #07 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 

Alliance A091101 
 
Version Date: 08/11/2017 
19 
Update #07 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
20 
Update #07 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
2.6.4 Clinical Investigations 
A single-dose pharmacokinetic and pharmacodynamic endpoint study in cancer patients was 
initiated under an exploratory IND by the National Cancer Institute as the initial study in 
their phase 0 program (Kummar et al., 2009).  In this study, participants had baseline 
assessments of PAR in peripheral blood mononuclear cells (PBMCs) and at higher dose 
levels, in tumor from needle biopsies, assessed by a validated immunoassay.  Participants 
received a single dose of ABT-888 at 10, 25, or 50 mg.  PBMCs were collected over a 24 
hour period at all dose levels, and tumor biopsies were obtained at the 25 mg dose level, 
approximately 3 to 6 hours after administration of ABT-888. A total of 6 patients have been 
studied so far, 3 each for the 10 mg and 25 mg cohorts. No treatment related adverse events 
have been observed. The target plasma Cmax of 210 nM was exceeded in 2 of 3 patients at 
the 10 mg dose level, and in all three patients for at least 4 hours at the 25 mg dose level.  
Levels of PAR were reduced 80-99% from baseline levels after administration of ABT-888 
in both the PBMCs and tumor samples at the 25 mg dose level. Thus, there is reason to 
believe that target inhibition is seen at least at the 25 mg dose level, and may be occurring 
at doses lower than 25 mg. 
Currently, several combination phase I trials are underway.  Also, single agent trial had been 
initiated in the BRCA deficient population. Most recently, a phase I trial of ABT-888 with 
doxorubicin(A) and cycyphosphamide (C) was reported.44 ABT-888 (doses ranged from 50 
to 150 mg every 12 h on days 1 - 4 with fixed dosing of AC (60/600 mg/m2) on day 3 every 
21 days. Further A was omitted after a cumulative dose of 420 mg/m2. The MTD of ABT-
888 was 100 mg every 12 h with AC every 21 days. Two instances of grade 3 febrile 
neutropenia were considered dose-limiting at the 150 mg ABT-888 dose level. MTD of 
ABT-888 was 100 mg every 12 h with AC. Drug-related toxicities included fatigue and 
myelosuppression.  
Another phase I study sought to evaluate ABT-888 with irinotecan in solid tumors.45 Cycles 
were administered every 21 days. Irinotecan was given intravenoulsy. 100 mg/m2 over 90 

Alliance A091101 
 
Version Date: 08/11/2017 
21 
Update #07 
min on Days 1 and 8. Twice daily (BID) oral dosing of ABT-888 (10-50mg) occurred  on 
days 3-14  (Cycle 1) and Days -1-14 (subsequent cycles) followed by a 6-day rest. The MTD 
and recommended phase II dose was established as 100 mg/m2 of irinotecan given days 1 
and 8 combined with 40 mg of ABT-888 given BID 15 days on/6 days off  in a 21 day cycle. 
Most frequent drug-related toxicities included: diarrhea (59%), nausea (56%), leukopenia 
(50%), fatigue (47%), neutropenia (47%), anemia (34%), and vomiting (31%). DLTs 
included fatigue, diarrhea, febrile neutropenia (grade 3), leukopenia and, neutropenia (grade 
4). 
Further detailed information regarding ABT-888 clinical development, safety and efficacy 
is provided in the Investigator’s Brochure. 
2.7 
Rationale for Combination of ABT-888 and Induction Chemotherapy 
With respect to chemotherapy and radiotherapy modifiers, a promising new area investigation 
is the use of PARPi to improve both cytotoxic modalities. PARP is involved in several forms of 
DNA repair including single and double strand break repair as well as base excision repair. It is 
likely that PARP also provides accessibility of the chromatin to DNA repair enzymes through 
relaxation of chromatin structure. Inhibition of PARP decreases the repair of single stranded 
DNA breaks through an interaction with ERCC1 and newly synthesized replication forks are 
particularly sensitive to PARP inhibition. It is likely that PARP inhibition directly impedes the 
repair of double strand DNA breaks although its effects may also be achieved by inhibiting the 
repair of multiple single strand breaks. PARP is a major pharmacological target for improving 
chemotherapy and radiotherapy and clinical trials in breast ovary, brain tumors and pancreatic 
cancer are underway with additional clinical trials in other tumors about to be initiated. The 
concept of “synthetic lethality” that is blocking a repair pathway in tumors that are defective in 
another repair pathway has become an important model for the use of PARPi in breast and 
ovarian cancer patients. Patients defective in BRAC1 and BRAC2 mediated homologous repair 
are proposed to be sensitive to PARPi which block the non-homologous repair pathway.  
However the therapeutic effects of PARPi alone even in patients with BRCA1 and BRAC2 
mutations is fairly modest pointing to combination therapy as the most promising direction for 
the use of PARPi. In general tumor cell death achieved through the interaction of PARP 
inhibition with chemotherapy and radiotherapy is proposed to occur through mitotic (necrotic) 
or apoptotic cell death. A novel set of data underpinning our proposal is that inhibition of PARP 
combined with radiotherapy and chemotherapy also accelerates senescence and might provide 
an alternative pathway to achieve anti-tumor effects especially in tumor cells resistant to necrotic 
or apoptotic death. We propose that accelerating DNA damage induced senescence by PARPi 
may be a novel approach to cancer therapy. The hypothesis is that the addition of a PARP 
inhibitor (ABT-888) to induction chemotherapy for LAHNC will be feasible and lead to 
measureable differences in clinical outcome parameters, especially complete (or near complete) 
response rate, as well as correlate with expression of cellular targets and potential biomarkers. 
2.8 
Correlatives Studies Background  
PARP is a nuclear enzyme that recognizes DNA damage and facilitates DNA repair.26,46,47 
Activation of PARP-1 and PARP-2 enzymes is an essential step in the recognition of DNA 
damage that results in the poly(ADP-ribosyl)ation of many nuclear target proteins, including 
those that facilitate DNA repair. DNA repair pathways can be divided into those that involve 
single-stranded DNA breaks and those that involve double-stranded DNA breaks. PARP activity 
is essential for the repair of single-stranded DNA breaks through the Base Excisional Repair 
(BER) pathways.18,30,48 PARP activity also has been demonstrated to be an important modulator 
of the nonhomologous end-joining and homologous recombination double-stranded break repair 
pathways. Consequently, inhibition of PARP should enhance the effects of DNA-damaging 

Alliance A091101 
 
Version Date: 08/11/2017 
22 
Update #07 
agents, including alkylators, platinums, topoisomerase poisons, and radiation therapy. Higher 
expression of PARP in cancer cells compared to normal cells has been linked to drug resistance 
and the overall ability of cancer cells to sustain genotoxic stress.14,15,20,49 Therefore, PARP 
inhibitors are proposed as sensitizing agents for a variety of DNA-damaging agents.  
A novel set of data underpinning our proposal is that inhibition of PARP combined with 
radiotherapy and chemotherapy also accelerates senescence and might provide an alternative 
pathway to achieve anti-tumor effects especially in tumor cells resistant to necrotic or apoptotic 
death. We thus propose that accelerating DNA damage induced senescence by PARPi may be a 
novel approach to cancer therapy. 
As such, this study will be amended after phase 1 is completed to ask patients to undergo 
research tumor biopsy prior to induction chemotherapy and during carboplatin-paclitaxel 
administration in order to optimize measurements of the interaction of ABT-888 with 
carboplatin-paclitaxel chemotherapy and its effects on tumor cells on-treatment, biopsies will 
be obtained on day 4 of the carboplatin-paclitaxel chemotherapy administration during cycle 1. 
The investigators believe that day 4 biopsy will be able to demonstrate DNA damage, activation 
of P21 and P16 pathways, and γH2Ax. The investigators expect that the peak without PARP 
inhibitors will have passed at day 4.  The reason for biopsying at day 4 is to see if in the presence 
of PARP inhibitors, the DSDNA breaks persist longer than without ABT 888. 
γ-H2AXand poly (ADP-ribose) as suggested by Redon et al., 2010: tumor cells are often 
deficient in DNA damage response (DDR) pathways, and anticancer therapies are commonly 
based on genotoxic treatments using radiation and/or drugs that damage DNA directly or 
interfere with DNA metabolism, leading to the formation of DNA double-strand breaks (DSB), 
and ultimately to cell death. Because DSBs induce the phosphorylation of histone H2AX 
(γH2AX) in the chromatin flanking the break site, an antibody directed against γH2AX can be 
employed to measure DNA damage levels before and after patient treatment. Poly(ADP-ribose) 
polymerases (PARP1 and PARP2) are also activated by DNA damage, and PARP inhibitors show 
promising activity in cancers with defective homologous recombination (HR) pathways for DSB 
repair. 
Other markers of value in SCCHN or determinants of sensitivity to PARP inhibitors, including 
testing for EGFR, MET and p16 (HPV) expression and analysis of PTEN, P16 and BRCA1 
mutations will also be analyzed. 

Alliance A091101 
 
Version Date: 08/11/2017 
23 
Update #07 
3.0 
PATIENT SELECTION 
3.1 
Eligibility Criteria for Phase 1 Component 
3.1.1  Documentation of Disease: Patients who are treatment naïve, high risk, stage IVa/IVb (all 
other sites) and histologically proven squamous cell carcinoma of the head and neck 
(SCCHN) with no definitive evidence of metastatic disease, excluding patients with 
oropharynx HPV-positive tumors. 
 
In summary, those patients eligible are newly diagnosed and treatment naive:  
• Stage IVa-b Squamous Cell Carcinoma other than Oropharyngeal Cancer (OPC), OR 
• Oropharyngeal Cancer (OPC) HPV-negative, Stage IVa-b 
3.1.2 Measurable Disease: Patients must have at least one measurable site of disease according 
to RECIST criteria. i.e., patients must have measurable disease, defined as at least one lesion 
that can be accurately measured in at least one dimension (longest diameter to be recorded 
for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional 
techniques or as ≥10 mm with spiral CT scan MRI, or calipers by clinical exam.  See Section 
11.2 for the evaluation of measurable disease. 
3.1.3 ECOG performance status 0-1.   
3.1.4 Age >18 years.   
3.1.5 Patients must be able to swallow the drug. 
3.1.6  Ability to understand and the willingness to sign a written informed consent document. 
3.1.7 Required Lab Values:  
leukocytes ≥ 3,000/mm3 
absolute neutrophil count ≥ 1,500/ mm3 
platelets ≥ 100,000/ mm3 
total bilirubin ≤ 1.5 Institutional upper limit of normal (ULN) 
SGOT(AST) and SGPT(ALT) ≤ 2.5 X institutional ULN 
creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with 
creatinine levels above ULN* 
* As calculated by Cockcroft-Gault. 
3.1.8 Patients who are receiving any other investigational agents are not eligible.  
3.1.9 Patients with active seizure or a history of seizure are not eligible. 
3.1.10 Patients with a history of allergic reactions attributed to compounds of similar chemical or 
biologic composition to ABT-888 or other agents used in study, including cremophor, 
carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar 
chemical or biologic composition are not eligible. 
3.1.11 Patients with impairment of gastrointestinal function or gastrointestinal disease that may 
significantly alter the absorption of ABT-888 (e.g., ulcerative disease, uncontrolled nausea, 
vomiting, diarrhea, malabsorption syndrome or small bowel resection) are not eligible to 
participate in this study. 

Alliance A091101 
 
Version Date: 08/11/2017 
24 
Update #07 
3.1.12 Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that would limit compliance with study 
requirements are not eligible to participate in the study. 
3.1.13 Pregnant women are not eligible to participate in this study. NOTE: Women of child 
bearing potential must have a negative serum or urine pregnancy test within 7 days prior to 
treatment. ABT-888 is a PARP inhibitor with the potential for teratogenic or abortifacient 
effects. 
• Women of child-bearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence) prior to study entry and for 
the duration of study participation. Should a woman become pregnant or suspect she is 
pregnant while she or her partner is participating in this study, she should inform her 
treating physician immediately. 
• Because there is an unknown but potential risk for adverse events in nursing infants 
secondary to treatment of the mother with ABT-888, breastfeeding should be 
discontinued if the mother is treated with ABT-888. These potential risks may also 
apply to other agents used in this study. 
3.1.14 HIV-positive patients on combination antiretroviral therapy are not eligible because of the 
potential for pharmacokinetic interactions with ABT-888.  
3.1.15 Patients receiving chronic, systemic treatment with corticosteroids or another 
immunosuppressive agent are not eligible to participate in this study. Topical or inhaled 
corticosteroids are allowed. 
3.1.16 Patients with other malignancies within the past 2 years, except for adequately treated 
carcinoma of the cervix or basal or squamous cell carcinomas of the skin or surgically 
treated early stage solid tumors are ineligible to participate in this study. 
3.2 
Eligibility Criteria for Phase 2 Component 
3.2.1 Documentation of Disease: Patients who are treatment naïve, high risk, stage IVa/IVb (all 
other sites) histologically proven Squamous Cell Carcinoma of the Head and Neck 
(SCCHN) with no definitive evidence of metastatic disease. 
In summary, those patients eligible are: 
• Stage IVa-b SCCHN other than oropharyngeal Cancer (OPC), OR  
• OPC, HPV-negative, IVa-b, OR 
• OPC, HPV positive, with greater than 10 pack-year smoking history and N2b-N3 
disease  
3.2.2 Measurable disease: Patients must have at least one measurable site of disease according 
to RECIST criteria. i.e., patients must have measurable disease, defined as at least one lesion 
that can be accurately measured in at least one dimension (longest diameter to be recorded 
for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional 
techniques or as ≥10 mm with spiral CT scan MRI, or calipers by clinical exam.  See Section 
11.2 for the evaluation of measurable disease. 
3.2.3 ECOG performance status 0-1. 

Alliance A091101 
 
Version Date: 08/11/2017 
25 
Update #07 
3.2.4 Age ≥18 years.   
3.2.5 Patients must be able to swallow the drug. 
3.2.6 Ability to understand and the willingness to sign a written informed consent document. 
3.2.7 Required Lab Values:  
leukocytes ≥ 3,000/mm3 
absolute neutrophil count ≥ 1,500/ mm3 
platelets ≥ 100,000/ mm3 
total bilirubin ≤ 1.5 Institutional upper limit of normal (ULN) 
SGOT(AST) and SGPT 
(ALT) 
≤ 2.5 X institutional ULN 
creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine 
levels above ULN* 
* As calculated by Cockcroft-Gault. 
3.2.8 Patient History: Patients who are receiving any other investigational agents are not eligible.  
3.2.9 Patients with active seizure or a history of seizure are not eligible. 
3.2.10 Patients with a history of allergic reactions attributed to compounds of similar chemical or 
biologic composition to ABT-888 or other agents used in study, including cremophor, 
carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar 
chemical or biologic composition are not eligible. 
3.2.11 Patients with impairment of gastrointestinal function or gastrointestinal disease that may 
significantly alter the absorption of ABT-888 (e.g., ulcerative disease, uncontrolled nausea, 
vomiting, diarrhea, malabsorption syndrome or small bowel resection) are not eligible to 
participate in this study. 
3.2.12 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, 
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or 
psychiatric illness/social situations that would limit compliance with study requirements are 
not eligible to participate in this study. 
3.2.13 Pregnant women are not eligible to participate in this study. NOTE: Women of child 
bearing potential must have a negative serum or urine pregnancy test within 7 days prior to 
treatment. ABT-888 is a PARP inhibitor with the potential for teratogenic or abortifacient 
effects. 
• Women of child-bearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence) prior to study entry and for 
the duration of study participation. Should a woman become pregnant or suspect she 
is pregnant while she or her partner is participating in this study, she should inform her 
treating physician immediately. 
• Because there is an unknown but potential risk for adverse events in nursing infants 
secondary to treatment of the mother with ABT-888, breastfeeding should be 
discontinued if the mother is treated with ABT-888. These potential risks may also 
apply to other agents used in this study. 
3.2.14 HIV-positive patients on combination antiretroviral therapy are not eligible because of the 
potential for pharmacokinetic interactions with ABT-888.  

Alliance A091101 
 
Version Date: 08/11/2017 
26 
Update #07 
3.2.15 Patients receiving chronic, systemic treatment with corticosteroids or another 
immunosuppressive agent are not eligible to participate in this study. Topical or inhaled 
corticosteroids are allowed. 
3.2.16 Patients with other malignancies within the past 2 years, except for adequately treated 
carcinoma of the cervix or basal or squamous cell carcinomas of the skin or surgically 
treated early stage solid tumors are ineligible to participate in this study. 
3.3 
Inclusion of Women and Minorities  
Both men and women of all races and ethnic groups are eligible for this trial.  
4.0 
REGISTRATION/RANDOMIZATION PROCEDURES AND STRATIFICATION 
Informed Consent  
The patient must be aware of the neoplastic nature of his/her disease and willingly consent after being 
informed of the procedure to be followed, the experimental nature of the therapy, alternatives, 
potential benefits, side effects, risks, and discomforts. Human protection committee approval of this 
protocol and a consent form are required. 
Registration must occur prior to the initiation of therapy.  
OPEN Access Requirements 
• 
Site staff will need to be registered with CTEP and have a valid and active CTEP-IAM 
account. This is the same account (user id and password) used for the CTSU members' web 
site. 
• 
To perform registrations, the site user must have been assigned the 'Registrar' role on the 
relevant Group or CTSU roster. 
• 
To perform registrations on protocols for which you are a member of the Lead Group, you 
must have an equivalent 'Registrar' role on the Lead Group roster. Role assignments are 
handled through the Groups in which you are a member.  
• 
To perform registrations to trials accessed via the CTSU mechanism (i.e., non-Lead Group 
registrations) you must have the role of Registrar on the CTSU roster. Site and/or Data 
Administrators can manage CTSU roster roles via the new Site Roles maintenance feature 
under RSS on the CTSU members' web site. This will allow them to assign staff the 
"Registrar" role. 
Note: The OPEN system will provide the site with a printable confirmation of registration and 
treatment information. Please print this confirmation for your records. 
Further instructional information is provided on the OPEN tab of the CTSU members’ side of the 
CTSU website at https://www.ctsu.org or at https://open.ctsu.org. For any additional questions 
contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact@westat.com. 
Following registration, patients should begin protocol treatment within 14 days. Issues that would 
cause treatment holds should be discussed with the Study Chair. 
4.1 
Phase I Patient Registration 
4.1.1 OPEN Registration Procedures 
This study is supported by the NCI Cancer Trials Support Unit (CTSU). 
Prior to the recruitment of a patient for this study, investigators must be registered members 
of a Cooperative Group.  Each investigator must have an NCI investigator number and must 
maintain an “active” investigator registration status through the annual submission of a 

Alliance A091101 
 
Version Date: 08/11/2017 
27 
Update #07 
complete investigator registration packet (FDA Form 1572 with original signature, current 
CV, Supplemental Investigator Data Form with signature, and Financial Disclosure Form 
with original signature) to the Pharmaceutical Management Branch, CTEP, DCTD, NCI.  
These forms are available on the CTSU Web site (enter credentials at https://www.ctsu.org; 
then click on the Register tab) or by calling the PMB at 240-276-6575 Monday through 
Friday between 8:30 a.m. and 4:30 p.m. Eastern time. 
Each investigator or group of investigators at a clinical site must obtain IRB approval for 
this protocol and submit IRB approval and supporting documentation to the CTSU 
Regulatory Office before they can enroll patients. Study centers can check the status of their 
registration packets by querying the Regulatory Support System (RSS) site registration 
status page of the CTSU member web site by entering credentials at https://www.ctsu.org. 
Requirements for A091101 site registration: 
• 
CTSU IRB Certification 
• 
CTSU IRB/Regulatory Approval Transmittal Sheet 
• 
Study Chair approval 
Institutional Participation Requirements 
Institutions: Institutions listed on the protocol cover page may participate in this study. 
Conference Calls: One representative from each participating institution must participate 
in a conference call every 2 weeks for the Phase I portion. Institutions with patients enrolled 
to the Phase I portion must participate in this call. Institutions not participating in this 
conference call may be denied future registration to this study. A representative from CTEP 
may also take part in these calls. 
Dose Level Confirmation: During the Phase I portion of the trial, patient enrollment will 
be facilitated using the CTSU Slot Reservation System in conjunction with the Oncology 
Patient Enrollment Network (OPEN). Prior to discussing protocol entry with prospective 
patients, site staff must use the CTSU OPEN Slot Reservation System to ensure that a slot 
for the study is available to the patient. Once a slot reservation confirmation is obtained, site 
staff may then proceed to enroll patients to this study. Please note that a slot reservation will 
only be held for up to seven calendar days. After 7 calendar days, the slot reservation may 
only be renewed once for an additional 7 calendar days. 
Patient registration can occur only after pre-treatment evaluation is complete, eligibility 
criteria have been met, and the study site is listed as ‘approved’ in the CTSU RSS.  Patients 
must have signed and dated all applicable consents and authorization forms.   
All site staff will use OPEN to enroll patients to this study.  OPEN can be accessed at 
https://open.ctsu.org or from the OPEN tab on the CTSU members’ side of the website at 
https://www.ctsu.org. 
Prior to accessing OPEN site staff should verify the following: 
• 
All eligibility criteria has been met within the protocol stated timeframes. Site staff 
should use the registration forms provided on the group or CTSU web site as a tool 
to verify eligibility. 
• 
All patients have signed an appropriate consent form and HIPAA 
authorization form (if applicable).  

Alliance A091101 
 
Version Date: 08/11/2017 
28 
Update #07 
Access requirements for OPEN: 
• 
Site staff will need to be registered with CTEP and have a valid and active CTEP-
IAM account. This is the same account (user id and password) used for the CTSU 
members' web site.  
• 
To perform registrations, the site user must have been assigned the 'Registrar' role 
on the relevant Group or CTSU roster.  
• 
To perform registrations on protocols for which you are a member of the Lead 
Group, you must have an equivalent 'Registrar' role on the Lead Group roster.  Role 
assignments are handled through the Groups in which you are a member  
• 
To perform registrations to trials accessed via the CTSU mechanism (i.e., non-Lead 
Group registrations) you must have the role of Registrar on the CTSU roster. Site 
and/or Data Administrators can manage CTSU roster roles via the new Site Roles 
maintenance feature under RSS on the CTSU members' web site. This will allow 
them to assign staff the "Registrar" role.  
Note: The OPEN system will provide the site with a printable confirmation of registration 
and treatment information. Please print this confirmation for your records.  
Further instructional information is provided on the OPEN tab of the CTSU members’ side 
of the CTSU website at https://www.ctsu.org or at https://open.ctsu.org. For any additional 
questions contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact@westat.com. 
4.2 
Phase II Patient Registration 
4.2.1 Patient registration can occur only after pre-treatment evaluation is complete, eligibility 
criteria have been met, and the study site is listed as ‘approved’ in the CTSU RSS.  Patients 
must have signed and dated the applicable consent.   
All site staff will use OPEN to enroll patients to this study.  OPEN can be accessed at 
https://open.ctsu.org or from the OPEN tab on the CTSU members’ side of the website at 
https://www.ctsu.org. 
Prior to accessing OPEN site staff should verify the following: 
• 
All eligibility criteria has been met within the protocol stated timeframes. Site staff 
should use the registration forms provided on the group or CTSU web site as a tool 
to verify eligibility. 
• 
All patients have signed an appropriate consent form and HIPAA 
authorization form (if applicable).  
Access requirements for OPEN: 
• 
Site staff will need to be registered with CTEP and have a valid and active CTEP-
IAM account. This is the same account (user id and password) used for the CTSU 
members' web site.  
• 
To perform registrations, the site user must have been assigned the 'Registrar' role 
on the relevant Group or CTSU roster.  
• 
To perform registrations on protocols for which you are a member of the Lead 
Group, you must have an equivalent 'Registrar' role on the Lead Group roster.  Role 
assignments are handled through the Groups in which you are a member  
• 
To perform registrations to trials accessed via the CTSU mechanism (i.e., non-
Lead Group registrations) you must have the role of Registrar on the CTSU roster. 
Site and/or Data Administrators can manage CTSU roster roles via the new Site 

Alliance A091101 
 
Version Date: 08/11/2017 
29 
Update #07 
Roles maintenance feature under RSS on the CTSU members' web site. This will 
allow them to assign staff the "Registrar" role.  
Note:  The OPEN system will provide the site with a printable confirmation of registration 
and treatment information.   Please print this confirmation for your records.  
Further instructional information is provided on the OPEN tab of the CTSU members’ side 
of the CTSU website at https://www.ctsu.org or at https://open.ctsu.org. For any additional 
questions contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact@westat.com. 
4.3 
Stratification Factors 
Randomization will be stratified by:  
1) 
Tumor nodal status: 
• T1-3, N0-N2a versus 
• N2b, N2c-N3 and /or T4 
2) 
Oropharyngeal disease/ HPV status: 
• non-oropharyngeal disease versus  
• oropharyngeal disease with HPV positive status versus  
• oropharyngeal disease with HPV negative status 
3) 
Institution 
* Note: stratification by institution implicitly stratifies by concomitant CRT, as it is planned that 
concomitant CRT will be an institution-level choice.  
5.0 
TREATMENT PLAN 
Study Overview 
Phase I portion: This will be a dose-escalation scheme to determine the MTD of ABT-888. Induction 
chemotherapy will be followed by one of 2 options of concomitant chemoradiotherapy, as described 
in Section 5.1.2. 
Phase II portion: Patients will be randomized in a 1:1 manner to receive induction chemotherapy 
with or without ABT-888 at the dose determined during Phase I. Randomization will be stratified by 
tumor/nodal status (T1-3, N0-N2a versus N2b-N3 and/or T4), oropharyngeal disease/ HPV status and 
institution (and implicitly, institutional-chosen concomitant CRT) as described in Section 2.5. 
Induction chemotherapy will be followed by one of 2 options of concomitant chemoradiotherapy, as 
described in Section 5.1.2. Treatment assignment will be double-blinded. Induction chemotherapy 
will be administered on an outpatient basis. Exceptions can be made if patients need hospitalization 
for any reason, which should not delay treatment. Chemoradiotherapy can be administered on an 
inpatient or outpatient basis.  Expected AEs and appropriate dose modifications for carboplatin, 
paclitaxel and 5-fluorouracil, hydroxyurea, and radiation are described below. No investigational or 
commercial agents or therapies other than those described below may be administered with the intent 
to treat the patient's malignancy. 
5.1 
Phase I  
5.1.1 Induction Chemotherapy 
There will be 2, three-week cycles (6 weeks total) in the induction chemotherapy portion of 
Phase I.  ABT-888 will be administered PO twice daily for the first 7 days of Cycle 1 and 2 
(starting on Day 1). This will be combined with a chemotherapy regimen of carboplatin and 

Alliance A091101 
 
Version Date: 08/11/2017 
30 
Update #07 
paclitaxel. Carboplatin will be administered on Day 1 of each 21 day cycle and paclitaxel 
will be administered on Days 1, 8, and 15 of each 21 day cycle. 
This will be a dose-escalation scheme to determine the MTD of ABT-888. Patients will be 
placed in one of the dose cohorts of ABT-888 listed below, using a conventional 3+3 design. 
Only the first cycle will be used to determine dose level. Two 3-week cycles of induction 
chemotherapy will be followed by one of two options for concomitant chemoradiotherapy.

Alliance A091101 
Version Date: 08/11/2017 
31 
 Update #07 
 
Dose Levels 
ABT-888 doses will be given at 200 mg bid for 7 days in combination with paclitaxel 100 
mg/m2 and carboplatin AUC 6. Please see the table below for dose cohorts that are planned 
for the study design. 
Dose Cohort 
ABT-888 
Paclitaxel 
(weekly) 
Carboplatin  
(every 3 weeks) 
-3 
50 mg BID x 7 days 
100 mg/m2 
 6 AUC 
- 2 
100 mg BID x 7 days 
100 mg/m2 
6 AUC 
-1 
150 mg BID x 7 days 
100 mg/m2 
6 AUC 
*0B 
200 mg BID x 7 days 
100 mg/m2 
6 AUC 
1 
250 mg BID x 7 days 
100 mg/m2 
6 AUC 
2 
300 mg BID x 7 days 
100 mg/m2 
6 AUC 
3 
350 mg BID x 7 days 
100 mg/m2 
6 AUC 
* starting dose 
Drugs are given sequentially; start next drug after completion of previous one.  
ABT-888 PO twice daily on days 1-7, every three weeks for 2 cycles.  Dose according to 
assigned cohort.  
Paclitaxel: 100 mg/m2 IV infusion (on Day 1), every week on days 1, 8, and 15 for 2 cycles, 
followed by…. 
Carboplatin: AUC 6, every 3 weeks for 2 cycles. Carboplatin will be administered as an 
intravenous infusion over 30 minutes. The carboplatin dose will be calculated using 
the Calvert formula using AUC of 6 as follows: 
Carboplatin dose in mg* = 6 X (GFR + 25)  
* Calculated total dose is in mg, not mg/m2 
The Creatinine Clearance (to replace GFR) will be calculated for each treatment 
course using the formula: 
CrCl = (140 - age ) X weight in kg. X (0.85 only if female) 
 
 
 
 
 
       72 X serum creatinine 
Note: The GFR (calculated by Cockcroft-Gault) used in the Calvert formula to 
calculate AUC-based dosing should not exceed 125 mL/min (i.e., maximum 
carboplatin dose is 900mg). 
At this time, there is no data for ABT-888 administration through PEG-tube.  Therefore, 
patients who are unable to swallow capsules at baseline need to be excluded.  Patients who 
develop dysphagia during treatment may not be able to complete the planned doses of ABT-
888.  Given the plan is to give this induction regimen for 2 cycles and 7 days of ABT-888, 
a significant number of missed doses of ABT-888 due to dysphagia is not expected. 
Nevertheless, if patients missed planned doses during cycle 1 of the phase I trial, they will 
be replaced. If they miss doses during cycle 2, they will not be given later doses, and the 
patients will not be replaced during the phase I portion of this study.  
5.1.1.1 
Definition of Dose-Limiting Toxicity – Phase 1  

Alliance A091101 
 
Version Date: 08/11/2017 
32 
Update #07 
In the Phase 1 portion, DLTs will be assessed during the first cycle of induction 
chemotherapy. 
Dose Limiting Toxicity (DLT) will be defined as follows, during the first cycle of induction 
chemotherapy: 
• Hematological toxicities: 
- Grade 4 neutropenia (ANC < 500) lasting more than 14 days 
- Febrile neutropenia  
- Grade 4 thrombocytopenia 
- Dose delay of greater than 3 weeks due to failure to recover counts. 
• Non-hematological toxicities: 
- Study treatment-related grade 3 or grade 4 non-hematological toxicity 
(excluding alopecia, fatigue, hypersensitivity reaction, nausea, vomiting, 
constipation, diarrhea, hypokalemia, hypomagnesemia, hypocalcemia, 
hypophosphatemia, and grade 3 hypertension). 
- Dose delay of greater than 3 weeks for non-hematological toxicity despite 
replacement of electrolytes, maximum treatment for diarrhea, nausea, 
vomiting, and hypertension. 
• Any drug-related death. 
Management and dose modifications associated with the above adverse events are outlined 
in Section 6.0. 
5.1.1.2 
 Dose Escalation 
Dose escalation will proceed according to the following scheme.  
 
Number of Patients with DLT at 
a Given Dose Level 
Escalation Decision Rule 
0 out of 3 
Enter 3 patients at the next dose level. 
>2 
Dose escalation will be stopped.  This dose level will 
be declared the maximally administered dose (highest 
dose administered).  Three (3) additional patients will 
be entered at the next lowest dose level if only 3 
patients were treated previously at that dose. 
1 out of 3 
Enter at least 3 more patients at this dose level. 
• If 0 of these 3 patients experience DLT, proceed to 
the next dose level. 
•  If 1 or more of this group suffer DLT, then dose 
escalation is stopped, and this dose is declared the 
maximally administered dose.   
•  Three (3) additional patients will be entered at the 
next lowest dose level if only 3 patients were treated 
previously at that dose. 
<1 out of 6 at highest dose 
level 
below 
the 
maximally 
administered dose 
This is generally the recommended phase 2 dose. At 
least 6 patients must be entered at the recommended 
phase 2 dose. 

Alliance A091101 
 
Version Date: 08/11/2017 
33 
Update #07 
5.1.2 Concomitant Chemoradiotherapy Regimen Options 
Following induction chemotherapy, patients will be placed into one of 2 regimens of 
radiation and chemotherapy, based on the guidelines of the institution where they are being 
treated. It is expected that the institutional choice of concomitant CRT will apply to all 
patients enrolled at that institution. 
OPTION 1: Concomitant Chemoradiotherapy with Cisplatin 
5.1.2.1 
Cisplatin Treatment during concurrent cisplatin/radiation treatment  
Cisplatin, 100 mg/m2, IV on days 1 and 22 (cisplatin may be given within 24 hours of 
days 1 and 22). 
Adjustment for actual or ideal body weight is per institutional standard.  
High dose cisplatin is a highly emetogenic regimen with significant incidence of delayed 
nausea and vomiting. Institutional guidelines for highly emetogenic regimens should be 
followed. In the absence of such guidelines, see Section 5.3. 
Hydration and diuresis: per institutional guidelines. 
5.1.2.2 
Dose Specifications for 3D Radiotherapy during concurrent cisplatin/radiation 
treatment 
The initial target volume encompassing the gross and subclinical disease sites will receive 
1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. The boost 
volume covering gross tumor and clinically/radiologically involved nodes will receive boost 
irradiation of 1.5 Gy/Fx delivered as a second daily fraction (with at least a six-hour interval) 
for a total of 12 treatment days (18 Gy total). The boost irradiation should commence during 
week 4 of the large field irradiation at the latest at 32.4 Gy/18 Fx of the initial target volume 
(i.e., latter part of week 4). All treatment times must be documented on the treatment record. 
The primary tumor and clinically/radiologically-involved nodes (PTVHD) will thus receive 
72 Gy in 42 fractions over 6 weeks, and uninvolved upper neck nodes (PTVED) will receive 
an elective dose of 54 Gy in 6 weeks.  
When desired, PTVINT can receive a total dose of 63 Gy, i.e., by delivering 9 fractions of 
1.5 Gy to PTVINT before making a second cone down to PTVHD. Clinically/radiologically 
negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. 
The uninvolved lower neck nodes will receive 1.8 Gy per fraction at 3-cm depth to a total 
dose of 50.4 Gy in 28 fractions in 5.6 weeks through a matching AP or AP/PA lower neck 
field. Involved lower neck nodes can receive a total dose of up to 69-72 Gy when it is 
possible to limit the dose to the brachial plexus to ≤ 60 Gy. If this is not possible, the total 
dose can be limited to 60 Gy, in which case, neck dissection is mandatory regardless of the 
response. 
Technical Factors 
• 
Photon beams of ≥4 MV and/or electron beams from 6-25 MeV are required. 
• 
Treatment distance must be ≥ 80 cm SAD for isocentric techniques. 
Immobilization 
Although a thermoplastic head mask may suffice for conformal radiotherapy, the use of a 
head and shoulder mask is recommended for better reproducibility 
Planning CT scan 

Alliance A091101 
 
Version Date: 08/11/2017 
34 
Update #07 
A treatment planning CT scan is mandatory for defining target volumes CT scan thickness 
should be at most 0.5 cm for conformal radiotherapy or 0.3 cm for IMRT.  The treatment 
planning CT scan should be acquired with the patient in the same position and using the 
same immobilization device as for treatment.  All tissues receiving irradiation should be 
include in the CT scan. 
Treatment Planning/Target Volumes 
• 
CT based treatment planning is mandatory for every patient.   
• 
Gross Tumor Volume (GTV) represents the region judged to contain gross primary 
tumor or involved node(s) based on clinical and endoscopic examinations, CT scan, 
and, when applicable, other imaging techniques.  Grossly positive lymph nodes are 
defined as any lymph nodes > 1 cm or nodes with a necrotic center. 
• 
Clinical Target Volume (CTV) is defined as the GTV plus areas considered at risk 
for containing microscopic disease delineated by the treating physician.  CTV1 
represents GTV plus a margin of generally 1 cm and CTV2 represents GTV with a 
margin of about 2 cm and nodal regions to receive elective irradiation.  When the tumor 
is infiltrative (endophytic) or when the border is ill defined, it might be desirable to 
deliver an intermediate dose (e.g., 59-63 Gy) to a volume (CTVINT) that is slightly 
larger than CTV1.  The CTV margins can be narrower when GTV is in the proximity 
of the spinal cord or critical normal tissues. 
• 
Planning Target Volume  (PTVHD and PTVED) represents an additional margin 
around CTV1 and CTV2 to compensate for the variability of treatment set up and 
internal organ motion. A minimum margin of 0.5 cm around the CTV is required in all 
directions to define each respective PTV, except for situations in which the CTV is 
adjacent to spinal cord or other critical normal tissues. In such situations, the margin 
can be reduced judiciously. A minimum margin of 3 mm can be used in all directions 
as long as an institution implements a study to define the appropriate magnitude of the 
uncertain components of the PTV. Careful consideration should be made when defining 
the superior and inferior margins in three dimensions. 
• 
The density corrected dose distributions shall be calculated and the dose 
prescription is to be based on a dose distribution corrected for heterogeneities. 
Critical Structures 
• 
Spinal cord:  A margin of 0.5-1cm around the spinal cord may be added to create 
a Planning Organ at Risk Volume (PRV).  The dose to any point within the spinal cord 
should not exceed 48 Gy to any volume larger than 0.03 cc (approximately equivalent 
to a 3x3x3 mm cube). 
• 
Glottic larynx: In patients with oropharyngeal carcinoma without extension to the 
larynx, placing the isocenter just above the arytenoids and irradiating the lower neck 
with an anterior matching field with larynx block can minimize the dose to the glottic 
larynx.  Alternatively, the dose to the larynx should be kept <45 Gy whenever feasible. 
• 
Brachial plexus:  The dose to the brachial plexus must be limited to ≤ 60 Gy in 
patients with level IV node(s). 
• 
Unspecified tissue outside the target volumes: ≤ 100% of the dose prescribed to 
CTV1. No more than 5% of the non-target tissue can receive greater than the dose to 
CTV1. 
Compliance Criteria 

Alliance A091101 
 
Version Date: 08/11/2017 
35 
Update #07 
• 
Treatment breaks must be clearly indicated in the treatment record along with the 
reason(s) for the treatment break(s). Missed treatments due to holidays or logistic 
reasons can be compensated for by delivering additional BID treatments with a 
minimum interfraction interval of 6 hours. 
• 
Treatment breaks should be allowed only for resolution of severe acute toxicity 
and/or for intercurrent illness and ideally, should not exceed 5 treatment days at a time 
and 10 treatment days in total. Any treatment break(s) exceeding two treatment days 
for reasons other than toxicity/illness will be considered a protocol deviation.  
• 
Plan normalization should provide coverage of 95% of the volume of the PTV of 
the GTV (PTVHD) with the prescribed dose of 69.96 Gy.   No more than 1% of the 
volume of the PTVHD should receive less than 64 Gy.  Additionally, no more than 
20% of the PTV of the GTV should receive more than 76 Gy, and no more than 5% of 
this volume should receive more than 79 Gy.  These numbers describe the DVH shown 
in the figure below with the diamond shaped symbols. Obviously, better DVHs (i.e., 
with smaller amounts of either underdose or overdose) are preferable. 
• 
A region of “minor deviation” is also defined in the figure as the DVH represented 
by the square symbols.  Deviations of this magnitude are not desirable, but will be 
deemed acceptable. That is, a DVH with at least 97% of the volume receiving 64 Gy 
is acceptable as a minor deviation. Additionally, as a minor deviation for the overdose 
region, as much as 40% of the PTVHD   volume can receive 76 Gy and up to 20% of 
this volume can receive 79 Gy.  DVHs for the PTVHD falling outside the limits for a 
minor deviation (i.e., increased under or overdose) will be scored as unacceptable 
“major deviations.” 
• 
The DVHs for the other target regions should deliver the prescribed dose, as much 
as possible, to at least 95% of the volume of that PTV. 
 
Overall 
Evaluation 
Radiotherap
y 
Prolongation
Total 
Dose 
Variation 3-D RT 
Total Dose Variation 
IMRT** 
Per Protocol 
≤ 5 days 
≤ 4% deviation from 
prescribed dose 
See parameters in the figure and 
table below 
Minor Variation 
(Acceptable) 
6-10 days 
> 4% to ≤ 9% 
See parameters in the figure and 
table below 
Major Deviation 
(Unacceptable) 
> 10 days 
> 9% 
Deviations greater than presented
in the figure/table below 
*These criteria are to be reassessed based on the results of the recently completed RTOG trial, 
0129. 
**Note: For IMRT, prescription dose is the isodose surface that encompasses at least 95% 
of the planning target volume (PTV) with no more than 20% of any PTVHD receiving ≥ 

Alliance A091101 
 
Version Date: 08/11/2017 
36 
Update #07 
110% of the prescribed dose and no more than 1% of any PTVHD and PTVED receiving ≤ 
93% of the prescribed dose. 
 
 
 
Dose (Gy) 
Per Prescription 
Minor variation 
65 
99% 
97% 
70 
95% 
95% 
77 
20% 
40% 
80 
5% 
20% 
OPTION 2: Concomitant Chemoradiotherapy with TFHX  
5.1.2.3 Chemotherapy should be administered during all 5 weeks of radiotherapy.  If less than 3 
days of radiation therapy (RT) are required during Week 5, chemotherapy may be omitted. 
Repeat every 14 days for a total of 5 cycles. 
P.M.:  hydroxyurea 500 mg PO q 12 hours for 11 doses beginning the evening before 
radiotherapy start. During radiotherapy, the morning dose of hydroxyurea is given 2 hours 
prior to the first fraction of daily radiotherapy. 
6:00 P.M.: 5-FU 600 mg/m2/day IV infusion over 120 hours beginning the evening before 
radiotherapy starts.  Total dose 3000mg/m2 per cycle. (5-FU may begin in the morning prior 
to the first daily radiotherapy fraction) 
Paclitaxel 100 mg/m2 IV infusion on the first day of radiotherapy.  Premedication for 
paclitaxel according to institutional procedures. 
Radiation therapy is administered twice daily for 5 days (Mon- Fri) at 150 cGy per 
fraction. 
Chemoradiotherapy cycles are repeated every 14 days until the completion of radiotherapy. 
5.1.2.4 Radiotherapy Guidelines for concurrent TFHX treatment 
1. 
All patients will have a complete dental evaluation prior to the start of radiation 
therapy, ideally prior to the start of chemotherapy. 
2. 
Prior to the initiation of induction chemotherapy, all patients will be properly 
immobilized and simulated in the treatment position with a contrast enhanced CT scan for 
planning purposes.  Additionally, after the completion of induction chemotherapy and prior 
to the initiation of concurrent chemoradiotherapy, all patients will undergo a second 
planning CT scan.  The pre- and post-chemotherapy scans will be fused to define the targets 
below. Slice thickness for all planning CT scans should optimally be 3mm and no greater 
than 5 mm. 
3. 
Target volume definition:  Three volumes will be defined on each planning CT 
slice where appropriate.  Gross disease based on all available imaging and clinical 
information will be designated as gross tumor volume (GTV).  Planning target volume 1 
(PTV1) will include the GTV + a 1.5 cm margin for set-up uncertainty, organ motion, and 
microscopic extension.  High risk microscopic disease (PTV2) will include the entirety of 
PTV1 and will also include the nodal stations at risk for microscopic spread.   

Alliance A091101 
 
Version Date: 08/11/2017 
37 
Update #07 
• 
Contouring the primary and involved neck nodes (GTV) will be performed per 
consensus recommendations [Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, 
Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS.  Clinical Practice Guidance 
for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced 
Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys. 2009 Apr 11.] In general, the pre-
induction chemotherapy scan is used to define the primary tumor GTV and the post-
induction chemotherapy volume is used to define the nodal volume GTV. 
• 
PTV1 will be created by uniformly expanding the GTV by 1.5 cm.   
• 
PTV2 will include all of PTV1 as well as the next regional nodal not involved with 
pathologic lymphadenopathy.  Anatomic guidelines for lymph node stations will be 
defined using the RTOG Head and Neck Atlas Guidelines for delineation of the Nodal 
CTV.   
Additionally site by site guidelines are provided below. 
i. 
 Guidelines for definition of PTV2: 
• 
PTV2 is defined as the entirety of PTV1 as well as the next nodal station at risk. 
• 
For example, a patient have an ipsilateral level 2 LN involved as GTV, PTV2 will 
encompass ipsilateral level 3. 
• 
PTV2 may not differ significantly from PTV1 if the required GTV expansion 
includes the next nodal station at risk. 
• 
For tumors that cross midline in the oral cavity or oropharynx, PTV 2 may include 
contralateral level 2 LN.  An example would be a soft palate tumor or a base of tongue 
tumor that crosses midline.   
• 
PTV1 and PTV2, can be modified at the discretion of the treating physician for the 
constraints of normal tissue tolerance and to avoid extension beyond the skin.  Variations 
in anatomy and tumor size make it necessary for the radiation oncologist to carefully 
define the PTV on each individual CT slice.  Reasonable attempts should be made to 
provide an adequate treatment volume without encroaching on critical organs (e.g. spinal 
cord) or extending to the skin. 
4. 
Radiotherapy Techniques Allowed: Either 3-D CT based treatment planning or 
Intensity Modulated Radiation Treatment (IMRT) techniques will be acceptable. 
• 
Planning Goals:  In both instances the physician will attempt to deliver an even 
dose to the target tissue and minimize doses to surrounding normal structures.  
• 
Blocking will be individualized for each patient.  Either custom Cerrobend blocks 
or mutileaf collimation will be acceptable. 
• 
Field Size: Appropriate field sizes will be determined at the time of simulation to 
treat gross disease and areas of potential microscopic disease.  Initial field size and 
arrangement will be at the discretion of the attending radiation oncologist.  The optimal 
field arrangement will be determined based on the treatment planning techniques 
employed.  All fields must be treated during each treatment session. 
5. 
3D Conformal technique and prescription: 
i. 
The neck should be treated with opposed lateral fields using a half-field technique.   
ii. 
In general, the lower neck should be treated with an anterior field to a depth of 3 
cm.  Opposed fields for the lower neck are permitted in order to improve PTV coverage and 
increase homogeneity.   

Alliance A091101 
 
Version Date: 08/11/2017 
38 
Update #07 
iii. 
Wedges, tissue compensators or segmented fields should be used to insure 
uniformity of PTV coverage.   
iv. 
Electron fields of the posterior neck are permitted to limit the spinal cord dose.   
v. 
A cord block is permitted on the anterior or lateral fields provided it does not cover 
tumor 
vi. 
A moving match line is permitted in cases where a cord block would cover tumor. 
vii. 
Acceptable plans will encompass the PTV within the 95% isodose line. 
viii. 
The dose variation in the PTV will be +7% and -5% of the prescription point dose.   
ix. 
Electron fields shall be prescribed to the depth of maximum dose with the energy 
and field size chosen so that the target volume is encompassed within 90% of the prescribed 
dose. 
6. 
IMRT technique and prescription 
i. 
Optimal IMRT planning will depend on the planning system employed.   
ii. 
We anticipate that the optimal plan will use 7 to 11 gantry positions.   
iii. 
Acceptable plans will encompass the PTV with the 95% isodose line.   
iv. 
No more than 1% of the PTV should receive less than 1% of the prescribed dose.   
v. 
Plans should be reviewed to ensure that any part of the PTV getting less than 95% 
of the prescription dose is at the edge of the volume.   
vi. 
In no situation should a central area of the PTV receive less than 95% of the 
prescribed dose.   
vii. 
No more than 1% of the PTV should receive 110% of the prescription dose.   
Radiation Dose: each cycle of treatment will consist of 5 consecutive days of 
hyperfractionated radiation with 150 cGy given bid with a 6 hour interval between radiation 
fractions (300 cGy per day and 1500 cGy per week) in conjunction with chemotherapy. 
i. 
The dose for PTV1 will be 70-75 Gy. 
ii. 
The dose for PTV2 will be 45-54 Gy 
iii. 
In the case of mechanical failure or a holiday, one day of BID radiotherapy can be 
replaced with a single QD fraction of 200cGy.  Accordingly, the final cumulative dose will 
be slightly less. 
The dose limit to the spinal cord will vary depending upon the technique used.  Attempts 
should be made to limit the spinal cord dose to < 40 Gy with conventional 3D radiation 
treatment.  Doses should be limited to 46 Gy with IMRT techniques and reduced fraction 
size to the spinal cord.  
Countouring Atlas for Head and Neck: 
http://www.rtog.org/atlases/hnatlas/tableneck.html 
Detailed Site by Site Instructions for Nodal Planning Target Volume 2 Delineation: 
Base of Tongue:  Lateralized 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 2 includes: 
 
 
 
 
 
 
 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
39 
Update #07 
Ipsilateral 
IB, II 
IA, 
II 
IB, 
III 
II, 
IV 
II,III 
II, 
III 
IA, IB, II 
II 
II 
II 
II 
II 
Contralateral 
IA 
II 
II 
II 
II 
II 
IB 
II 
IB 
II, 
IV 
II, 
III 
II, 
III 
 
Base of Tongue:  Crosses Midline 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
IB, 
III 
II, 
IV 
II,III 
II, 
III 
IA, IB, II 
II 
II 
II 
II 
II 
Contralateral 
IA 
--- 
II 
II 
II 
II 
IB 
II 
IB, 
III 
II, 
IV 
II, 
III 
II, 
III 
 
Soft Palate: 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
II 
IB, 
III 
II, 
IV 
II,III 
II, 
III 
IA, IB, II 
II 
II 
II 
II 
II 
Contralateral 
IA 
II 
II 
II 
II 
II 
IB 
IA(?), 
II 
IB, 
III 
II, 
IV 
II, 
III 
II, 
III 
 
 
Tonsil:  No BOT invasion 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
IB, 
III 
II, 
IV 
II,III 
II, 
III 
IA, IB, II 
II 
II 
II 
II 
II 
Contralateral 
IA 
--- 
--- 
--- 
--- 
--- 
IB 
IA(?), 
II 
IB, 
III 
II, 
IV 
II, 
III 
II, 
III 
 
Tonsil:  BOT Invasion 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 

Alliance A091101 
 
Version Date: 08/11/2017 
40 
Update #07 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
IB, 
III 
II, 
IV 
II,III 
II, III 
IA, IB, II 
II 
II 
II 
II 
II 
Contralateral 
IA 
--- 
II 
II 
II 
II 
IB 
II 
IB, 
III 
II, 
IV 
II, 
III 
II, 
III 
 
Larynx: T1-2 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
III 
II, 
IV 
II,III 
II, 
III 
IA, IB, II 
II 
II 
III 
III 
II 
Contralateral 
IA 
--- 
II 
II 
II 
II 
IB 
II 
 III 
II, 
IV 
II, 
III 
II, 
III 
 
Larynx: T3-4 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
III 
II, 
IV 
II,III 
II, 
III 
IA, IB, II 
II 
II 
III 
III 
II 
Contralateral 
IA 
--- 
II 
II 
II 
II 
IB 
II 
 III 
II, 
IV 
II, 
III 
II, 
III 
 
Hypopharynx 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
II, 
III,  
III,IV 
II, 
IV 
II,III 
II, 
III,IV 
IA, IB, II 
II 
II 
III 
III 
II 
Contralateral 
IA 
--- 
II, III 
II, 
III 
II, III 
II,III 
IB 
II 
 
III 
II, 
IV 
II, 
III 
II, 
III 
 
Lower Gingiva 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
41 
Update #07 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
IA, 
IB, 
III 
IA, 
IB,II, 
IV 
IB, 
IA, 
II,III 
IA, 
IB, 
II, 
III 
IA, IB 
IA 
,II 
IA, 
IB, 
II,  
IA, 
IB, 
II 
IA, 
IB, 
II, 
IA, 
IB, 
II, 
Contralateral 
IA, IB 
--- 
--- 
--- 
--- 
--- 
IB, II 
IA, 
II 
 IA, 
IB, 
III 
IB, 
IA, 
II, 
IV 
IA, 
IB, 
II, 
II, 
III 
II, 
III 
 
Retromolar Trigone 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
IB, 
III 
IB,II, 
IV 
IB, 
II,III 
IB, 
II, 
III 
IA, IB 
IA 
,II 
IB, 
II,  
, IB, 
II 
IB, 
II, 
IB, 
II, 
Contralateral 
IA, IB 
--- 
--- 
--- 
--- 
--- 
IB, II 
IA, 
II 
 IB, 
III 
IB, 
II, 
IV 
IB, 
II, 
II, 
III 
II, 
III 
 
Oral Tongue:  Lateralized 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
IA, 
IB, 
III 
IA, 
IB,II, 
IV 
IB, 
IA, 
II,III 
IA, 
IB, 
II, 
III 
IA, IB, II 
IA 
,II 
IA, 
IB, 
II,  
IA, 
IB, 
II 
IA, 
IB, 
II, 
IA, 
IB, 
II, 
Contralateral 
IA, IB 
--- 
--- 
--- 
--- 
--- 
IB, II 
IA, 
II 
 IA, 
IB, 
III 
IB, 
IA, 
II, 
IV 
IA, 
IB, 
II, 
II, 
III 
II, 
III 
 
Oral Tongue:  Crosses Midline 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
42 
Update #07 
 
Floor of Mouth 
Changes to the proposed schedule are to be discussed with Dr. Daniel Haraf [(773) 702-
5976, dharaf@radonc.bsd.uchicago.edu]. 
Missed treatments due to holidays or logistical reasons can be compensated for by delivering 
additional BID treatments with a minimum interfraction interval of 6 hours or by treating 
on a Saturday or Sunday. 
5.1.3  Duration of Follow up 
See Section 5.5 for clinical and survival follow-up schedule. 
5.2 
Phase II 
Patients will be randomized in a 1:1 manner to receive induction chemotherapy with or without 
ABT-888 at the dose determined during Phase I. Within 10 days after the completion of 
induction chemotherapy (i.e., week 6, day 7) patients will begin one of 2 options of concomitant 
chemoradiotherapy (as described in Section 5.1.2). It is expected that the institutional choice of 
concomitant CRT will apply to all patients enrolled at that institution. Treatment assignment 
will be double-blinded.  
5.2.1 Carboplatin-Paclitaxel Induction Chemotherapy-Repeat every 3 weeks for 2 cycles 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
IA, 
IB, 
III 
IA, 
IB,II, 
IV 
IB, 
IA, 
II,III 
IA, 
IB, 
II, 
III 
IA, IB, II 
IA 
,II 
IA, 
IB, 
II,  
IA, 
IB, 
II 
IA, 
IB, 
II, 
IA, 
IB, 
II, 
Contralateral 
IA, IB 
IA, 
IB 
IA, 
IB 
IA, 
IB 
IA, 
IB 
--- 
IB, II 
IA, 
II 
 
IA, 
IB, 
III 
IB, 
IA, 
II, 
IV 
IA, 
IB, 
II, 
II, 
III 
II, 
III 
 
Adenopathy 
Level 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
 
 
 
 
 
Contralateral 
 
 
 
 
 
Involved 
nodes: 
IA 
IB 
II 
III 
IV 
V 
IA 
IB 
II 
III 
IV 
V 
PTV 
2 
includes: 
 
 
 
 
 
 
 
 
 
 
 
 
Ipsilateral 
IB, II 
IA, 
II 
IA, 
IB, 
III 
IA, 
IB,II, 
IV 
IB, 
IA, 
II,III 
IA, 
IB, 
II, 
III 
IA, IB, II 
IA 
,II 
IA, 
IB, 
II,  
IA, 
IB, 
II 
IA, 
IB, 
II, 
IA, 
IB, 
II, 
Contralateral 
IA, IB 
IA, 
IB 
IA, 
IB 
IA, 
IB 
IA, 
IB 
--- 
IB, II 
IA, 
II 
 
IA, 
IB, 
III 
IB, 
IA, 
II, 
IV 
IA, 
IB, 
II, 
II, 
III 
II, 
III 

Alliance A091101 
 
Version Date: 08/11/2017 
43 
Update #07 
The doses of carboplatin and paclitaxel will remain the same during the phase I and II 
induction chemotherapy (refer to Section 5.1.1) Dose delays and dose modifications should 
take place as described below. The total duration of induction chemotherapy should be 
6 weeks and not exceed 8 weeks. 
 ABT-888/placebo 
Twice daily at the dose determined in phase I, on days 1-7 (for a 
total of 7 days and 14 doses). 
Paclitaxel: 
100 mg/m2 IV infusion over 60 minutes on Days 1, 8, and 15 
Carboplatin: AUC 6, every 3 weeks for 2 cycles. Carboplatin will be administered as an 
intravenous infusion over 30 minutes. The carboplatin dose will be calculated using 
the Calvert formula using AUC of 6 as follows: 
Carboplatin dose in mg* = 6 X (GFR + 25)  
* Calculated total dose is in mg, not mg/m2 
The Creatinine Clearance (to replace GFR) will be calculated for each treatment 
course using the formula: 
CrCl = (140 - age ) X weight in kg. X (0.85 only if femail) 
 
 
 
 
 
       72 X serum creatinine 
Note: The GFR (calculated by Cockcroft-Gaul) used in the Calvert formula to 
calculate AUC-based dosing should not exceed 125 mL/min (i.e., maximum 
carboplatin does is 900mg). 
5.2.2 Concomitant Chemoradiotherapy 
Concomitant chemoradiotherapy will start within 10 days from the completion of cycle 2 
of carboplatin-pactlitaxel induction chemotherapy (as the cycles are 21 days long, patients 
should start concomitant therapy by day 31 of cycle 2). It is expected that the institutional 
choice of concomitant CRT will apply to all patients enrolled at that institution. 
OPTION 1: Concomitant Chemoradiotherapy with Cisplatin as described in Cisplatin, 
100 mg/m2, IV on days 1 and 22 (cisplatin may be given within 24 hours of days 2 and 
23). 
Adjustments for actual or ideal body weight is per institutional standard.  
High dose cisplatin is a highly emetogenic regimen with significant incidence of 
delayed nausea and vomiting. Institutional guidelines for highly emetogenic regimens 
should be followed. In the absence of such guidelines, see Section 5.3.  
Hydration and diuresis: per institutional guidelines.  
For dose specifications for 3D Radiotherapy refer to Section 5.1.2.2. 
OR 
OPTION 2: Concomitant Chemoradiotherapy with TFHX  
Chemotherapy should be administered during all 5 weeks of radiotherapy.  If less than 3 
days of radiation therapy (RT) are required during Week 5, chemotherapy may be 
omitted. Repeat every 14 days for a total of 5 cycles. 
P.M.:  
hydroxyurea 500 mg PO q 12 hours for 11 doses beginning the evening 
before radiotherapy start. During radiotherapy, the morning dose of hydroxyurea is given 
2 hours prior to the first fraction of daily radiotherapy. 

Alliance A091101 
 
Version Date: 08/11/2017 
44 
Update #07 
6:00 P.M.: 5-FU 600 mg/m2/day IV infusion over 120 hours beginning the evening 
before radiotherapy starts.  Total dose 3000mg/m2 per cycle. (5-FU may begin in the 
morning prior to the first daily radiotherapy fraction) 
Paclitaxel 100 mg/m2 IV infusion on the first day of radiotherapy. Premedication for 
paclitaxel according to institutional procedures. 
Radiation therapy is administered twice daily for 5 days (Mon- Fri) at 150 cGy per 
fraction. 
Chemoradiotherapy cycles are repeated every 14 days until the completion of 
radiotherapy. 
For dose specifications for 3D Radiotherapy refer to Section 5.1.2.4. 
5.3 
Concomitant Medication and Supportive Care Guidelines 
5.3.1 Supportive care for Carboplatin-Paclitaxel Induction 
Pre-medications, hydration, and antiemetics should be given according to institutional 
procedures. 
• 
Breakthrough nausea and vomiting and delayed nausea and vomiting should be 
managed aggressively according to institutional procedures. 
• 
Colony stimulating factors should be given as described in Section 6.0. 
5.4 
Duration of Therapy 
The total duration of induction chemotherapy should be 6 weeks, and not exceed 8 weeks. In no 
case should the duration of induction chemotherapy exceed 8 weeks or 2 cycles. In the absence 
of treatment delays due to adverse event(s), treatment may continue for 2 cycles or until one of 
the following criteria applies: 
Disease progression, 
Unacceptable adverse event(s), 
Patient decides to withdraw from the study, or 
General or specific changes in the patient's condition render the patient unacceptable for further 
treatment in the judgment of the investigator. 
5.5 
Duration of Follow Up  
5.5.1 Clinical Follow-Up  
Medical Oncology and/or Radiation Oncology: A brief history and physical by a medical 
oncologist and/or radiation oncologist must be done at 2 weeks, 1 month and 3 months from 
the end of chemoradiotherapy treatment, then every 3 months through year 2, every 6 
months in year 3 and annually in years 4 and 5. 
ENT or Head and Neck Surgeon: An examination by an ENT or Head and Neck Surgeon, 
including laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure), must be 
completed at months 1 and 3 from the end of chemoradiotherapy treatment, then every 3 
months through year 2, every 6 months in year 3, and annually in years 4 and 5. 
Imaging: 3, 6, 12, 18, 24, 30, 36, 48, and 60 months following the end of CRT, any of the 
following options: a) CT scan of the neck (with contrast) and a chest CT scan (with or 
without contrast); b) MRI of the neck and a chest CT scan (with or without contrast); c) CT 
scan of the neck and a PET/CT of neck and chest (with or without contrast). 

Alliance A091101 
 
Version Date: 08/11/2017 
45 
Update #07 
5.5.2  Survival Follow-up 
Patients who have progressed will be followed every 6 months through year 5.   
5.6 
Criteria for Removal from Study 
Patients will be removed from study treatment when any of the criteria listed in Section 5.4 
applies.  

Alliance A091101 
 
Version Date: 08/11/2017 
46 
Update #07 
6.0 
DOSE MODIFICATIONS FOR PHASE I ONLY 
Please note, the dose modifications for the phase II portion will be determined once the dose of ABT-
888 is known for the phase II portion. When we reach the phase II portion, an amendment will detail 
the new dose modifications. 
General rules for dose modification: 
• 
If multiple adverse events are seen, administer dose based on greatest reduction required for 
any single adverse event observed.   
• 
Reductions apply to treatment given in the preceding cycle and are based on adverse events 
observed since the prior dose. 
• 
Paclitaxel will not be re-escalated once reduced 
• 
If dose reductions beyond dose level -1 is required induction will be discontinued, and patient 
will move to concurrent chemoradiotherapy 
• 
If treatment is held 21 days or more, patient will move on to concurrent chemoradiotherapy 
• 
CTEP-AERS reporting may be required for some adverse events (See Section 7.0) 
Growth Factors: 
In general, patients will NOT receive prophylactic filgrastim (G-CSF), tbo-filgrastim, PEG-
filgrastim (Neulasta), or sargramostim (GM-CSF) unless they experience treatment delays, dose 
omissions, or recurrent neutropenic complications after treatment modifications as specified. In 
particular, hematopoietic growth factors should not be used to avoid initial chemotherapy dose 
modifications as stipulated in the protocol. However, patients may also receive growth factors 
for management of neutropenic complications in accordance with clinical treatment guidelines. 
When GCSF is utilized, given the weekly chemotherapy doses, it is recommended that filgrastim, 
tbo-filgrastim or sargramostim (dosed according to institutional standard) will be administered 
daily subcutaneously starting 24-72 hours after the last dose of weekly paclitaxel. 
As a reminder, dose cohorts for the phase I trial are: 
Dose Cohort 
ABT-888 
Paclitaxel 
(weekly) 
Carboplatin  
(every 3 weeks) 
-3 
50 mg BID x 7 days 
100 mg/m2 
 6 AUC 
- 2 
100 mg BID x 7 days 
100 mg/m2 
6 AUC 
-1 
150 mg BID x 7 days 
100 mg/m2 
6 AUC 
*0B 
200 mg BID x 7 days 
100 mg/m2 
6 AUC 
1 
250 mg BID x 7 days 
100 mg/m2 
6 AUC 
2 
300 mg BID x 7 days 
100 mg/m2 
6 AUC 
3 
350 mg BID x 7 days 
100 mg/m2 
6 AUC 
* starting dose 
6.1 
Dose Reduction and Delays during Induction 
Dose modification tables for phase I induction by cohort: 
Cohort 0B: 
Dose level 
ABT-888 
Carboplatin 
Paclitaxel 
0 (starting dose) 
200 mg bid x 7 days 
6 AUC 
100 mg/m2 
-1 
150 mg bid x 7 days 
5 AUC 
80 mg/m2 

Alliance A091101 
 
Version Date: 08/11/2017 
47 
Update #07 
 
Cohort 1: 
Dose level 
ABT-888 
Carboplatin 
Paclitaxel 
0 (starting dose) 
250 mg bid x 7 days 
6 AUC 
100 mg/m2 
-1 
200 mg bid x 7 days 
5 AUC 
80 mg/m2 
Cohort 2: 
Dose level 
ABT-888 
Carboplatin 
Paclitaxel 
0 (starting dose) 
300 mg bid x 7 days 
6 AUC 
100 mg/m2 
-1 
250 mg bid x 7 days 
5 AUC 
80 mg/m2 
Cohort 3: 
Dose level 
ABT-888 
Carboplatin 
Paclitaxel 
0 (starting dose) 
350 mg bid x 7 days 
6 AUC 
100 mg/m2 
-1 
300 mg bid x 7 days 
5 AUC 
80 mg/m2 
Cohort -1: 
Dose level 
ABT-888 
Carboplatin 
Paclitaxel 
0 (starting dose) 
150 mg bid x 7 days 
6 AUC 
100 mg/m2 
-1 
100 mg bid x 7 days 
5 AUC 
80 mg/m2 
Cohort -2: 
Dose level 
ABT-888 
Carboplatin 
Paclitaxel 
0 (starting dose) 
100 mg bid x 7 days 
6 AUC 
100 mg/m2 
-1 
50 mg bid x 7 days 
5 AUC 
80 mg/m2 
Cohort -3: 
Dose level 
ABT-888 
Carboplatin 
Paclitaxel 
0 (starting dose) 
50 mg bid x 7 days 
6 AUC 
100 mg/m2 
-1 
Discontinue ABT-888 
5 AUC 
80 mg/m2 
6.1.1 Dose Modifications for Hematologic Toxicity During Induction 
For grade 2 neutropenia on day 1, proceed with carboplatin 1 dose level decreased, 
paclitaxel at same dose, and ABT-888 at same dose. For grade 3 or 4 neutropenia on day 1, 
delay day 1 until grade ≤ 2, then proceed with carboplatin 1 dose level decreased, paclitaxel 
at same dose, and ABT-888 1 dose level decreased. For febrile neutropenia on day 1, delay 
day 1 until recovery, then proceed with carboplatin 1 dose level decreased, paclitaxel at 
same dose, and ABT-888 1 dose level decreased.  
For grade 4 neutropenia on day 8, omit paclitaxel on day 8, and upon reaching day 1 proceed 
with carboplatin 1 dose level decreased, paclitaxel at same dose, and ABT-888 at same dose 
on day 1. For grade 4 neutropenia on day 15, omit paclitaxel on day 15, and upon reaching 
day 1 proceed with carboplatin 1 dose level decreased, paclitaxel at same dose, and ABT-
888 at same dose on day 1. 
For grade 1 thrombocytopenia on day 1, proceed with carboplatin at 1 dose level decreased, 
paclitaxel at same dose, and ABT-888 at same dose. For grade 2 thrombocytopenia on day 
1, delay day 1 until grade ≤ 1, then proceed with carboplatin 1 dose level decreased, 
paclitaxel at same dose, and ABT-888 at same dose. For grade 3 thrombocytopenia on day 
1, delay day 1 until grade ≤ 1, then proceed with carboplatin 1 dose level decreased, 
paclitaxel at same dose, and ABT-888 at 1 dose level decreased. For grade 4 
thrombocytopenia on day 1, delay day 1 until grade ≤ 1, then proceed with carboplatin 1 
dose level decreased, paclitaxel 1 dose level decreased, and ABT-888 at 1 dose level 
decreased.  

Alliance A091101 
 
Version Date: 08/11/2017 
48 
Update #07 
For grade 3 or 4 thrombocytopenia on day 8, omit paclitaxel on day 8, and upon reaching 
day 1 proceed with carboplatin 1 dose level decreased , paclitaxel at same dose, and ABT-
888 at 1 dose level decreased on day 1. For grade 3 or 4 thrombocytopenia on day 15, omit 
paclitaxel on day 15, and upon reaching day 1 proceed with carboplatin 1 dose level 
decreased, paclitaxel at same dose, and ABT-888 at 1 dose level decreased on day 1. 
6.1.2 Dose Modifications for Neurotoxicity (CTCAE Nervous System Disorders) during 
Induction 
• 
For any grade seizure, discontinue ABT-888.  Continue carboplatin and paclitaxel at 
same dose. 
• 
For grade 2 peripheral motor or sensory neuropathy, decrease paclitaxel by one dose 
level. Continue carboplatin and ABT-888 at the same dose. 
• 
For grade 3 or 4 peripheral motor or sensory neuropathy, delay all subsequent protocol-
directed therapy for a maximum of three weeks until grade ≤ 2, then decrease paclitaxel 
and carboplatin by one dose level for the next cycle and give ABT-888 at the same dose. 
• 
If induction (cycle 2) is delayed for more than three weeks, proceed to 
chemoradiotherapy. 
6.1.3 Musculoskeletal and Connective Tissue Toxicity During Induction 
• 
For grade 3 or 4 arthralgia, delay all subsequent protocol-directed therapy for a 
maximum of three weeks until grade ≤ 2, then decrease paclitaxel by one dose level for 
the next cycle, and give carboplatin and ABT-888 at the same dose. 
• 
If Induction (cycle 2) is delayed for more than 2 weeks for arthralgia or myalgia, proceed 
to chemoradiotherapy. 
6.1.4 Fatigue (CTCAE General Disorders and Administration Site Conditions) during 
Induction 
• 
For grade 3 or 4 fatigue, delay all subsequent protocol-directed therapy for a maximum 
of three weeks until grade ≤ 2, then decrease paclitaxel by one dose level for the next 
cycle, and give carboplatin and ABT-888, at the same dose. 
• 
If Induction (cycle 2) is delayed for more than three weeks for fatigue, proceed to 
chemoradiotherapy. 
6.1.5 GI Toxicity During Induction 
• 
For grade 2 mucositis, oral, decrease paclitaxel by one dose level for the next cycle, and 
give carboplatin and ABT-888 at the same dose. 
 • For grade 3 or 4 mucositis, oral, delay all subsequent protocol-directed therapy for a 
maximum of three weeks until grade ≤ 2, then decrease paclitaxel and carboplatin by 
one dose level for the next cycle, and give ABT-888 at the same dose. 
• 
For grade 3 or 4 nausea or vomiting, delay all subsequent protocol-directed therapy for 
a maximum of three weeks until grade ≤ 2, then decrease carboplatin 1 dose level, and 
give paclitaxel and ABT-888 at the same dose.  
• 
If Induction (cycle 2) is delayed for more than three weeks for mucositis, nausea, or 
vomiting, proceed to chemoradiotherapy. 

Alliance A091101 
 
Version Date: 08/11/2017 
49 
Update #07 
6.1.6 Dose Modifications for Liver Function During Induction 
• 
For grade 3 or 4 ALT, or AST, or alkaline phosphatase increase (CTCAE version 4.0, 
investigations section), delay all subsequent protocol-directed therapy for a maximum 
of three weeks until recovered until ALT, AST, and alkaline phosphatase improve to 
grade ≤ 2, then decrease paclitaxel and carbolatin by one dose level for the next cycle, 
and give the ABT-888 at the same dose. 
• 
For grade > 1 blood bilirubin increase, delay all subsequent protocol-directed therapy 
for a maximum of three weeks until recovered until bilirubin level improved to grade ≤ 
1, then decrease paclitaxel and carboplatin 1 dose level and give ABT-888 at the 
previous dose. 
• 
If Induction (cycle 2) is delayed for more than three weeks for abnormal liver function 
tests, proceed to chemoradiotherapy. 
6.1.7 Allergic Reactions 
• 
For grade 4 allergic reactions, or anaphylaxis, stop the infusion(s). Manage the reaction 
according to institutional procedure. Discontinue all protocol therapy. 
6.1.8 Other non-Hematologic Toxicity During Induction 
• 
For grade 3 or 4 other non-hematologic toxicity considered at least possibly related to 
treatment, delay all subsequent protocol-directed therapy for a maximum of three weeks 
until recovered to grade ≤ 1, then decrease the suspected drug(s) by one dose level for 
the next cycle. 
• 
If Induction (cycle 2) is delayed for more than three weeks, proceed to 
chemoradiotherapy. 
6.2 
Dose Modifications during Chemoradiotherapy, Option 1 (cisplatin) for phase I 
6.2.1 Hematologic Toxicity During Chemoradiotherapy 
• 
For grade 3 or 4 decrease in neutrophil count, delay cisplatin until ANC < grade 2, then 
give cisplatin at the planned dose (i.e., no dose reduction). If ANC does not improve to 
< grade 2 within 2 weeks, skip cisplatin. Continue radiotherapy. 
• 
For febrile neutropenia grade 3 or 4, wait for resolution before proceeding, and decrease 
cisplatin to 75mg/m2 for the next dose. 
• 
For grade > 2 platelet count decrease; delay cisplatin until platelets improve to grade < 
1, then give cisplatin at the planned dose (i.e., no dose reduction). If thrombocytopenia 
does not improve to < grade 1 within 2 weeks, skip cisplatin.  Continue radiotherapy. 
• 
For any grade platelet count decrease associated with bleeding, decrease cisplatin to 
75mg/m2 for the next dose. 
6.2.2 GI Toxicity during Chemoradiotherapy 
• 
For grade 3 or 4 nausea or vomiting during cisplatin, hold next cycle until grade 2 or 
less, then give next cycle cisplatin 75mg/m2 
• 
For grade 3 or 4 mucositis, continue cisplatin at same dose with no delays 
• 
For grade 3 or 4 dysphagia, continue cisplatin at same dose with no delays 
6.2.3 Skin Toxicity during Chemoradiotherapy 
For all grades radiation dermatitis, do not change dosing and do not delay cisplatin. 

Alliance A091101 
 
Version Date: 08/11/2017 
50 
Update #07 
6.2.3 Neurotoxicity during Chemoradiotherapy 
• 
For grade 2 neurotoxicity decrease cisplatin to 75mg/m2.  Start/continue radiotherapy. 
• 
For grade 3 or 4 neurotoxicity, discontinue cisplatin. Continue radiotherapy. 
6.2.4 Ototoxicity 
• 
For grade 2 hearing impairment or grade 2 tinnitus, decrease cisplatin to 50mg/m2.  
• 
For grade 3 hearing impairment or grade 3 tinnitus, discontinue cisplatin.  
• 
For patients with hearing impairment, audiogram is encouraged.  
6.2.5 Nephrotoxicity  during Chemoradiotherapy 
• 
For CRCL 40-50 mL/min, decrease cisplatin to 50 mg/m2 for that dose only. 
• 
For CRCL <40mL/min, discontinue cisplatin. Continue radiotherapy. 
6.3 
Dose modifications during Chemoradiotherapy, Option 2 (hydroxyurea/5FU/paclitaxel) 
for phase I 
Dose levels for chemotherapy during chemoradiotherapy 
 
Hydroxyurea 
5-FU 
Paclitaxel 
Dose Level 
 
 
 
0 
500 mg every 12 hr. 
x 11 doses 
600 mg/m2/day  
100 mg/m2 
–1 
500 mg every 24 hr. 
x 6 doses 
500 mg/m2/day 
75mg/ m2 
 
6.3.1 Hematologic toxicity 
• 
For grade 3 neutrophil count decreased on days of treatment in any cycle, decrease 
hydroxyurea by one dose level for this and all subsequent cycles. Continue paclitaxel, 
5-FU and radiotherapy at the planned doses. 
• 
For grade 4 neutrophil count decrease on days of treatment in any cycle, skip 
hydroxyurea for this cycle, and decrease hydroxyurea by one dose level for all 
subsequent cycles. Continue paclitaxel, 5-FU, and radiotherapy at the planned doses. 
• 
For grade 2 platelet count decrease on days of treatment in any cycle, decrease 
hydroxyurea by one dose level for this and all subsequent cycles.  Continue paclitaxel, 
5-FU and radiotherapy at the planned doses. 
• 
For grade 3 or 4 platelet count decrease on days of treatment in any cycle, skip 
hydroxyurea for this cycle and decrease paclitaxel and 5-FU by one dose level for the 
remainder of this cycle. Decrease hydroxyurea by one dose level for all subsequent 
cycles. Continue radiotherapy at the planned dose. 
• 
For > grade 2 neutrophil count decreased on any day of treatment with TFHX, 
administer filgrastim (or sargramostim per institutional procedures) SQ daily for 7 days, 
beginning at least 24 hours after the completion of 5-FU in this and all subsequent 
cycles. 
6.3.2  GI Toxicity During Chemoradiotherapy 

Alliance A091101 
 
Version Date: 08/11/2017 
51 
Update #07 
• 
For grade 4 mucositis, oral, lasting > 7 days or present on day 1 of any cycle, decrease 
5-FU by one dose level for this and all subsequent cycles.  Continue hydroxyurea, 
paclitaxel, and radiotherapy at the planned doses. 
• 
For grade 4 diarrhea lasting > 7 days or present on day 1 of any cycle, decrease 5-FU 
by one dose level for this and all subsequent cycles.  Continue hydroxyurea, paclitaxel, 
and radiotherapy at the planned doses. 
• 
For grade 4 dysphagia lasting > 7 days or present on day 1 of any cycle, decrease 5-FU 
by one dose level for this and all subsequent cycles.  Continue hydroxyurea, paclitaxel, 
and radiotherapy at the planned doses. 
6.3.3 Skin Toxicity during Chemoradiotherapy 
For grade 4 radiation dermatitis (CTCAE Injury, poisoning, and procedural complications) 
lasting > 7 days or present on day 1 of any cycle, decrease 5-FU by one dose level for this 
and all subsequent cycles.  Continue hydroxyurea, paclitaxel, and radiotherapy at the 
planned doses. 
6.3.4 Neurotoxicity during Chemoradiotherapy 
• 
For grade 2 peripheral neuropathy during chemoradiotherapy, decrease paclitaxel by 
one dose level and do not delay treatment. If neuropathy improves to grade 1 or less, 
can return to original dose level. Continue hydroxyurea and 5-FU at same dose.  
• 
For grade 3 or 4 peripheral neuropathy, discontinue paclitaxel. Continue hydroxyurea 
and 5FU at same dose. 
6.3.5 Nephrotoxicity During Chemoradiotherapy 
• 
For grade 2 nephrotoxicity, decrease hydroxyurea by one dose level for this cycle only. 
Do not change dose of paclitaxel or 5FU.  
• 
For grade 3 or 4 nephrotoxicity, skip hydroxyurea for this cycle only. Do not change 
dose of paclitaxel or 5FU. 
6.3.6 Dose Modifications for Liver Function during Chemoradiotherapy 
For grade 3 or 4 ALT or AST or alkaline phosphatase increase (CTCAE version 4.0, 
Investigations section), skip hydroxyurea for this cycle only. 
6.3.7 Other non-Hematologic Toxicity during Chemoradiotherapy 
For grade 3 or 4 other non-hematologic toxicity considered at least possibly related to 
treatment, hold the suspected drug ONLY until toxicity improves to grade < 1, then add 
back and decrease the suspected drug(s) by one dose level for the next cycle. Do not make 
any changes in drugs that are not related to the toxicity, and do not delay any cycles due to 
toxicity. 
7.0 
ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The following 
list of AEs (Section 7.1) and the characteristics of an observed AE (Section 7.2) will determine 
whether the event requires expedited reporting (via CTEP-AERS) in addition to routine reporting.   
7.1 
Comprehensive Adverse Events and Potential Risks List (CAEPR) 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform 

Alliance A091101 
 
Version Date: 08/11/2017 
52 
Update #07 
presentation of events by body system. In addition to the comprehensive list, a subset, the Agent 
Specific Adverse Event List (ASAEL), appears in a separate column and is identified with bold 
and italicized text. This subset of AEs (ASAEL) contains events that are considered 'expected' 
for expedited reporting purposes only. Refer to the 'CTEP, NCI Guidelines: Adverse Event 
Reporting 
Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for 
further clarification. The CAEPR does not provide frequency data; refer to the Investigator's 
Brochure for this information. 
For protocols with CAEPRs not including a “SPEER” category, protocol-specific exceptions to 
the CTEP-AERS reporting table can be found in the CAEPR’s “ASAEL” category instead.  This 
protocol-specific exception is limited to Grade 1 and Grade 2 ASAEL events, i.e. Grade 3 
through Grade 5 ASAEL-listed events are NOT exceptions to CTEP-AERS reporting. 
7.1.1 CAEPR for ABT-888 
Comprehensive Adverse Events and Potential Risks list (CAEPR) For ABT-888 
(Veliparib, NSC 737664) 
 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform presentation 
of events by body system. In addition to the comprehensive list, a subset, the Specific Protocol 
Exceptions to Expedited Reporting (SPEER), appears in a separate column and is identified with 
bold and italicized text. This subset of AEs (SPEER) is a list of events that are protocol specific 
exceptions to expedited reporting to NCI (except as noted below).  Refer to the 'CTEP, NCI 
Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for 
further clarification. Frequency is provided based on 2310 patients. Below is the CAEPR for ABT-
888 (Veliparib). 
 
NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses next to 
the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple 
investigational agents and has an AE listed on different SPEERs, use the lower of the grades to 
determine if expedited reporting is required. 
Version 2.3, March 4, 20161 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

Alliance A091101 
 
Version Date: 08/11/2017 
53 
Update #07 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
  
 
  
 
 
 
  
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by contacting 
PIO@CTEP.NCI.NIH.GOV.  Your name, the name of the investigator, the protocol and the agent should 
be included in the e-mail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
54 
Update #07 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
7.1.2 Radiation 
Radiation to the head and neck will cause skin irritation, dry mucous membranes due to 
salivary gland dysfunction, mucositis and stomatitis.  The concomitant administration of 
chemotherapy will aggravate these side effects.  Long-term side effects include myelitis, 
osteoradionecrosis, hoarseness, hypothyroidism, trismus, swallowing dysfunction, and 
fibrosis of soft tissues. 
7.1.3 Radiation Adverse Events 
Grade 3-4 therapy-induced mucositis and/or dysphagia, which are enhanced by cisplatin, 
are expected to develop in about two thirds of patients. Nutritional evaluation prior to the 
initiation of therapy for a prophylactic gastrostomy (PEG) tube placement is highly 
recommended. Placement of a feeding tube should be recorded, as should use of a feeding 
tube during and after treatment (e.g., greater than or less than 50% of nutrition by tube). 
Other common radiation adverse events include: fatigue, weight loss, regional alopecia, 
xerostomia, hoarseness, transient ear discomfort, dysgeusia, and skin erythema and 
desquamation within the treatment fields 

Alliance A091101 
 
Version Date: 08/11/2017 
55 
Update #07 
Less common long-term treatment adverse events include: hypothyroidism, loss of hearing, 
chronic swallowing dysfunction requiring permanent feeding tube, and cervical fibrosis. 
Much less common radiation adverse events include: mandibular osteoradionecrosis (< 5% 
incidence with attention to the dental recommendations provided in Appendix VI), and 
cervical myelopathy (<1% with restriction of spinal cord dose to ≤ 45 Gy). 
7.2 
Adverse Event Characteristics  
CTCAE term (AE description) and grade:  The descriptions and grading scales found in the 
revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be 
utilized for both routine and expedited AE reporting.  All appropriate treatment areas should 
have access to a copy of the CTCAE version 4.0.  A copy of the CTCAE version 4.0 can be 
downloaded 
from 
the 
CTEP 
web 
site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
For expedited reporting purposes only: 
AEs for the agent that are bold and italicized in the CAEPR (i.e., those listed in the SPEER 
column, Section 7.1.1) should be reported through CTEP-AERS only if the grade is above the 
grade provided in the SPEER. 
Other AEs for the protocol that do not require expedited reporting are outlined in Section 7.3.3. 
7.3 
Expedited Adverse Event Reporting 
Investigators are required by federal regulations to report serious adverse events as defined 
below. Alliance investigators are required to notify the Investigational Drug Branch, the 
Alliance Central Protocol Operations Program, the Study Chair, and their Institutional Review 
Board if a patient has an adverse event requiring expedited reporting. The descriptions and 
severity grading scales found in the NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0 will be utilized for reporting.  All treatment areas should have access to a 
copy of the CTCAE version 4.0. It can be downloaded from the CTEP website  
(http://ctep.cancer.gov). Be sure to read this entire protocol section, as requirements are 
described in both the table and bullet points following the table.  Note that the additional 
instructions or exclusions are protocol specific, and in the case of a conflict, the additional 
instructions or exclusions supercede the table.  
7.3.1 Expedited AE reporting for this study must use CTEP-AERS ( CTEP Adverse Event 
Reporting System), accessed via the CTEP Web site (http://ctep.cancer.gov). The reporting 
procedures to be followed are presented in the “NCI Guidelines for Investigators: Adverse 
Event Reporting Requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs” which 
can be downloaded from the CTEP Web site (http://ctep.cancer.gov). These requirements 
are briefly outlined in the tables below (Section 7.3.3). In the rare occurrence when Internet 
connectivity is lost, a 24-hour notification is to be made to CTEP by telephone at 301-897-
7497. Once Internet connectivity is restored, the 24-hour notification phoned in must be 
entered electronically into CTEP-AERS by the original submitter at the site. 
7.3.2 CTEP-AERS is programmed for automatic electronic distribution of reports to the following 
individuals: Protocol Coordinator, Study Chair, and the local treating physician. CTEP-
AERS provides a copy feature for other e-mail recipients. 
7.3.3 Expedited Reporting Guidelines 
Note: A death on study requires both routine and expedited reporting regardless of causality, 
unless as noted below. Attribution to treatment or other cause must be provided. Use the 

Alliance A091101 
 
Version Date: 08/11/2017 
56 
Update #07 
NCI protocol number and the protocol-specific patient ID assigned during trial registration 
on all reports.  
A091101: Expedited Reporting Requirements for Adverse Events that occur on studies under 
and IND within 30 Days of the last administration of the Investigational Agent/Intervention1 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312) 
NOTE:  Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events, 
whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 
312.64) 
An adverse event is considered serious if it results in ANY of the following outcomes:   
1) 
Death 
2) 
A life-threatening adverse event  
3) 
An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization 
for ≥ 24 hours  
4) 
A persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions  
5) 
A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon medical judgment, they may 
jeopardize the patient or subject and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6). 
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the NCI 
via CTEP-AERS within the timeframes detailed in the table below. 
Hospitalization 
Grade 1 and Grade 2 Timeframes 
Grade 3-5 
Timeframes 
Resulting in 
Hospitalization ≥ 24 hrs 
10 Calendar Days 
24-Hour 5 Calendar Days 
Not resulting in 
Hospitalization ≥ 24 hrs 
Not required 
Expedited AE reporting timelines are defined as: 
• “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP-AERS within 24 hours 
of learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 
24-hour report. 
• “10 Calendar Days” - A complete expedited report on the AE must be submitted within 10 calendar 
days of learning of the AE. 
1Serious adverse events that occur more than 30 days after the last administration of treatment require 
reporting as follows:  
Expedited 24-hour notification followed by complete report within 5 calendar days for: 
• All Grade 3, 4, and Grade 5 AEs that are at least possibly related to treatment 
Expedited 10 calendar day reports for: 
• Grade 2 AEs resulting in hospitalization or prolongation of hospitalization, and that are at least 
possibly related to treatment 
Effective Date:  May 5, 2011 

Alliance A091101 
 
Version Date: 08/11/2017 
57 
Update #07 
Additional instructions or exclusions to CTEP-AERS expedited reporting requirements 
for Alliance A091101: 
Treatment expected adverse events include those listed in Section 8.0 and in the package inserts 
for carboplatin, cisplatin, 5-FU, hydroxyurea, paclitaxel, and in the CAEPR for ABT-888.  Note 
that in the CAEPR, the ASAEL has been replaced by the Specific Protocol Exceptions to 
Expedited Reporting (SPEER) list. The SPEER includes “expected” severity grades in addition 
to event terms. All of these expected adverse events do not require CTEP-AERS reporting 
• Grade 3/4 hematosuppression and hospitalization from such do not require CTEP-AERS, but 
should be reported via routine data submission. 
• Grade 3/4 nausea or vomiting from cisplatin or carboplatin, and hospitalization from such do 
not require CTEP-AERS, but should be reported via routine data submission. 
•  Grade 3/4 dysphagia during chemoradiotherapy, and hospitalization from such, do not 
require CTEP-AERS, but should be reported via routine data submission. 
• Grade 3/4 dehydration or increased creatinine from cisplatin, and hospitalization from such, 
do not require CTEP-AERS, but should be reported via routine data submission. 
• Grade 3/4 hypersensitivity reactions to carboplatin, cisplatin, or paclitaxel do not require 
CTEP-AERS, but should be reported via routine data reporting. 
• Deaths due to progressive disease do not require CTEP-AERS, but should be reported via 
routine data submission. 
• The reporting of adverse events via CTEP-AERS is in addition to routine data submission, 
for those events requiring expedited reporting. 
• All new malignancies should be reported through CTEP-AERS independent of attribution to 
treatment.  This includes solid tumors (including non-melanoma skin cancers), hematologic 
malignancies, MOS, AML, and in-situ tumors. In CTCAE, new malignancies (second and 
secondary) may be reported as one of the following: leukemia secondary to oncology 
chemotherapy, myelodysplastic syndrome, treatment-related secondary malignancy, or 
neoplasm other, malignant (grade 3 or 4). Whenever possible, CTEP-AERS reports for new 
malignancies should include tumor pathology, history of prior tumors, prior treatment/ 
current treatment including duration, any associated risk factors or evidence regarding how 
long the new malignancy may have been present, when and how it was detected, molecular 
characterization or cytogenetics of the original and new malignancy (if available), and 
treatment and outcome of the new malignancy, if available. 
• All pregnancies and suspected pregnancies occurring in female patients during therapy or 
within 28 days after completion of therapy should be reported via CTEP-AERS. In CTCAE, 
pregnancy or suspected pregnancy should be reported as pregnancy, puerperium and 
perinatal conditions-other: fetal exposure (grade 4). 
7.4 
Routine Adverse Event Reporting 
All Adverse Events must be reported in routine study data submissions. AEs reported through 
CTEP-AERS must also be reported in routine study data submissions. 

Alliance A091101 
 
Version Date: 08/11/2017 
58 
Update #07 
8.0 
PHARMACEUTICAL INFORMATION 
8.1 
CTEP IND Agent ABT-888 (NSC 737664; IND #77840; veliparib) 
Availability 
 
Clinical Supplies:  ABT-888 (veliparib, NSC 737664/ IND 77840) and matching Placebo will 
be provided free of charge by AbbVie and distributed by the Pharmaceutical Management 
Branch (PMB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and 
Diagnosis (DCTD), National Cancer Institute (NCI). 
 
 
 
 
 
 
 
 
Phase I Open-label drug orders: No open-label starter supplies will be available for this study.  
Patient-specific supplies will be sent to the registering investigator at the time of registration 
and should arrive within 7 to 10 days. Once a patient has been registered, the Alliance 
Registration/Randomization Office will electronically transmit a clinical drug request for that 
patient to the PMB. This request will be entered and transmitted by the Alliance 
Registration/Randomization Office the day the patient is registered and will be processed by 
PMB the next business day and shipped the following business day.  Shipments within the 
United States will be sent by FedEx Ground (up to 5 business days).  Shipments to United States 
sites can be expedited by the provision of an express courier account name and number to the 
Alliance Registration/Randomization Office at the time the patient is registered/randomized. 
 
Initial supplies for patients registered to All Dose Levels 
The request will be for 64 capsule bottles of 50 mg ABT-888, a 2-cycle / 6-week supply at the 
prescribed dose level given orally BID on days 1 through 7 of each cycle.  This supply will be 
sufficient for the patient to complete the prescribed maximum of two cycles of induction with 
ABT-888. 
 
Dose 
Cohort 
ABT-888 (veliparib) Dose 
Supplies provided 
(50 mg capsules x 64 capsules/bottles) 
-3 
50 mg BID x 7 days 
1 bottle 
-2 
100 mg BID x 7 days 
2 bottles 
-1 
150 mg BID x 7 days 
2 bottles 
*0B 
200 mg BID x 7 days 
3 bottles 
1 
250 mg BID x 7 days 
3 bottles 
2 
300 mg BID x 7 days 
4 bottles 
3 
350 mg BID x 7 days 
4 bottles 
*starting dose level 
 
Note: In order to dispense a single cycle at a time, ABT-888/placebo capsules may be 
repackaged from the supplied HDPE bottles into amber (or other low-actinic) child resistant 
pharmacy dispensing bottles. The bottles should be labeled according to State regulations and 
also include the information from the original patient specific bottle sent from the PMB. 

Alliance A091101 
 
Version Date: 08/11/2017 
59 
Update #07 
Expiration will be 30 days from the repackaging date (or the original retest date, whichever is 
earlier) when stored at 15°C to 25°C (59°F to 77°F). 
 
Note: Partial bottles of patient specific supplies remaining after completion of treatment should 
be destroyed on-site per institutional policy and be recorded on the patient specific 
accountability log. 
 
Phase II Blinded drug orders: Once the Phase II dose has been determined, a protocol 
amendment will be completed to incorporate appropriate ordering instructions. 
 
ABT-888 (veliparib) and matching Placebo will be supplied in bottles containing either 64 – 50 
mg capsules ABT-888 (veliparib) or 64 – 0 mg capsules [Placebo for 50 mg ABT-888 (veliparib)] 
with a child-resistant cap and a tamper-evident seal.   Each blinded, patient-specific bottle will 
be labeled with … 
 
• the protocol number (i.e., “A091101”) 
• the bottle number (i.e., “Bottle 1 of 2” and “Bottle 2 of 2”) 
• the number of capsules (i.e., “64 capsules”) 
• the patient ID number (e.g.,"9999999", where “9999999” represents the unique patient 
identifier assigned at registration) 
• the patient initials (i.e., first initial, last initial [e.g., "FML"]) 
• the agent identification [i.e., “ABT-888 (veliparib) 50 mg or Placebo”] 
• a blank line for the pharmacist to enter the patient’s name  
• administration instructions (i.e., “Take __ capsules twice daily.”) 
• storage instructions (i.e., “Store at room temperature (15ºC to 25ºC; 59ºF to 77ºF).” 
• emergency contact instructions 
• a Julian date 
 
The Julian date indicates the day the bottle was labeled and shipped and is composed of the last 
two digits of the calendar year (e.g., 2009 = 09, 2010 = 10) and a day count (e.g., January 1 = 
001, December 31 = 365). For example, a bottle labeled and shipped on January 1, 2009 would 
have a Julian date of ‘09001’ and a bottle labeled and shipped on December 31, 2009 would 
have a Julian date of ‘09365’. The Julian date will be used by PMB for recalls. The Julian date 
should be recorded in the Lot No. field on the drug accountability record (DARF). When a lot 
expires, PMB will determine the last date the expired lot was shipped and will recall all bottles 
(i.e., both ABT-888 and Placebo) shipped on or before that date thus eliminating any chance of 
breaking the blind. 
 
Questions about drug orders, transfers, returns, or accountability should be addressed to the 
PMB by calling (240) 276-6575 Monday through Friday between 8:30am and 4:30pm Eastern 
Time. You may also contact the PMB via e-mail at: pmbafterhours@mail.nih.gov. 
 
Agent Transfers: Bottles MAY NOT be transferred from one patient to another patient or from 
one protocol to another protocol. All other transfers (e.g., a patient moves from one 
participating clinical site to another participating clinical site, the principal investigator at a 
given clinical site changes) must be approved in advance by the PMB. To obtain an approval 
for transfer, investigators should complete and submit to the PMB (fax number 240-276-7893) 
a 
Transfer 
Investigational 
Agent 
Form 
available 
on 
the 
CTEP 
home 
page 
(http://ctep.cancer.gov). The patient ID number (e.g., "9999999"') and the patient initials (e.g., 

Alliance A091101 
 
Version Date: 08/11/2017 
60 
Update #07 
"FML”) should be entered in the "Received on NCI Protocol No." and the "Transferred to NCI 
Protocol No." fields in addition to the protocol number (i.e., "A091101"). 
 
Agent Returns: Only undispensed clinical supplies should be returned to the PMB. 
When it is necessary to return study drug (e.g., sealed bottles remaining when a patient 
permanently discontinues protocol treatment, expired bottles recalled by the PMB), 
investigators should return the study drug to the PMB using the NCI Return Drug List available 
on the CTEP home page (http://ctep.cancer.gov) or by calling the PMB at (240) 276-6575. The 
patient ID number (e.g., "9999999") and the patient initials (e.g., "FML") should be entered in 
the "Lot Number" field.  Opened bottles with remaining capsules should be documented in the 
patient-specific NCI ORAL Investigational Agent Accountability Record (i.e., logged in as 
“returned by patient” and logged out as “destroyed on site”) and destroyed on-site in 
accordance with institutional policy. 
 
Agent Accountability: The investigator, or a responsible party designated by the investigator, 
must maintain a careful record of the receipt, disposition, and return of all drugs received from 
the PMB using the ORAL NCI Investigational Agent Accountability Record available on the 
CTEP home page (http://ctep.cancer.gov) or by calling the PMB at (240) 276-6575.  A separate 
NCI ORAL Investigational Agent Accountability Record must be maintained for each patient 
ID number (e.g., "9999999”) on this protocol (Phase I and Phase II).  
 
Emergency Unblinding Procedures (Phase II only): Unblinding can be done only in cases 
of an emergency.  Follow the directions below to unblind patient treatment.  Please note that, 
if a treatment assignment is unblinded, the patient must discontinue protocol therapy. Examples 
of emergencies include 1) a life-threatening unexpected adverse event that is at least possibly 
related to the investigational agent and for which unblinding would influence treatment 
decisions; or 2) medication error, such as accidental overdose.  Expected adverse events are 
listed in the “Toxicities” section below. 
 
Contact the Alliance Executive Office on call by calling 773-702-6800, pressing 1 to speak 
with an operator, and then asking for pager ID 8625 to return the call. 
 
The institution must provide the following information to the Alliance Executive Officer: 
• Alliance study ID (i.e., “A091101”) 
• Alliance patient ID number (e.g., “9999999”) 
• Patient initials (e.g., “L,FM”) 
• Institution name 
• Name and telephone number of treating physician 
• Name and contact information of person requesting the unblinding procedure 
• Name and contact information of person to inform of treatment assignment 
• Reason for emergency unblinding 
Please remember that emergency unblinding request may be authorized only by an Alliance 
Executive Officer, and emergency unblinding applies only if unblinding would influence 
management of the medical situation.  After the Executive Officer deems unblinding is 
warranted, the treatment assignment will be provided to the contact person at the treating site. 
 
 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
61 
Update #07 
 
 
 
 
Administration: ABT-888 is administered orally.  It may be taken without regard to meals. 
 
Potential Drug Interactions: Clinical studies evaluating the metabolism of ABT-888 have not 
been conducted. However, results from the in vitro analysis reveal that this agent is metabolized 
by multiple isoenzymes – CYP1A1, 2D6, 2C19 and 3A4. ABT-888 is neither a potent inhibitor 
nor a potent inducer of the CYP-450 isoenzymes. Use caution when concomitantly 
administered with drugs that are substrate, inhibitor, inducer of CYP1A1, 2D6, 2C19 and 3A4.  
ABT-888 clears primarily in the urine as intact parent drug along with metabolites suggesting 
that renal function plays an important role in the drug clearance and its metabolites. 
 
 
 
8.2 
Commercial Agents 
8.2.1 Carboplatin 
Please refer to the package insert for full prescribing information. 
Availability: Carboplatin is commercially available as a sterile lyophilized powder available 
in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin.  Each vial contains 
equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin 
will be used for this study. Carboplatin is also available as an aqueous solution in 50 mg/5 
mL, 150 mg/15 mL, 450 mg/45 mL and 600 mg/60 mL multidose vials. 
Preparation: Reconstitute lyophilized powder with Sterile Water, 0.9% Sodium Chloride, or 
5% Dextrose Injection with volumes of diluents specified below.  The reconstituted solution 
can be further diluted to a concentration as low as 0.5 mg/mL with 0.9% Normal Saline or 
5% Dextrose Injection. 
Vial Strength  
Diluent Volume 
50 mg 
 
5 mL 
150 mg  
15 mL 
450 mg  
45 mL 
Storage and Stability: When prepared as directed, the resultant carboplatin solutions, when 
protected from light, are stable for 8 hours at room temperature. No antibacterial 
preservative is contained in the formulation, and therefore, it is recommended that 
carboplatin solutions be discarded 8 hours after dilution. 
NOTE: Aluminum reacts with carboplatin, causing precipitate formation and loss of 
potency. Therefore, needles or intravenous sets containing aluminum parts that may 
come in contact with the drug must not be used for the preparation or administration of 
carboplatin. 
Unopened vials of carboplatin are stable for the life indicated on the package when stored 
at controlled room temperature (59 - 86°F) and protected from light. When prepared, 

Alliance A091101 
 
Version Date: 08/11/2017 
62 
Update #07 
carboplatin solutions are stable for 8 hours at room temperature. Carboplatin aqueous 
solution multidose vials maintain microbial, chemical, and physical stability for up to 14 
days at 25º C following multiple needle entries. 
8.2.2 Cisplatin 
Formulation:  Cisplatin is a sterile aqueous solution, each mL containing 1 mg cisplatin and 
9 mg sodium chloride.  Cisplatin is supplied in multidose vials of 50 mg and 100 mg 
cisplatin. 
NOTE:  Aluminum reacts with cisplatin causing precipitate formation and loss of potency; 
therefore, needles or intravenous sets containing aluminum parts that may come in contact 
with the drug must not be used for the preparation or administration of cisplatin. 
Storage and Stability: Storage Store intact vials at room temperature 15°C to 25°C (59°F to 
77°F) and protect from light. Do not refrigerate solution as a precipitate may form. Further 
dilution stability is dependent on the chloride ion concentration and should be mixed in 
solutions of NS (at least 0.3% NaCl). After initial entry into the vial, solution is stable for 
28 days protected from light or for at least 7 days under fluorescent room light at room 
temperature. 
Adverse effects: Leukopenia, thrombocytopenia, anemia, nausea, vomiting, nephrotoxicity, 
ototoxicity, peripheral neuropathy, electrolyte imbalance, hypocalcemia, hypomagnesemia, 
ocular toxicity, and allergic reactions.  Infrequent:  cardiac abnormalities, anorexia, elevated 
SGOT, rash, alopecia, and acute myeloid leukemia.   
NOTE:  Aminoglycoside antibiotics given before, with, or after cisplatin may potentiate 
renal toxicity and should be avoided whenever possible.   
Severe renal toxicity can largely be avoided by induction of a diuresis before, during and 
after treatment.  Mild renal dysfunction is a common complication (10%) of chronic therapy 
and may require discontinuation of therapy according to protocol specifications. 
Refer to package insert for complete details. 
Availability: Cisplatin is commercially available from Bristol Laboratories Oncology 
Products. 
8.2.3 Fluorouracil 
5-Fluorouracil (Adria, OH): commercially available as 10 ml ampules containing 
500 mg/10 ml.  No dilution is necessary for administration, but it may be further diluted in 
D5W or normal saline.  It is stored at room temperature and is stable for 24 hours.  It will 
be administered by intravenous continuous infusion.  Please refer to the package insert for 
full prescribing information. 
8.2.4 Paclitaxel 
Paclitaxel: Please refer to the package insert for information on preparation and for full 
prescribing information.  
Drug interactions: There is a potential for interaction with Ketoconazole, which might 
interfere with paclitaxel metabolism. Contraindications: Known hypersensitivity to either 
paclitaxel or Cremaphor EL. 
8.2.5 Hydroxyurea 
Hydroxyurea (Bristol-Myers Squibb, Princeton, NY): commercially available as 500 mg 
capsules. It is stored at room temperature and will be administered orally.  Please refer to 

Alliance A091101 
 
Version Date: 08/11/2017 
63 
Update #07 
the package insert for solution preparation and expected AE.  Please refer to the package 
insert for full prescribing information. 
Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred 
in patients with myeloproliferative disorders during therapy with hydroxyurea. These 
vasculitic toxicities were reported most often in patients with a history of, or currently 
receiving, interferon therapy. Due to potentially severe clinical outcomes for the cutaneous 
vasculitic ulcers reported in patients with myeloproliferative disease, hydroxyurea should 
be discontinued if cutaneous vasculitic ulcerations develop and alternative cytoreductive 
agents should be initiated as indicated. 
Geriatric Use:  Elderly patients may be more sensitive to the effects of hydroxyurea, and 
may require a lower dose regimen.   
This drug is known to be excreted by the kidney, and the risk of toxic reactions to this drug 
may be greater in patients with impaired renal function. Because elderly patients are more 
likely to have decreased renal function, care should be taken in dose selection, and it may 
be useful to monitor renal function. 
 
9.0 
CORRELATIVE SCIENCE COMPANION STUDY 
Description of correlative science sample collection, analysis, and statistical consideration to be 
added after the completion of the Phase I portion of the study. 

Alliance A091101 
 
Version Date: 08/11/2017 
64 
Update #07 
10.0 STUDY CALENDAR  
Baseline evaluations are to be conducted <4 weeks prior to start of protocol therapy.  Scans and x-
rays must be done <4 weeks prior to the start of therapy.  In the event that the patient’s condition is 
deteriorating, laboratory evaluations should be repeated within 48 hours prior to initiation of the next 
cycle of therapy.  
 
Pre-
Treatment 
Treatment 
Clinical Follow-Up 
Item 
Pre-
therapy 
Induction 
chemo- 
therapy 
(Wks 1-6)* 
CRT** 
2 wks 
after 
CRT 
1 month 
after 
CRT 
3 mos 
after 
CRT 
Clinical 
Follow-
up*** 
History and physical 
X 
X 
X  
X 
X 
X 
X 
ENT/Surgeon’s 
evaluation1 
X 
 
 
 
X 
X 
X 
Tumor map 
X 
 
 
 
 
 
 
Dental assessment 
X 
 
 
X 
X 
 
 
Barium swallowing 
assessment2 
X 
 
 
 
 
X 
X 
Patient Medication 
Calendar` 
 
X 
 
 
 
 
 
Performance status 
X 
X 
X 
X 
X 
X 
X 
Concomitant meds 
assessment3  
X 
X 
X  
X 
X 
X 
 
Adverse events 
 
X 
X  
X 
X 
X 
X 
Imaging4 
A 
B 
 
 
 
X 
X 
CBC, diff, platelets 
X 
weekly 
X 
X 
X 
X 
X 
Electrolytes (Na, K, Cl, 
bicarb) 
X 
weekly 
X 
X 
X 
X 
X 
Mg, Ca, Phosphorous  
X 
weekly 
X 
X 
X 
X 
C 
AST, ALT, Alk. Phos. 
bili 
X 
weekly 
X 
X 
X 
X 
X 
Albumin, total protein 
X 
weekly 
X 
X 
X 
X 
X 
Serum Creatinine 
X 
weekly 
X 
X 
X 
X 
X 
Creatinine Clearance5 
X 
X 
 
 
 
 
 
BUN 
X 
weekly 
X 
X 
X 
X 
X 
Glucose 
X 
weekly 
X 
X 
X 
X 
 
TSH, uric acid, PT/INR 
As clinically indicated 
mvHPV status in 
Oropharyngeal tumors 
X 
 
 
 
 
 
 
ECG 
X 
 
 
 
 
 
 
Pregnancy test 
X 
 
 
 
 
 
 
Biopsy 
X 
As clinically indicated 
 

Alliance A091101 
 
Version Date: 08/11/2017 
65 
Update #07 
* 
At the beginning of each cycle, unless otherwise noted 
** 
Concurrent CRT therapy is to begin within 10 days following the end of induction therapy. Tests and evaluations are to 
be done prior to beginning CRT, then weekly. 
*** 
6, 12, 18, 24, 30, 36, 48, and 60 months following the end of CRT. Patients who progress will move to the Survival 
Only Follow-up Phase and be followed every 6 months through year 5. 
1. 
An examination by an ENT or Head & Neck Surgeon, including laryngopharyngoscopy (mirror and/or fiberoptic 
and/or direct procedure). 
2. 
Barium swallowing assessments should be performed pre-treatment and in Months 10, 16, and 25 from the completion 
of chemoradiotherapy and as otherwise indicated. 
3. 
Document use of concomitant medications in physician or nursing note. 
4. 
The same imaging method should be used throughout the study. 
5. 
Can be calculated using Cockcroft-Gault formula. Recalculate if creatinine or weight change > 30%. In cases of low 
Creatinine Clearance or clinic disparities obtain 24-hour urine for CrCl calculation.  
6. 
PT (INR) evaluation will be included at pre-therapy only unless otherwise indicated. 
A 
Pre-therapy imaging options per physician preference: a) CT scan of the neck (with contrast) and a chest CT scan 
(with or without contrast); b) or an MRI of the neck and a chest CT scan (with or without contrast); c) or a CT scan of 
neck (with contrast) and a PET/CT of neck and chest (with or without contrast) within 4 weeks prior to registration.  
B 
During the last week of induction chemotherapy (week 6), patients will undergo primary endpoint image 
assessment. The same evaluation method as pre-treatment imaging must be used.  
C 
Only calcium and not magnesium and phosphorous need be measured during clinical follow-up. 
11.0 TREATMENT EVALUATION USING RECIST GUIDELINE 
NOTE:  This study uses protocol RECIST v1.1 template dated 2/16/2011.  See the footnote for the 
table regarding measureable disease in Section 11.4.4, as it pertains to data collection and analysis. 
Response and progression will be evaluated in this study using the new international criteria proposed 
by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1)52. 
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the short 
axis measurements in the case of lymph nodes are used in the RECIST guideline. 
11.1 
Schedule of Evaluations 
 
In order not to delay the start of concurrent CRT, patients should be reevaluated prior to 
concomitant CRT (during the last week of induction chemotherapy), where the response to 
induction chemotherapy will be assessed and measured (primary endpoint). The same imaging 
evaluation method that was used pre-treatment should also be used for imaging during the last 
week of induction chemotherapy.  
11.2 
Definitions of Measurable and Non-Measurable Disease 
11.2.1 Measurable Disease 
•  A non-nodal lesion is considered measurable if its longest diameter can be accurately 
measured as ≥2.0 cm with chest x-ray, or as ≥1.0 cm with CT scan, CT component of a 
PET/CT, or MRI.  
•  A superficial non-nodal lesion is measurable if its longest diameter is ≥ 1.0 cm in diameter 
as assessed using calipers (e.g. skin nodules) or imaging.  In the case of skin lesions, 
documentation by color photography, including a ruler to estimate the size of the lesion, is 
recommended. 
• A malignant lymph node is considered measurable if its short axis is >1.5 cm when 
assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm).   
NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease.   

Alliance A091101 
 
Version Date: 08/11/2017 
66 
Update #07 
11.2.2 Non-Measurable Disease 
All other lesions (or sites of disease) are considered non-measurable disease, including 
pathological nodes (those with a short axis ≥1.0 to <1.5 cm).  Bone lesions, leptomeningeal 
disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory 
breast disease, and abdominal masses (not followed by CT or MRI), are considered as non-
measurable as well. 
Note:  ‘Cystic lesions’ thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above. However, 
if non-cystic lesions are present in the same patient, these are preferred for selection as target 
lesions.  In addition, lymph nodes that have a short axis <1.0 cm are considered non-
pathological (i.e., normal) and should not be recorded or followed. 
11.3 
Guidelines for Evaluation of Measurable Disease 
11.3.1 Measurement Methods:   
• All measurements should be recorded in metric notation (i.e., decimal fractions of 
centimeters) using a ruler or calipers. 
• The same method of assessment and the same technique must be used to characterize each 
identified and reported lesion at baseline and during follow-up. For patients having only 
lesions measuring at least 1 cm to less than 2 cm must use CT imaging for both pre- and 
post-treatment tumor assessments.   
• Imaging-based evaluation is preferred to evaluation by clinical examination when both 
methods have been used at the same evaluation to assess the antitumor effect of a treatment.  
11.3.2 Acceptable Modalities for Measurable Disease: 
Conventional CT and MRI:  This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice 
thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the 
slice thickness.     
As with CT, if an MRI is performed, the technical specifications of the scanning sequences 
used should be optimized for the evaluation of the type and site of disease.  The lesions 
should be measured on the same pulse sequence.  Ideally, the same type of scanner should 
be used and the image acquisition protocol should be followed as closely as possible to prior 
scans.  Body scans should be performed with breath-hold scanning techniques, if possible. 
PET-CT:  If the site can document that the CT performed as part of a PET-CT is of identical 
diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the 
PET-CT can be used for RECIST measurements and can be used interchangeably with 
conventional CT in accurately measuring cancer lesions over time.   
Chest X-ray:  Lesions on chest x-ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung.  However, CT scans are preferable. 
Physical Examination:  For superficial non-nodal lesions, physical examination is 
acceptable, but imaging is preferable, if both can be done. In the case of skin lesions, 
documentation by color photography, including a ruler to estimate the size of the lesion, is 
recommended. 
FDG-PET:  FDG-PET scanning is allowed to complement CT scanning in assessment of 
progressive disease [PD] and particularly possible 'new' disease.  A ‘positive’ FDG-PET 
scanned lesion is defined as one which is FDG avid with an update greater than twice that 
of the surrounding tissue on the attenuation corrected image; otherwise, an FDG-PET 

Alliance A091101 
 
Version Date: 08/11/2017 
67 
Update #07 
scanned lesion is considered ‘negative.’  New lesions on the basis of FDG-PET imaging can 
be identified according to the following algorithm: 
a. Negative FDG-PET at baseline with a positive FDG-PET at follow-up is a sign of PD 
based on a new lesion. 
b. No FDG-PET at baseline and a positive FDG-PET at follow-up:   
i. 
If the positive FDG-PET at follow-up corresponds to a new site of disease 
confirmed by CT, this is PD.   
ii. 
If the positive FDG-PET at follow-up is not confirmed as a new site of disease on 
CT at the same evaluation, additional follow-up CT scans (i.e., additional follow-up scans 
at least 4 weeks later) are needed to determine if there is truly progression occurring at 
that site. In this situation, the date of PD will be the date of the initial abnormal PDG-PET 
scan.   
iii 
If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease 
on CT that is not progressing on the basis of the anatomic images, it is not classified as 
PD. 
c. After concurrent chemoradiotherapy, FDG-PET may be used to upgrade a response to a 
CR in a manner similar to a biopsy in cases where a residual radiographic abnormality is 
thought to represent fibrosis or scarring.  This post-treatment FDG-PET should be 
performed within 8-12 weeks after completion of concurrent chemoradiotherapy. The use 
of FDG-PET in this circumstance has been described in the protocol and supported by 
disease-specific medical literature for the indication. However, it must be acknowledged 
that both approaches may lead to false positive CR due to limitations of FDG-PET and 
biopsy resolution/sensitivity. 
11.4 
Measurement of Effect 
11.4.1 Target Lesions & Target Lymph Nodes 
• Measurable lesions (as defined in Section 11.2.1) up to a maximum of 5 lesions, 
representative of all involved organs, should be identified as “Target Lesions” and recorded 
and measured at baseline.  These lesions can be non-nodal or nodal (as defined in 11.2.1), 
where no more than 2 lesions are from the same organ and no more than 2 malignant nodal 
lesions are selected.  
Note: If fewer than 5 target lesions and target lymph nodes are identified (as there often will 
be), there is no reason to perform additional studies beyond those specified in the protocol 
to discover new lesions.   
• Target lesions and target lymph nodes should be selected on the basis of their size, be 
representative of all involved sites of disease, but in addition should be those that lend 
themselves to reproducible repeated measurements.  It may be the case that, on occasion, 
the largest lesion (or malignant lymph node) does not lend itself to reproducible 
measurements in which circumstance the next largest lesion (or malignant lymph node) 
which can be measured reproducibly should be selected.   
• Baseline Sum of Dimensions (BSD):  A sum of the longest diameter for all target lesions 
plus the sum of the short axis of all the target lymph nodes will be calculated and reported 
as the baseline sum of dimensions (BSD).  The BSD will be used as reference to further 
characterize any objective tumor response in the measurable dimension of the disease.   
• Post-Baseline Sum of the Dimensions (PBSD):  A sum of the longest diameter for all target 
lesions plus the sum of the short axis of all the target lymph nodes will be calculated and 
reported as the post-baseline sum of dimensions (PBSD).  If the radiologist is able to provide 
an actual measure for the target lesion (or target lymph node), that should be recorded, even 

Alliance A091101 
 
Version Date: 08/11/2017 
68 
Update #07 
if it is below 0.5 cm.  If the target lesion (or target lymph node) is believed to be present and 
is faintly seen but too small to measure, a default value of 0.5 cm should be assigned.  If it 
is the opinion of the radiologist that the target lesion or target lymph node has likely 
disappeared, the measurement should be recorded as 0 cm. 
The minimum sum of the dimensions (MSD) is the minimum of the BSD and the PBSD. 
11.4.2 Non-Target Lesions & Non-Target Lymph Nodes 
Non-measurable sites of disease (Section 11.2.2) are classified as non- target lesions or non-
target lymph nodes and should also be recorded at baseline.  These lesions and lymph nodes 
should be followed in accord with Section 11.4.3. 
11.4.3 Response Criteria 
All target lesions and target lymph nodes followed by CT/MRI/PET-CT/Chest X-
ray/physical examination must be measured on re-evaluation at evaluation times specified 
in Section 11.1.  Specifically, a change in objective status to either a PR or CR cannot be 
done without re-measuring target lesions and target lymph nodes.  
Note: Non-target lesions and non-target lymph nodes should be evaluated at each 
assessment, especially in the case of first response or confirmation of response.  In selected 
circumstances, certain non-target organs may be evaluated less frequently.  For example, 
bone scans may need to be repeated only when complete response is identified in target 
disease or when progression in bone is suspected. 
Evaluation of Target Lesions 
Complete Response (CR): 
All of the following must be true: 
a. 
Disappearance of all target lesions. 
b. 
Each target lymph node must have reduction in short axis to <1.0 cm. 
Partial Response (PR): 
At least a 30% decrease in PBSD (sum of the longest diameter for 
all target lesions plus the sum of the short axis of all the target lymph nodes at current 
evaluation) taking as reference the BSD (see Section 11.4.1). 
Progression (PD): 
At least one of the following must be true: 
a. 
At least one new malignant lesion, which also includes any lymph node that was 
normal at baseline (< 1.0 cm short axis) and increased to ≥ 1.0 cm short axis during follow-
up.  
b. 
At least a 20% increase in PBSD (sum of the longest diameter for all target lesions 
plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as 
reference the MSD (Section 11.4.1).  In addition, the PBSD must also demonstrate an 
absolute increase of at least 0.5 cm from the MSD.  
See Section 11.3.2 for details in regards to the requirements for PD via FDG-PET imaging. 
 Stable Disease (SD): 
Neither sufficient shrinkage to qualify for PR, nor sufficient 
increase to qualify for PD taking as reference the MSD. 
Evaluation of Non-Target Lesions & Non-target Lymph Nodes 
Complete Response (CR):All of the following must be true: 
a. 
Disappearance of all non-target lesions.  
b. 
Each non-target lymph node must have a reduction in short axis to <1.0 cm. 
Non-CR/Non-PD: Persistence of one or more non-target lesions or non-target lymph nodes. 
Progression (PD): At least one of the following must be true: 

Alliance A091101 
 
Version Date: 08/11/2017 
69 
Update #07 
a. 
At least one new malignant  
lesion, which also includes any lymph node that 
was normal at baseline (< 1.0 cm short axis) and increased to ≥ 1.0 cm short axis during 
follow-up.   
b. 
Unequivocal progression of existing non-target lesions and non-target lymph 
nodes.  (NOTE:  Unequivocal progression should not normally trump target lesion and target 
lymph node status.  It must be representative of overall disease status change.)  
c. 
See Section 11.3.2 for details in regards to the requirements for PD via FDG-PET 
imaging. 
11.4.4 Overall Objective Status 
The overall objective status for an evaluation is determined by combining the patient’s status 
on target lesions, target lymph nodes, non-target lesions, non-target lymph nodes, and new 
disease as defined in the following tables:  
For Patients with Measurable Disease  
Target Lesions & 
Target Lymph Nodes 
Non-Target Lesions & 
Non-Target Lymph 
Nodes 
New  
Sites of Disease 
Overall Objective 
Status 
CR 
CR 
No 
CR 
CR 
Non-CR/Non-PD 
No 
PR 
PR 
CR 
Non-CR/Non-PD 
No 
PR 
CR/PR 
Not All Evaluated* 
No 
PR** 
SD 
CR 
Non-CR/Non-PD 
Not All Evaluated* 
No 
SD 
Not all Evaluated 
CR 
Non-CR/Non-PD 
Not All Evaluated* 
No 
Not Evaluated 
(NE) 
PD 
Unequivocal PD 
CR 
Non-CR/Non-PD 
Not All Evaluated* 
Yes or No 
PD 
CR/PR/SD/PD/Not all 
Evaluated 
Unequivocal PD 
Yes or No 
PD 
CR/PR/SD/PD/Not all 
Evaluated 
CR 
Non-CR/Non-PD 
Not All Evaluated* 
Yes 
PD 
*See Section 11.4.3 
** NOTE:  This study uses the protocol RECIST v1.1 template dated 2/16/2011.  For data 
collection and analysis purposes the objective status changed from SD to PR in the NCCTG 
protocol RECIST v1.1 template as of 2/16/2011 and to match RECIST v1.1 requirements. 
11.4.5 Symptomatic Deterioration 
 Patients with global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time, and not either related to study 
treatment or other medical conditions, should be reported as PD due to “symptomatic 
deterioration.”  Every effort should be made to document the objective progression even 
after discontinuation of treatment due to symptomatic deterioration.  A patient is classified 

Alliance A091101 
 
Version Date: 08/11/2017 
70 
Update #07 
as having PD due to “symptomatic deterioration” if any of the following occur that are not 
either related to study treatment or other medical conditions: 
Worsening of tumor-related symptoms. 
Decline in performance status of >1 level on ECOG scale. 
11.5 
Formal statistical definitions  
Formal statistical definitions of analysis variables involving response and disease progression 
are contained in Section 13.0. 
12.0 DATA REPORTING / REGULATORY REQUIREMENTS 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 
(Adverse Events: List and Reporting Requirements). 
12.1 
Data Reporting 
12.1.1 Method 
This study will be monitored by the Clinical Data Update System (CDUS) Version 3.0.  
Cumulative protocol- and patient-specific CDUS data will be submitted electronically to 
CTEP on a quarterly basis, either by FTP burst of data or via the CDS web application.  
Reports are due January 31, April 30, July 31, and October 31.  Instructions for submitting 
data 
using 
the 
CDUS 
can 
be 
found 
on 
the 
CTEP 
Web 
site 
(http://ctep.cancer.gov/reporting/cdus.html).    
Note:  If your study has been assigned to CDUS-Complete reporting, all adverse events 
(both routine and expedited) that have occurred on the study and meet the mandatory CDUS 
reporting guidelines must be reported via the monitoring method identified above.  If your 
study has been assigned to CDUS-Abbreviated reporting, no adverse event reporting 
(routine or expedited) is required to be reported via CDUS. 
12.1.2 Data Submission 
This study will use Medidata Rave® for remote data capture (RDC) of all study data. The 
Rave system can be accessed through the iMedidata portal at https://login.imedidata.com. 
For additional information regarding account setup or training, please visit the training 
section of the Alliance website. 
Common Terminology Criteria for Adverse Events: This study will utilize the Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0 for toxicity and adverse 
event reporting. 
12.2 
Collaborative Agreements Language 
The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI 
under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical 
Company(ies) (hereinafter referred to as “Collaborator(s)”) and the NCI Division of Cancer 
Treatment and Diagnosis.  Therefore, the following obligations/guidelines, in addition to the 
provisions 
in 
the 
“Intellectual 
Property 
Option 
to 
Collaborator” 
http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm) contained within the 
terms of award, apply to the use of the Agent(s) in this study: 
1.   Agent(s) may not be used for any purpose outside the scope of this protocol, nor can 
Agent(s) be transferred or licensed to any party not participating in the clinical study.  
Collaborator(s) data for Agent(s) are confidential and proprietary to Collaborator(s) and shall be 
maintained as such by the investigators.  The protocol documents for studies utilizing Agents 

Alliance A091101 
 
Version Date: 08/11/2017 
71 
Update #07 
contain confidential information and should not be shared or distributed without the permission 
of the NCI.  If a copy of this protocol is requested by a patient or patient’s family member 
participating on the study, the individual should sign a confidentiality agreement.  A suitable 
model agreement can be downloaded from: http://ctep.cancer.gov. 
2.   For a clinical protocol where there is an investigational Agent used in combination with 
(an)other Agent(s), each the subject of different Collaborative Agreements, the access to and 
use of data by each Collaborator shall be as follows (data pertaining to such combination use 
shall hereinafter be referred to as "Multi-Party Data”): 
a.  
NCI will provide all Collaborators with prior written notice regarding the existence and 
nature of any agreements governing their collaboration with NCI, the design of the proposed 
combination protocol, and the existence of any obligations that would tend to restrict NCI's 
participation in the proposed combination protocol. 
b.  
Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical trial 
by any other Collaborator solely to the extent necessary to allow said other Collaborator to 
develop, obtain regulatory approval or commercialize its own Agent. 
c.  
Any Collaborator having the right to use the Multi-Party Data from these trials must agree 
in writing prior to the commencement of the trials that it will use the Multi-Party Data solely for 
development, regulatory approval, and commercialization of its own Agent. 
3.   Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement 
will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless 
additional disclosure is required by law or court order as described in the IP Option to 
Collaborator 
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm).  
Additionally, all Clinical Data and Results and Raw Data will be collected, used and disclosed 
consistent with all applicable federal statutes and regulations for the protection of human 
subjects, including, if applicable, the Standards for Privacy of Individually Identifiable Health 
Information set forth in 45 C.F.R. Part 164. 
4.   When a Collaborator wishes to initiate a data request, the request should first be sent to the 
NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group 
studies, or PI for other studies) of Collaborator's wish to contact them. 
5.   Any data provided to Collaborator(s) for Phase 3 studies must be in accordance with the 
guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC 
for this clinical trial. 
6.   Any manuscripts reporting the results of this clinical trial must be provided to CTEP by 
the Group office for Cooperative Group studies or by the principal investigator for non-
Cooperative Group studies for immediate delivery to Collaborator(s) for advisory review and 
comment prior to submission for publication.  Collaborator(s) will have 30 days from the date 
of receipt for review.  Collaborator shall have the right to request that publication be delayed for 
up to an additional 30 days in order to ensure that Collaborator’s confidential and proprietary 
data, in addition to Collaborator(s)’s intellectual property rights, are protected.  Copies of 
abstracts must be provided to CTEP for forwarding to Collaborator(s) for courtesy review as 
soon as possible and preferably at least three (3) days prior to submission, but in any case, prior 
to presentation at the meeting or publication in the proceedings. Press releases and other media 
presentations must also be forwarded to CTEP prior to release.  Copies of any manuscript, 
abstract and/or press release/ media presentation should be sent to: 
Email: ncicteppubs@mail.nih.gov  

Alliance A091101 
 
Version Date: 08/11/2017 
72 
Update #07 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No publication, 
manuscript or other form of public disclosure shall contain any of Collaborator’s confidential/ 
proprietary information. 
13.0 STATISTICAL CONSIDERATIONS 
13.1 
Study Design/Endpoints 
13.1.1 Phase 1 
The maximum tolerated dose (MTD) will be determined in the Phase I portion of this trial. 
Patients will be placed in one of the dose cohorts of ABT-888 listed in Section 5.1.1, using 
a conventional 3+3 design. All patients will receive concomitant paclitaxel and carboplatin. 
The initial dose cohort is anticipated to be 30 mg BID (Abbott Personal Communication) 
and, together with doses for subsequent cohorts will be adjusted at the time of protocol 
initiation based on available data from other phase I studies in discussion with Abbott 
Pharmaceuticals and NCI. The Alliance will notify CTEP when the Recommended Phase II 
Dose (RP2D) is reached, and an amendment will be submitted to open the phase II portion 
of the study. 
13.1.2 Randomized Phase 2 
The primary endpoint will be the relative change in tumor size following 2 cycles of 
induction, rather than a dichotomous objective response rate.50,51 This trial design is based 
on the ratio of tumor size measurements (post-treatment/baseline) which has been shown to 
follow the log-normal distribution; a two-sample t-test is then commonly used to compare 
the log-ratios between treatment arms. Tumor size will be measured using the RECIST 
criteria (i.e. the sum of the longest diameters of all target lesions will be used). The 
advantage of using continuous tumor size change is the reduction in sample size relative to 
a two-arm design with a dichotomous endpoint, which can be 44%-64% under several 
scenarios considered by Lavin. Furthermore, a single-arm trial will not be appropriate due 
to the lack of reliable historical data. 
Formulated in terms of “good response” rate following induction chemotherapy (defined as 
> 50% reduction in the sum of target lesions), detecting a difference between 20% vs. 40% 
"good response" rates would be of interest. This difference in proportions corresponds to a 
difference in log-ratios of -1.091 versus -1.453. Based on the tumor size changes among 
patients enrolled on the carboplatin-paclitaxel induction regimen in UC protocol 13362B [A 
Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients with 
N2/N3 Locally Advanced Head and Neck Cancer], the standard deviation (SD) of the log-
ratios of tumor size change was SD=0.616, and the log-normality assumption was satisfied. 
Because a CR rate of 5-10% is expected based on prior trials with induction chemotherapy 
at the University of Chicago, the use of a t-test would be problematic, given that the log-
ratio will be undefined for CR's. Instead, patients with CR will be assigned the lowest rank 
(lower rank corresponds to better outcome), and treatment arms will be compared using the 
nonparametric Wilcoxon rank-sum test. Similarly, patients who die during treatment will be 
assigned the highest rank (corresponding to the worst outcome).  
An interim analysis for futility will be performed when half of the patients have completed 
induction. The trial will be stopped early if the sum of ranks is lower than expected in the 
placebo arm and the Wilcoxon rank-sum test statistic is Z<0, i.e. when the interim analysis 
does not favor the treatment group. 
A simulation study was performed to determine the sample size. Data were generated from 
a mixture distribution where the outcome was CR with probability pj, not evaluable (drop-

Alliance A091101 
 
Version Date: 08/11/2017 
73 
Update #07 
out or death) with probability dj, and lognormally distributed with probability (1 - pj - dj);  
j=1,2 denotes placebo and ABT-888 arms, respectively. An early stopping rule was 
incorporated. The following scenario was considered: CR rates p1=0.05 and p2=0.10; drop-
our rates d1=0.10 and d2=0.07 (assuming fewer deaths in the ABT-888 arm); tumor size log-
ratios distributed with μ1 = -1.091, μ2=-1.091 and σ1 = σ2 = 0.616 (as described above). Based 
on R=10,000 simulations, the sample size of 46 patients/arm (92 total) will have 81% power 
with one-sided α=0.05. Note that the sample size is almost 45% less than 64 patients/arm 
that would be required for a randomized two-arm trial comparing response rates. 
13.2 
Sample Size/Accrual Rate 
We plan to enroll 18 patients in the Phase 1 portion of the study at an accrual rate of 1 to 4 
patients per month. In the Phase 2 portion we plan to enroll 92 patients, at an accrual rate of 5 
to 10 patients per month. Study accrual will be monitored and an accrual plan will be instituted 
if deemed necessary. 
 
TARGETED/PLANNED ENROLLMENT - NUMBER OF SUBJECTS 
 
 
 
 
Hispanic or Latino Category 
 
Phase I/II Trial – total anticipated sample 
size is up to 110 subjects (up to 18 subjects to be 
enrolled in the Phase I portion and 46 patients per 
induction chemotherapy treatment arm). 
Sex 
Female 
Male 
Total 
Hispanic or Latino 
3 
7 
10 
Not Hispanic or Latino 
20 
80 
100 
Ethnic Category: Total of All Subjects 
23 
87 
110 
Racial Categories 
 
 
 
Others and Mixed 
1 
2 
3 
Asian 
2 
3 
5 
Black or AA 
8 
22 
30 
White or Caucasian 
12 
60 
72 
Ethnic Categories: Total of All Subjects 
23 
87 
110 
 
13.3 
Stratification Factors 
13.3.1 Phase II: 
In the Phase II part of this trial, patients will be randomized in a double-blinded fashion to 
induction therapy with carboplatin and paclitaxel plus ABT-888 or placebo; and the patient's 
subsequent therapy will be determined by institution guidelines between two options of 
concurrent chemoradiotherapy options. Randomization will be stratified by tumor/nodal 
status (T1-3 and N0-N2a versus T4 and/or N2b-N3 respectively), oropharyngeal 
disease/HPV status (non-oropharyngeal disease versus oropharyngeal disease with HPV 
positive status versus oropharyngeal disease with HPV negative status) and institution 
(implicitly stratifies by concomitant CRT, as it is planned that concomitant CRT will be an 
institution level choice) and permuted blocks will be used to balance patient allocation. 
13.4 
Analysis of Secondary Endpoints 
Secondary endpoints include evaluation and comparison of toxicity rates during induction and 
overall; time-to-event endpoints [progression-free survival (PFS), disease-free survival (DFS), 

Alliance A091101 
 
Version Date: 08/11/2017 
74 
Update #07 
time to local or distant progression, disease-specific survival (DSS), and overall survival (OS)]. 
Toxicity rates will be summarized by group, and compared between groups using the chi-
squared or Fisher's exact test. Time-to-event endpoints (PFS, DFS and OS) will be summarized 
using the method of Kaplan-Meier, and compared between groups using the log-rank test. 
Multivariate Cox proportional hazards regression models will be used to further explore group 
differences adjusting for other prognostic factors, as well as to estimate hazard ratios. Cause-
specific survival will be summarized using cumulative incidence, and will be compared between 
groups using Gray's test. Other methods appropriate for the analysis of competing risks data 
(e.g. Fine-Gray regression models) may also be used. 
13.5 
Reporting and Exclusions 
13.5.1 Evaluation of toxicity 
All patients will be evaluable for toxicity from the time of their first treatment with ABT-
888.  
13.5.2 Evaluation of response  
All patients included in the study must be assessed for response to treatment, even if there 
are major protocol treatment deviations or if they are ineligible.  Each patient will be 
assigned one of the following categories:  1) complete response, 2) partial response, 3) stable 
disease, 4) progressive disease, 5) early death from malignant disease, 6) early death from 
toxicity, 7) early death because of other cause, or 9) unknown (not assessable, insufficient 
data).  [Note:  By arbitrary convention, category 9 usually designates the “unknown” status 
of any type of data in a clinical database.] 
All of the patients who met the eligibility criteria (with the possible exception of those who 
received no study medication) should be included in the main analysis of the response rate.  
The 95% confidence interval will also be provided. Patients in response categories 4-9 
should be considered to have a treatment failure (disease progression).  Thus, an incorrect 
treatment schedule or drug administration does not result in exclusion from the analysis of 
the response rate.  Precise definitions for categories 4-9 will be protocol specific.  
All conclusions should be based on all eligible patients.  Subanalyses may then be performed 
on the basis of a subset of patients, excluding those for whom major protocol deviations 
have been identified (e.g., early death due to other reasons, early discontinuation of 
treatment, major protocol violations, etc.).  However, these subanalyses may not serve as 
the basis for drawing conclusions concerning treatment efficacy, and the reasons for 
excluding patients from the analysis should be clearly reported  
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
75 
Update #07 
14.0 REFERENCES 
1. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous 
cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. 
Journal of Clinical Oncology. March 1, 1996 1996;14(3):838-847. 
2. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for 
head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. The Lancet. 
2000;355(9208):949-955. 
3. Pignon J-P, le Maitre A, Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer 
(MACH-NC): An Update. International Journal of Radiation Oncology*Biology*Physics. 
2007;69(2, Supplement 1):S112-S114. 
4. Pignon J-P, Maître Al, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck 
cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and 
Oncology. 2009;92(1):4-14. 
5. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent 
accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck 
squamous cell carcinomas (HNC). ASCO Meeting Abstracts. June 9, 2011 2011;29(15_suppl):5500. 
6. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival 
in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-
year, 337-patient, multi-institutional experience. Annals of Oncology. August 1, 2004 
2004;15(8):1179-1186. 
7. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in 
unresectable head and neck cancer. N Engl J Med. Oct 25 2007;357(17):1695-1704. 
8. Hitt R, Grau JJ, Lopez-Pousa A, et al. Final results of a randomized phase III trial comparing 
induction 
chemotherapy 
with 
cisplatin/5-FU 
or 
docetaxel/cisplatin/5-FU 
follow 
by 
chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced 
head and neck cancer (LAHNC). J Clin Oncol (Meeting Abstracts). May 20, 2009 
2009;27(15S):6009-. 
9. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX 
chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 
Dec 1 2003;9(16 Pt 1):5936-5943. 
10. 
Salama JK, Stenson KM, Kistner EO, et al. Induction chemotherapy and concurrent 
chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II 
trial investigating three radiotherapy dose levels. Annals of Oncology. October 1, 2008 
2008;19(10):1787-1794. 
11. 
León X, Quer M, Orús C, del Prado Venegas M, López M. Distant metastases in head and 
neck cancer patients who achieved loco-regional control. Head & Neck. 2000;22(7):680-686. 
12. 
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with 
oropharyngeal cancer. N Engl J Med. Jul 1 2010;363(1):24-35. 
13. 
Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. Aug 
2004;26(8):882-893. 
14. 
Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced 
expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol. Aug 
1991;37(4):223-227. 

Alliance A091101 
 
Version Date: 08/11/2017 
76 
Update #07 
15. 
Shiobara M, Miyazaki M, Ito H, et al. Enhanced polyadenosine diphosphate-ribosylation 
in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol 
Hepatol. Mar 2001;16(3):338-344. 
16. 
Fukushima M, Kuzuya K, Ota K, Ikai K. Poly(ADP-ribose) synthesis in human cervical 
cancer cell-diagnostic cytological usefulness. Cancer Lett. Dec 1981;14(3):227-236. 
17. 
Alderson T. New targets for cancer chemotherapy--poly(ADP-ribosylation) processing and 
polyisoprene metabolism. Biol Rev Camb Philos Soc. Nov 1990;65(4):623-641. 
18. 
Wielckens K, Garbrecht M, Kittler M, Hilz H. ADP-ribosylation of nuclear proteins in 
normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. Eur J Biochem. Feb 
1980;104(1):279-287. 
19. 
Berger NA, Adams JW, Sikorski GW, Petzold SJ, Shearer WT. Synthesis of DNA and 
poly(adenosine diphosphate ribose) in normal and chronic lymphocytic leukemia lymphocytes. J Clin 
Invest. Jul 1978;62(1):111-118. 
20. 
Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphate-ribose) 
metabolism in human colon adenomatous polyps and cancers. Cancer Res. Jul 1983;43(7):3441-
3446. 
21. 
Fernet M, Ponette V, Deniaud-Alexandre E, et al. Poly(ADP-ribose) polymerase, a major 
determinant of early cell response to ionizing radiation. Int J Radiat Biol. Dec 2000;76(12):1621-
1629. 
22. 
Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the 
deficient mouse model? Mutat Res. Jun 30 2000;460(1):1-15. 
23. 
Masutani M, Nozaki T, Nakamoto K, et al. The response of Parp knockout mice against 
DNA damaging agents. Mutat Res. Apr 2000;462(2-3):159-166. 
24. 
Ame JC, Rolli V, Schreiber V, et al. PARP-2, A novel mammalian DNA damage-
dependent poly(ADP-ribose) polymerase. J Biol Chem. Jun 18 1999;274(25):17860-17868. 
25. 
Menissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 
and PARP-2 in chromosome stability and embryonic development in mouse. Embo J. May 1 
2003;22(9):2255-2263. 
26. 
Schreiber V, Ame JC, Dolle P, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required 
for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem. Jun 21 
2002;277(25):23028-23036. 
27. 
Johansson M. A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA 
cloning of two novel poly(ADP-ribose) polymerase homologues. Genomics. May 1 1999;57(3):442-
445. 
28. 
Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-
dependent cell death by apoptosis-inducing factor. Science. Jul 12 2002;297(5579):259-263. 
29. 
D'Amours D, Sallmann FR, Dixit VM, Poirier GG. Gain-of-function of poly(ADP-ribose) 
polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis. J Cell Sci. Oct 
2001;114(Pt 20):3771-3778. 
30. 
Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res. Jun 30 
2000;451(1-2):39-51. 
31. 
Ruscetti T, Lehnert BE, Halbrook J, et al. Stimulation of the DNA-dependent protein 
kinase by poly(ADP-ribose) polymerase. J Biol Chem. Jun 5 1998;273(23):14461-14467. 

Alliance A091101 
 
Version Date: 08/11/2017 
77 
Update #07 
32. 
Galande S, Kohwi-Shigematsu T. Poly(ADP-ribose) polymerase and Ku autoantigen form 
a complex and synergistically bind to matrix attachment sequences. J Biol Chem. Jul 16 
1999;274(29):20521-20528. 
33. 
Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) 
polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. 
Carcinogenesis. Feb 1999;20(2):199-203. 
34. 
Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of 
base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to 
methylating agents. Clin Cancer Res. Oct 1999;5(10):2908-2917. 
35. 
Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its 
inhibitors. Nat Rev Drug Discov. May 2005;4(5):421-440. 
36. 
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours 
with inhibitors of poly(ADP-ribose) polymerase. Nature. Apr 14 2005;434(7035):913-917. 
37. 
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant 
cells as a therapeutic strategy. Nature. Apr 14 2005;434(7035):917-921. 
38. 
Masutani M, Suzuki H, Kamada N, et al. Poly(ADP-ribose) polymerase gene disruption 
conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci U S A. Mar 2 
1999;96(5):2301-2304. 
39. 
de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) 
polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A. Jul 8 
1997;94(14):7303-7307. 
40. 
Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and 
DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and 
poly(ADP-ribose) polymerase-1. Cancer Res. Sep 15 2003;63(18):6008-6015. 
41. 
Brock WA, Milas L, Bergh S, Lo R, Szabo C, Mason KA. Radiosensitization of human 
and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 
Mar 18 2004;205(2):155-160. 
42. 
Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and 
radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer 
Inst. Jan 7 2004;96(1):56-67. 
43. 
Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic 
parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. Oct 
1997;283(1):46-58. 
44. 
Tan AR, Toppmeyer D, Stein MN, et al. Phase I trial of ABT-888 (veliparib), (ABT-888), 
a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and 
cyclophosphamide in breast cancer and other solid tumors. ASCO Meeting Abstracts. June 9, 2011 
2011;29(15_suppl):3041. 
45. 
LoRusso P, Ji JJ, Li J, et al. Phase I study of the safety, pharmacokinetics (PK), and 
pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib) 
(ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid 
tumors. ASCO Meeting Abstracts. June 9, 2011 2011;29(15_suppl):3000. 
46. 
Chiarugi A. Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' 
revisited. Trends Pharmacol Sci. Mar 2002;23(3):122-129. 
47. 
Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. 
Pharmacol Rev. Sep 2002;54(3):375-429. 

Alliance A091101 
 
Version Date: 08/11/2017 
78 
Update #07 
48. 
Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Reconstitution of DNA 
base excision-repair with purified human proteins: interaction between DNA polymerase beta and 
the XRCC1 protein. EMBO J. Dec 2 1996;15(23):6662-6670. 
49. 
D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in 
temozolomide-induced apoptosis. Mol Pharmacol. Aug 1998;54(2):334-341. 
50. 
Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using 
a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in 
non small-cell lung cancer. J Natl Cancer Inst. Oct 3 2007;99(19):1455-1461. 
51. 
Lavin PT. An alternative model for the evaluation of antitumor activity. Cancer Clin Trials. 
Winter 1981;4(4):451-457. 
52. 
Eisenhauer EA, Therasse P, Bogaert J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck 
S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.  New 
response evaluation criteria in solid tumors:  revised RECIST guideline (version 1.1).  Eur J Cancer 
45(2):  228-247, 2009. 
53. 
Herman, L.C., et al., Comparison of carboplatin–paclitaxel to docetaxel–cisplatin-5–
flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced 
head and neck cancer. Oral Oncology, (0). 
54. 
Airoldi, M., et al., Induction chemotherapy with carboplatin and taxol followed by 
radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal 
carcinoma. Cancer Chemotherapy and Pharmacology, 2011. 67(5): p. 1027-1034. 
55. 
Cmelak, A.J., et al., Phase II Trial of Chemoradiation for Organ Preservation in Resectable 
Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern 
Cooperative Oncology Group Study E2399. Journal of Clinical Oncology, 2007. 25(25): p. 3971-
3977. 
56. 
Machtay, M., et al., Organ Preservation Therapy Using Induction Plus Concurrent 
Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania 
Phase II Trial. Journal of Clinical Oncology, 2002. 20(19): p. 3964-3971. 
57. 
Salama, J.K., et al., Induction chemotherapy and concurrent chemoradiotherapy for 
locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three 
radiotherapy dose levels. Annals of Oncology, 2008. 19(10): p. 1787-1794. 
58. 
Vokes, E.E., et al., Weekly Carboplatin and Paclitaxel Followed by Concomitant 
Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving 
Therapy for Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2003. 21(2): p. 320-
326. 

Alliance A091101 
 
Version Date: 08/11/2017 
79 
Update #07 
APPENDIX A- PERFORMANCE STATUS CRITERIA 
 
ECOG Performance Status Scale 
Grade 
Descriptions 
0 
Normal activity.  Fully active, able to 
carry on all pre-disease performance 
without restriction. 
1 
Symptoms, 
but 
ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able to 
carry out work of a light or sedentary 
nature (e.g., light housework, office 
work). 
2 
In bed <50% of the time.  Ambulatory 
and capable of all self-care, but unable 
to carry out any work activities.  Up 
and about more than 50% of waking 
hours. 
3 
In bed >50% of the time.  Capable of 
only limited self-care, confined to bed 
or chair more than 50% of waking 
hours. 
4 
100% 
bedridden. 
 
Completely 
disabled.  Cannot carry on any self-
care.  Totally confined to bed or chair. 
5 
Dead. 
 

Alliance A091101 
 
Version Date: 08/11/2017 
80 
Update #07 
APPENDIX B - HEAD & NECK STAGING 
Edge, SB, ed. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010. 
 
PRIMARY TUMOR (T) 
TX 
Primary tumor cannot be assessed 
T0 
No evidence of primary tumor 
Tis 
Carcinoma in situ 
 
 
LIP and ORAL CAVITY 
 
TX 
Primary tumor cannot be assessed 
T0 
No evidence of primary tumor 
Tis 
Carcinoma in situ 
T1 
Tumor 2 cm or less in greatest dimension 
T2 
Tumor more than 2 cm but not more than 4 cm in greatest dimension 
T3 
Tumor more than 4 cm in greatest dimension 
T4a 
Moderately advanced local disease* 
 
(lip) Tumor invades through cortical bone, inferior alveolar nerve, floor of 
mouth, or skin of face (i.e., chin or nose) 
 
(oral cavity) Tumor invades adjacent structures only (e.g., through cortical bone 
[mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, 
hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face) 
T4b 
Very advanced disease 
 
Tumor  invades  masticator  space,  pterygoid  plates  or  skull base and/or  encases  
internal carotid artery 
*Note: Superficial erosion alone of bone/tooth socket by gingival primary is not sufficient to classify a 
tumor as T4. 
NASAL CAVITY and PARANASAL SINUSES Maxillary Sinus 
T1 
Tumor limited to maxillary sinus mucosa with no erosion or destruction of bone 
T2 
Tumor causing bone erosion or destruction including extension into the hard palate 
and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and 
pterygoid plates 
T3 
Tumor invades any of the following: bone of the posterior wall of maxillary sinus, 
subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses 
T4a 
Moderately advanced local disease 
 
Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, 
infratemporal fossa, cribriform plate, sphenoid or frontal sinuses 
T4b 
Very advanced local disease 
 
Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, 
cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx or 
clivus 

Alliance A091101 
 
Version Date: 08/11/2017 
81 
Update #07 
Nasal Cavity and Ethmoid Sinus 
T1 
Tumor restricted to any one subsite, with or without bony invasion 
T2 
Tumor invading two subsites in a single region or extending to involve an adjacent 
region within the nasoethmoidal complex, with or without bony invasion 
T3 
Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, 
or cribriform plate 
T4a 
Moderately advanced local disease 
 
Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, 
minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal 
sinuses 
T4b 
Very advanced local disease 
 
Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, 
cranial nerves other than V2, nasopharynx, or clivus 
PHARYNX Nasopharynx 
T1 
Tumor confined to the nasopharynx, or tumor extends to oropharynx and/or nasal 
cavity with 
out parapharyngeal extension* 
T2 
Tumor with parapharyngeal extension* 
T3 
Tumor involves bony structures of skull base and/or paranasal sinuses 
T4 
Tumor with intracranial extension and/or involvement of cranial nerves, 
hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space 
 
*Note: Parapharyngeal extension denotes posterolateral infiltration of tumor. 
 
Oropharynx 
T1 
Tumor 2 cm or less in greatest dimension 
T2 
Tumor more than 2 cm but not more than 4 cm in greatest dimension 
T3 
Tumor more than 4 cm in greatest dimension or extension to lingual surface of 
epiglottis 
T4a 
Moderately advanced local disease 
 
Tumor  invades  the  larynx,  extrinsic  muscle  of  tongue,  medial  pterygoid,  hard  
palate,  or mandible* 
T4b 
Very advanced local disease 
 
Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or 
skull base or encases carotid artery 
 
*Note: Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the 
tongue and vallecula does not constitute invasion of larynx. 
 
Hypopharynx 
T1 
Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest 
dimension 
T2 
Tumor invades more than one subsite of hypopharynx or an adjacent site, or 
measures more than 2 cm but not more than 4 cm in greatest diameter without 

Alliance A091101 
 
Version Date: 08/11/2017 
82 
Update #07 
fixation of hemilarynx 
T3 
Tumor measures more than 4 cm in greatest dimension or with fixation of 
hemilarynx or extension to esophagus 
T4a 
Moderately advanced local disease 
 
Tumor  invades  thyroid/cricoid  cartilage,  hyoid  bone,  thyroid  gland,  esophagus  
or  central compartment soft tissue.* 
T4b 
Very advanced local disease 
 
Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal 
structures 
 
*Note: Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat. 
LARYNX 
 
Supraglottis 
T1 
Tumor limited to one subsite of supraglottis with normal vocal cord mobility 
T2 
Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis 
or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial 
wall of pyriform sinus) without fixation of the larynx 
T3 
Tumor limited to larynx with vocal cord fixation and/or invades any of the following:  
postcricoid area, pre-epiglottic tissues, paraglottic space, and/or inner cortex of thyroid 
cartilage 
T4a 
Moderately advanced local disease 
 
Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of the neck including deep extrinsic muscle of the tongue, 
strap muscles, thyroid, or esophagus) 
T4b 
Very advanced local disease 
 
Tumor invades prevertebral space, encases carotid artery, or invades mediastinal 
structures 
 
Glottis 
T1 
Tumor limited to the vocal cord(s) [may involve anterior or posterior commissure] 
with normal mobility 
T1a 
Tumor limited to one vocal cord 
T1b 
Tumor involves both vocal cords 
T2 
Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord 
mobility 
T3 
Tumor limited to the larynx with vocal cord fixation, and/or invasion of 
paraglottic space, and/or inner cortex of the thyroid cartilage 
T4a 
Moderately advanced local disease 
 
Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues 
beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle 
of the tongue, strap muscles, thyroid, or esophagus) 
T4b 
Very advanced local disease 
 

Alliance A091101 
 
Version Date: 08/11/2017 
83 
Update #07 
Tumor invades prevertebral space, encases carotid artery, or invades mediastinal 
structures. 
 
 
 
 
Subglottis 
 
T1 
Tumor limited to the subglottis 
 
T2 
Tumor extends to vocal cord(s) with normal or impaired mobility 
 
 
T3 
Tumor limited to larynx with vocal cord fixation 
 
 
T4a 
Moderately advanced local disease 
 
 
 
 
Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, 
strap muscles, thyroid, or esophagus) 
 
 
T4b 
Very advanced local disease 
 
Tumor invades prevertebral space, encases carotid artery, or invades mediastinal 
structures. 
 
 
REGIONAL LYMPH NODES (N) Excluding Nasopharynx 
 
NX 
Regional lymph nodes cannot be assessed 
N0 
No regional lymph node metastasis 
N1 
Metastasis in a single ipsilateral node, 3 cm or less in greatest dimension 
N2 
Metastasis in a single ipsilateral node, more than 3 cm, but not more than 6 cm in 
greatest dimension,  or  in  multiple  ipsilateral  lymph  nodes,  none  greater  than  6  
cm  in  greatest dimension, or bilateral or contralateral nodes, none more than 6 cm in 
greatest dimension 
N2a 
Metastasis in a single ipsilateral node more than 3 cm, but not more than 6 cm in 
greatest dimension 
N2b 
Metastasis in multiple ipsilateral nodes, none more than 6 cm in greatest dimension 
N2c                        Metastasis  in  bilateral  or  contralateral  lymph  nodes,  none  more  than  6  cm  in  
greatest dimension 
N3 
Metastases in a lymph node, more than 6 cm in greatest dimension 
 
REGIONAL LYMPH NODES (N) Nasopharynx 
NX 
Regional lymph nodes cannot be assessed 
N0 
No regional lymph node metastasis 
N1 
Unilateral metastasis in lymph node(s), 3 cm or less in greatest dimension 
N2 
Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 
6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 
cm in greatest dimension 

Alliance A091101 
 
Version Date: 08/11/2017 
84 
Update #07 
N2a 
Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 
6 cm in greatest dimension 
N2b 
Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest  
 
dimension 
N2c                        Metastasis  in  bilateral  or  contralateral  lymph  nodes,  none  more  than  6  cm  in  
greatest dimension 
N3 
Metastasis in a lymph node, more than 6 cm in greatest dimension 
 
DISTANT METASTASIS (M) 
 
M0 
No distant metastasis 
M1 
Distant metastasis 
 
 
 
 
STAGE GROUPING, Excluding Nasopharynx 
STAGE GROUPING 
Nasopharynx 
Stage 0 
Tis, N0, M0 
Stage 0 
Tis, N0, M0 
Stage I 
T1, N0, M0 
Stage I 
T1, N0, M0 
Stage II 
T2, N0, M0 
Stage II 
T2, N0, M0 
Stage III 
T3, N0, M0 
T1-3, N1, M0 
Stage IVA 
T4a, N0-1, M0 
Any T, N2, M0 
Stage IVB 
T4b, Any N, MO Any T, N3, M0 
Stage III 
T1-T3, N1, M0 
T3, N0, M0 
Stage IVA 
T4a, N0-2, M0 
T1-3, N2, MO 
Stage IVB 
Any T, N3, M0 
T4b, Any N, M0 
Stage IVC 
Any T, Any N, M1 
Stage IVC 
Any T, Any N, 
M1 
 
 
 

Alliance A091101 
 
Version Date: 08/11/2017 
85 
Update #07 
APPENDIX C - ABT-888 PATIENT MEDICATION CALENDAR 
Pill Calendar for ABT-888: 
Carboplatin-Paclitaxel Induction chemotherapy and ABT-888 (Veliparib) – a Phase 1/Randomized 
Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head 
and Neck 
 
Number of Pills Given:____________  
Pill Bottle(s) returned:  Circle Yes or No 
Total Daily Dose:________________ 
 
 
 
Number of Pills returned:_____________ 
(To be Completed by RN)  
    
PLEASE FILL OUT AND BRING THIS SHEET TO ALL VISITS. 
 
SPECIAL INSTRUCTIONS  
1. ABT-888 should be taken orally, twice a day, on days 1 through 7 of each induction 
chemotherapy cycle 
CYCLE #: _______   
DAY 
Medication 
DATE 
TIME/notes 
# of pills/mg 
taken 
Example ABT-888 
07/01/2012 
9:00 
AM 
9:00 
PM 
 
 
1 
ABT-888 
 
 
 
 
 
 
 
2 
ABT-888 
 
 
 
 
 
 
 
3 
ABT-888 
 
 
 
 
 
 
 
4 
ABT-888 
 
 
 
 
 
 
 
5 
ABT-888 
 
 
 
 
 
 
 
6 
ABT-888 
 
 
 
 
 
 
 
7 
ABT-888 
 
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
 
9 
 
 
 
 
 
 
 
 
10 
 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
 
12 
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
14 
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
 
16 
 
 
 
 
 
 
 
 
17 
 
 
 
 
 
 
 
 
18 
 
 
 
 
 
 
 
 
19 
 
 
 
 
 
 
 
 
20 
 
 
 
 
 
 
 
 
21 
 
 
 
 
 
 
 
 
  
Patient Signature: _________________________________________Date:__________ 
  
 Consenting Professional/Research RN Signature: ______________Date:__________  
 
Comments:_____________________________________________________________